Vaccine compositions and uses thereof
Patent Information
- Application Number
- HK62026124821
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-09
- Filing Date
- 2026-06-15
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 24 October 2024 (24.10.2024) lllllllllllllllllllllllllllllll^ (10) International Publication Number WO 2024 / 220936 Al WIPO I PCT (51) International Patent Classification: A61K 39 / 145 (2006.01) A61K9 / 127 (2006.01) (21) International Application Number: PCT / US2024 / 025583 (22) International Filing Date: 19 April 2024 (19.04.2024) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 63 / 497,404 20 April 2023 (20.04.2023) US 63 / 597,625 09 November 2023 (09.11.2023) US PCT / US23 / 079255 09 November 2023 (09.11.2023) US (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application: US PCT / US2023 / 079255 (CIP) Filed on 09 November 2023 (09.11.2023) (71) Applicant: CENTIVAX, INC. [US / US]; 1 Tower Place, Suite 800, South San Francisco, California 94080 (US). (72) Inventors: GLANVILLE, Jacob; 1 Tower Place, Suite 800, South San Francisco, California 94080 (US). BEDI, Rishi; 1 Tower Place, Suite 800, South San Francisco, Cal ifornia 94080 (US). BAYLESS, Nicholas; 1 Tower Place, Suite 800, South San Francisco, California 94080 (US). KIM, Sangil; 1 Tower Place, Suite 800, South San Fran cisco, California 94080 (US). ZEINER, Gusti; 1 Tower Place, Suite 800, South San Francisco, California 94080 (US). YOUSSEF, Sawsan; 1 Tower Place, Suite 800, South San Francisco, California 94080 (US). (74) Agent: NEGI, Vishakha; 650 Page Mill Road, Palo Alto, California 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, Nl, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, (54) Title: VACCINE COMPOSITIONS AND USES THEREOF w o 20 24 / 2 20 93 6 A l IIII III III III III III III III III III IN A'New_York / l / 1916 - A / Puerto_Rlco / 8 / 1934 - A / Denver / SU - A'New jersey / 8 / 19?6 - Α^Αίρη^ / ζβ / / ^^. - A / Calfom:»,'07 / 2009 - AWisconsin / 28 / 20n.2021 / 12 - A / Wisconsi:v!;88 / 2iH9 - / VHong_Kcng / l / 1968 - A / Nanchang / 933 / 1995 - A'Cafforn;a.O7 / 2004 - A / lndiane / ll / 201C - A'Cambodia,'eOS2fc360 / 2O2D - A / 'Memphis / l / lSBO - Α / Ηόί3Π3.Ό8 / 2011 - A / Alaska'01 / 2021 - B / Gua^dong-MaoneY3:i6 / 2021 - FIG. 1 (57) Abstract: The present disclosure provides vaccine composi- r 10 tions comprising a plurality of distinct antigens. Also provided are I nucleic acid vaccine composition comprising one or more nucle- Γ ' ic acids encoding for a plurality of distinct antigens. The plurality L 0 8 of distinct antigens comprises a combination of influenza antigens. The vaccine composition can be formulated for delivery as a mR- f 0.7 NA / LNP, a recombinant protein, a virus-like particle (VLP), or DNA. Methods of preventing an influenza infection and methods of indue - ' ing an immune response are also disclosed. -0.5 [Continued on next page] WO 2024 / 220936 Al IIIIIIIIIIIIIIIIIIIIIIIIIIIIM RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) WO 2024 / 220936 PCT / US2024 / 025583 VACCINE COMPOSITIONS AND USES THEREOF CROSS-REFERENCE
[0001] This application claims the benefit of PCT / US2023 / 079255, filed November 9, 2023, U.S. Provisional Application No. 63 / 497,404, filed April 20, 2023, and U.S. Provisional Application No. 63 / 597,625, filed November 9, 2023, which are incorporated herein by reference in their entirety. BACKGROUND OF THE INVENTION
[0002] Pathogenic agents, such as viruses, may evolve to evade detection and neutralization by a host’s immune system. Thus, most flu vaccines are effective against a limited subset of viruses that cause influenza. Vaccines that are effective against a wider variety of strains for flu are needed. SUMMARY OF THE INVENTION
[0003] In some aspects, the present disclosure provides a vaccine composition comprising a plurality of distinct antigens, the vaccine composition comprising at least one of an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical to SEQ ID NO: 16; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical to SEQ ID NO: 19; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical to SEQ ID NO: 21; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical to SEQ ID NO: 24; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38 or a sequence at least 70% identical to SEQ ID NO: 38; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39 or a sequence at least 70% identical to SEQ ID NO: 39; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40 or a sequence at least 70% identical to SEQ ID NO: 40; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41 or a sequence at least 70% identical to SEQ ID NO: 41; or an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42 or a sequence at least 70% identical to SEQ ID NO: 42. In some embodiments, the vaccine composition comprises at least one of: an antigen -1- WO 2024 / 220936 PCT / US2024 / 025583 comprising an amino acid sequence corresponding to SEQ ID NO: 3; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41; or an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42. In some embodiments, the plurality of distinct antigens comprises eight distinct antigens, each of which comprises amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42 or sequences at least 90% identical thereto. In some embodiments, the plurality of distinct antigens comprises twelve distinct antigens, each of which comprises amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42 or sequences at least 90% identical thereto. In some embodiments, the plurality of distinct antigens comprises eighteen distinct antigens, each of which comprises amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42 or sequences at least 90% identical thereto. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 2. In some embodiments, the vaccine composition comprises an -2- WO 2024 / 220936 PCT / US2024 / 025583 antigen comprising an amino acid sequence corresponding to SEQ ID NO: 4. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 5. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 6. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 7. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 8. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 17. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 20. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 22. In some embodiments, the plurality of distinct antigens comprises eighteen distinct antigens selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical thereto. In some embodiments, the plurality of distinct antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NO: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical thereto. In some embodiments, the vaccine composition further comprises a pharmaceutically acceptable carrier. In some embodiments, each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 5 micrograms (pg), such as between 1 ng and 5 pg. In some embodiments, each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 3 pg, such as between 1 ng and 3 pg. In some embodiments, the plurality of antigens comprises at 6, at least 8, at least 10, at least 12, at least 14, at least 16 or at least 17 distinct antigens. In some embodiments, the composition has no more than 30, no more than 25, or no more than 20 distinct antigens. In some embodiments, the plurality of antigens are collectively sufficient to elicit an immune response in a subject yet each individual antigen of the plurality of antigens in present in the composition in an amount that is insufficient to elicit in an immune response in a subject. In some embodiments, the vaccine composition comprises SEQ ID NOS: 2-9, 16-22, 24, and 38-42. In some embodiments, the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 90% identical thereto. In some embodiments, the vaccine composition comprises twenty- one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 95% identical thereto. In some embodiments, the vaccine composition -3- WO 2024 / 220936 PCT / US2024 / 025583 comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 98% identical thereto. In some embodiments, the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 99% identical thereto. In some embodiments, the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128.
[0004] In some aspects, the present disclosure provides a nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of distinct antigens, wherein the plurality of distinct antigens comprises at least one of: an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical to SEQ ID NO: 16; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical to SEQ ID NO: 19; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical to SEQ ID NO: 21; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical to SEQ ID NO: 24; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38 or a sequence at least 70% identical to SEQ ID NO: 38; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39 or a sequence at least 70% identical to SEQ ID NO: 39; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40 or a sequence at least 70% identical to SEQ ID NO: 40; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41 or a sequence at least 70% identical to SEQ ID NO: 41; or an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42 or a sequence at least 70% identical to SEQ ID NO: 42. In some embodiments, the plurality of distinct antigens comprises at least one of: an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41; or an antigen comprising an amino acid -4- WO 2024 / 220936 PCT / US2024 / 025583 sequence corresponding to SEQ ID NO: 42. In some embodiments, the one or more nucleic acids comprise messenger RNA (mRNA). In some embodiments, the mRNA is encapsulated in lipid nanoparticles (LNPs). In some embodiments, each nucleic acid encoding for each distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 5 pg. In some embodiments, each nucleic acid encoding for each distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 3 pg. In some embodiments, the one or more nucleic acids encode eight distinct antigens, each of which is selected from a group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42. In some embodiments, the one or more nucleic acids encode twelve distinct antigens, each of which is selected from a group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42. In some embodiments, the one or more nucleic acids encode eighteen distinct antigens, each of which is selected from a group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42. In some embodiments, the one or more nucleic acids encode for at least five distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 38-42. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 2. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 4. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 5. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino -5- WO 2024 / 220936 PCT / US2024 / 025583 acid sequence corresponding to SEQ ID NO: 6. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 7. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 8. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 17. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 20. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 22. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42. In some embodiments, the one or more nucleic acids encode for at least eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42. In some embodiments, the plurality of distinct antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42. In some embodiments, the nucleic acid vaccine composition further comprises a pharmaceutically acceptable carrier. In some embodiments, each nucleic acid encoding a distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 5 micrograms (pg), such as from about 1 ng to about 5 pg. In some embodiments, each nucleic acid encoding a distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 3 pg, such as from about 1 ng to about 3 pg. In some embodiments, the plurality of antigens comprises at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 distinct antigens. In some embodiments, the one or more nucleic acids encode for no more than 30, no more than 25, or no more than 20 distinct antigens. In some embodiments, upon administration of the vaccine to a subject, the vaccine elicits an immune response in the subject yet none of the plurality of distinct antigens is individually expressed at a level that is sufficient to elicit an immune response in a subject by itself. In some embodiments, the nucleic -6- WO 2024 / 220936 PCT / US2024 / 025583 acid vaccine composition is formulated as a LNP-encapsulated mRNA, DNA, or viral vector. In some embodiments, the one or more nucleic acids encode for SEQ ID NOS: 2-9, 16-22, 24, and 38-42. In some embodiments, the one or more nucleic acids further encode a transmembrane domain. In some embodiments, the transmembrane domain comprises any one of SEQ ID NOS: 43-63. In some embodiments, the one or more nucleic acids encode each of SEQ ID NOS: 43- 63. In some embodiments, the one or more nucleic acids further encode a signaling peptide. In some embodiments, the one or more nucleic acids comprise any one of SEQ ID NOS: 64-84. In some embodiments, the one or more nucleic acids comprise each of SEQ ID NOS: 64-84. In some embodiments, the one or more nucleic acids encode any one of SEQ ID NOS: 85-105. In some embodiments, the one or more nucleic acids encode each of SEQ ID NOS: 85-105. In some embodiments, the one or more nucleic acids comprise any one of SEQ ID NOS: 64-83. In some embodiments, the one or more nucleic acids comprise each of SEQ ID NOS: 64-83. In some embodiments, the one or more nucleic acids comprise any one of SEQ ID NOS: 64, 67-79, and 82-83. In some embodiments, the one or more nucleic acids comprise each of SEQ ID NOS: 64, 67-79, and 82-83. In some embodiments, the one or more nucleic acids encode any one of SEQ ID NOS: 85-104. In some embodiments, the one or more nucleic acids encode each of SEQ ID NOS: 85-104. In some embodiments, the one or more nucleic acids encode any one of SEQ ID NOS: 85-100. In some embodiments, the one or more nucleic acids encode each of SEQ ID NOS: 85-100. In some embodiments, the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 108-128, or sequences at least 90% identical thereto. In some embodiments, the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 108-128, or sequences at least 95% identical thereto. In some embodiments, the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 108-128, or sequences at least 98% identical thereto. In some embodiments, the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 1 OS- 128, or sequences at least 99% identical thereto.
[0005] In some aspects, the present disclosure provides a vaccine composition comprising a plurality of distinct antigens, the vaccine composition comprising at least one of: an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical to SEQ ID NO: 16; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical to SEQ ID NO: 19; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical to SEQ ID NO: -7- WO 2024 / 220936 PCT / US2024 / 025583 21; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23 or a sequence at least 70% identical to SEQ ID NO: 23; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical to SEQ ID NO: 24; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25 or a sequence at least 70% identical to SEQ ID NO: 25; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27 or a sequence at least 70% identical to SEQ ID NO: 27; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29 or a sequence at least 70% identical to SEQ ID NO: 29; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33 or a sequence at least 70% identical to SEQ ID NO: 33; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34 or a sequence at least 70% identical to SEQ ID NO: 34; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36 or a sequence at least 70% identical to SEQ ID NO: 36; and an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37 or a sequence at least 70% identical to SEQ ID NO: 37. In some embodiments,: the vaccine composition comprises at least one of: an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36; and an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37. In some embodiments, the plurality of distinct antigens comprises eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8 or sequences at least 70% identical thereto. In some embodiments, the plurality of distinct antigens comprises eight distinct antigens, wherein the eight distinct antigens correspond to amino acid sequences selected from the group consisting of SEQ ID NOS: 16-23 or sequences at least 70% identical thereto. In some embodiments, the plurality of distinct antigens comprises eight distinct antigens, wherein the eight distinct antigens correspond to amino acid sequences selected from the group consisting of SEQ ID NOS: 1-15 or sequences at least 70% identical thereto. In some embodiments, the -8- WO 2024 / 220936 PCT / US2024 / 025583 plurality of distinct antigens comprises six distinct antigens, wherein the six distinct antigens correspond to amino acid sequences selected from the group consisting of SEQ ID NOS: 16-28 or sequences at least 70% identical thereto. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 1. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 2. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 4. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 5. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 6. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 7. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 8. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid -9- WO 2024 / 220936 PCT / US2024 / 025583 sequence corresponding to SEQ ID NO: 16. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 17. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 20. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 22. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 26. In some embodiments, the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 28. In some embodiments, the plurality of distinct antigens comprises eighteen distinct antigens selected from the group consisting of SEQ ID NOS: 1-8, 16-23, and 29, or sequences at least 70% identical thereto. In some embodiments, the plurality of distinct antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1-8, 16-23, and 29, or sequences at least 70% identical thereto. In some embodiments, the vaccine composition further comprises a pharmaceutically acceptable carrier. In some embodiments, each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 5 micrograms (pg), such as between 1 ng and 5 pg. In some embodiments, each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 3 pg, such as between 1 ng and 3 pg. In some embodiments, the plurality of antigens comprises at 6, at least 8, at least 10, at least 12, at least 14, at least 16 or at least 17 distinct antigens. In some embodiments, the composition has no more than 30, no more than 25, or no more than 20 distinct antigens. In some embodiments, the plurality of antigens are collectively sufficient to elicit an immune response in a subject yet each individual antigen of the plurality of antigens in present in the composition in an amount that is insufficient to elicit in an immune response in a subj ect.
[0006] In some aspects, the present disclosure provides a nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of distinct antigens, wherein the plurality of distinct antigens comprises at least one of: an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13 or a sequence at least 70% identical to SEQ ID NO: 13; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical to SEQ ID NO: 19; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical to SEQ ID NO: 21; an -10- WO 2024 / 220936 PCT / US2024 / 025583 antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23 or a sequence at least 70% identical to SEQ ID NO: 23; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical to SEQ ID NO: 24; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25 or a sequence at least 70% identical to SEQ ID NO: 25; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27 or a sequence at least 70% identical to SEQ ID NO: 27; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29 or a sequence at least 70% identical to SEQ ID NO: 29; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33 or a sequence at least 70% identical to SEQ ID NO: 33; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34 or a sequence at least 70% identical to SEQ ID NO: 34; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36 or a sequence at least 70% identical to SEQ ID NO: 36; and an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37 or a sequence at least 70% identical to SEQ ID NO: 37. In some embodiments,: the plurality of distinct antigens comprises at least one of: an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34; an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36; and an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37. In some embodiments, the one or more nucleic acids comprise messenger RNA (mRNA). In some embodiments, the mRNA is encapsulated in lipid nanoparticles (LNPs). In some embodiments, each nucleic acid encoding for each distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 5 pg. In some embodiments, each nucleic acid encoding for each distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 3 pg. In some embodiments, the one or more nucleic acids encode for at least eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8. In some embodiments, the one or more nucleic acids encode for at least eight distinct antigens comprising amino acid -11- WO 2024 / 220936 PCT / US2024 / 025583 sequences selected from the group consisting of SEQ ID NOS: 16-23. In some embodiments, the one or more nucleic acids encode for at least eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-15. In some embodiments, the one or more nucleic acids encode for at least six distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 16-28. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 1. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 2. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 4. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 5. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 6. In some embodiments, the one or more nucleic -12- WO 2024 / 220936 PCT / US2024 / 025583 acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 7. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 8. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 17. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 20. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 22. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 26. In some embodiments, the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 28. In some embodiments, the one or more nucleic acids encode for at least eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16- 23, or 29. In some embodiments, the plurality of distinct antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29. In some embodiments, the nucleic acid vaccine composition further comprises a pharmaceutically acceptable carrier. In some embodiments, each nucleic acid encoding a distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 5 micrograms (pg), such as from about 1 ng to about 5 pg. In some embodiments, each nucleic acid encoding a distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 3 pg, such as from about 1 ng to about 3 pg. In some embodiments, the plurality of antigens comprises at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 distinct antigens. In some embodiments, the one or more nucleic acids encode for no more than 30, no more than 25, or no more than 20 distinct antigens. In some embodiments, upon administration of the vaccine to a subject, the vaccine elicits an immune response in the subject yet none of the plurality of distinct antigens is individually expressed at a level that is sufficient to elicit an immune response in a subject by itself. In some embodiments, the nucleic acid vaccine composition is formulated as an LNP- encapsulated mRNA or DNA or viral vector. In some embodiments, the one or more nucleic acids further encode a transmembrane domain. In some embodiments, the transmembrane domain comprises any one of SEQ ID NOS: 43-63. In some embodiments, the one or more nucleic acids encode any one of SEQ ID NOS: 43-63. In some embodiments, the one or more nucleic acids further encode a signaling peptide. In some embodiments, the one or more nucleic -13- WO 2024 / 220936 PCT / US2024 / 025583 acids comprise any one of SEQ ID NOS: 64-84. In some embodiments, the one or more nucleic acids comprise each of SEQ ID NOS: 64-84. In some embodiments, the one or more nucleic acids encode any one of SEQ ID NOS: 85-105. In some embodiments, the one or more nucleic acids encode each of SEQ ID NOS: 85-105. In some embodiments, the one or more nucleic acids comprise any one of SEQ ID NOS: 64-83. In some embodiments, the one or more nucleic acids comprise each of SEQ ID NOS: 64-83. In some embodiments, the one or more nucleic acids comprise any one of SEQ ID NOS: 64, 67-79, and 82-83. In some embodiments, the one or more nucleic acids comprise each of SEQ ID NOS: 64, 67-79, and 82-83. In some embodiments, the one or more nucleic acids encode any one of SEQ ID NOS: 85-104. In some embodiments, the one or more nucleic acids encode each of SEQ ID NOS: 85-104. In some embodiments, the one or more nucleic acids encode any one of SEQ ID NOS: 85-100. In some embodiments, the one or more nucleic acids encode each of SEQ ID NOS: 85-100. A vaccine composition comprising twenty-one distinct antigens, wherein each of the twenty-one distinct antigens comprises a sequence selected from SEQ ID NOS: 108-128, or a sequence having at least 90%, at least 95%, at least 98%, at least 99% sequence identity thereto. In some embodiments, each of the twenty-one distinct antigens comprises a sequence selected from SEQ ID NOS: 108-128. In some embodiments, each of the twenty-one distinct antigens comprises or consists of a sequence selected from SEQ ID NOS: 85-105 A nucleic acid vaccine composition comprising one or more nucleic acids encoding for at least twenty-one distinct antigens, wherein each the twenty-one distinct antigens comprises a sequence selected from SEQ ID NOS: 108-128, or a sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto. In some embodiments, each of the at least twenty-one distinct antigens comprises a sequence selected from SEQ ID NOS: 108-128. In some embodiments, each of the twenty-one distinct antigens comprises or consists of a sequence selected from SEQ ID NOS: 85-105. In some embodiments, the vaccine composition comprises each of SEQ ID NOS: 64-84.
[0007] In some aspects, the present disclosure provides a method for preventing an influenza infection in a subject, comprising administering to the subject any vaccine composition as disclosed herein. In some aspects, the present disclosure provides a method of inducing an immune response in a subject, the method comprising administering to the subject any vaccine composition as disclosed herein. In some embodiments, the immune response is a protective immune response. In some embodiments, the vaccine composition is administered to the subject intramuscularly, subcutaneously, intramuscularly, intranasally, or orally. In some embodiments, the nucleic acid vaccine composition is formulated for delivery as a LNP-encapsulated mRNA or DNA or viral vector. An infection rate in subjects receiving the vaccine may be reduced by -14- WO 2024 / 220936 PCT / US2024 / 025583 2% (or more) relative or more relative to a placebo control or relative to a subject who did not receive the vaccine composition.
[0008] Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive. BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Various features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0010] FIG. 1 depicts pairwise sequence identity for antigens in (or antigens expressed by nucleic acid sequences in) an exemplary influenza vaccine composition.
[0011] FIG. 2A depicts the amount of induced antibodies measured by ELISA reactive to a particular recombinant influenza hemagglutinin antigen in the serum of mice in response to vaccination with either Centi-Flu (0.031 ug of mRNA / antigen), Flu-Biv (0.25 ug / antigen), or Flu-Biv (0.031 ug / antigen). Reactivity is shown to antigens present in Centi-Flu (H3N2 Hong Kong / 1 / 1968, H3N2 Alaska / 01 / 2021), present in Centi-Flu and Flu-Biv (California / 07 / 2004), or heterologous antigens present in neither (H3N2 A / Victoria / 361 / 2011, A / Maryland / 02 / 2021). FIG. 2B depicts the amount of induced antibodies measured by ELISA reactive to a particular recombinant influenza hemagglutinin antigen in the serum of mice in response to vaccination with either Centi-Flu (0.25 ug of mRNA / antigen), Flu-Biv (2 ug / antigen), or Flu-Biv (0.25 ug / antigen). Reactivity is shown to antigens present in Centi-Flu (H3N2 Hong Kong / 1 / 1968, H3N2 Alaska / 01 / 2021), present in Centi-Flu and Flu-Biv (Califomia / 07 / 2004), or heterologous antigens present in neither (H3N2 A / Victoria / 361 / 2011, A / Maryland / 02 / 2021).
[0012] FIG. 3A depicts serum reactivity measured by ELISA in ferrets immunized with 1 pg of mRNA encoding influenza hemagglutinin antigens of H3N2 Alaska / 01 / 2021, H3N2 California / 07 / 2004, H3N2 Cambodia / 2020, H3N2 Indiana / 11 / 2018, H3N2 Bilthoven / 1761 / 1976, H3N2 Indiana / 08 / 2011, H3N2 Nanchang / 933 / 1995, orH3N2 Memphis / 1 / 1980, to the same antigen that the animal was immunized with; FIG. 3B depicts serum reactivity measured by ELISA in ferrets immunized with approximately 0.5 ug of mRNA -15- WO 2024 / 220936 PCT / US2024 / 025583 per antigen encoding 8 influenza hemagglutinin antigens of H3N2 Alaska / 01 / 2021, H3N2 California / 07 / 2004, H3N2 Cambodia / 2020, H3N2 Indiana / 11 / 2018, H3N2 Bilthoven / 1761 / 1976, H3N2 Nanchang / 933 / 1995, H3N2 Memphis / 1 / 1980, H3N2 Hong Kong / 1 / 1968, to the indicated recombinant protein antigens.
[0013] FIG. 4 depicts pairwise sequence identity between a set of H3N2 hemagglutinin homologous distinct antigen components.
[0014] FIG. 5 depicts the results of hemagglutinin inhibition (HAI) studies in mice immunized with a vaccine composition having twenty mRNAs encoding hemagglutinin antigens (LNP-20) at different doses.
[0015] FIG. 6 depicts the results of HAI studies in mice immunized with a vaccine composition having eighteen mRNAs encoding hemagglutinin antigens (LNP-18).
[0016] FIG. 7 depicts the results of HAI studies in rats immunized with a vaccine composition having eighteen mRNAs encoding hemagglutinin antigens (LNP-18). DETAILED DESCRIPTION OF THE INVENTION
[0017] The present disclosure provides vaccine compositions and methods for treating influenza. In some embodiments, the vaccine composition comprises one or more antigens. In some other embodiments, the vaccine composition comprises nucleic acids that encode for the plurality of antigens. In some embodiments, the plurality of antigens includes one or more influenza proteins, or derivatives thereof. In some embodiments, the one or more antigens comprise hemagglutinin proteins, or derivatives thereof. In some embodiments, the hemagglutinin proteins or derivatives thereof comprises one or more hemagglutinin subtypes selected from Hl, H2, H3, H4, H5, H6, H7, H8, H9, H10, Hll, H12, H13, H14, H15, H16, H17, orH18. In some embodiments, the one or more antigens include hemagglutinin proteins from multiple subtypes, such as from Hl and H3. In some embodiments, the antigens include hemagglutinin proteins from the influenza B subtype (HAB). In some embodiments, the plurality of antigens comprises the amino acid sequences of any one of SEQ ID NOS: 1-42, as disclosed in Table 1. In some embodiments, the plurality of antigens comprises the amino acid sequences of any one of SEQ ID NOS: 108-128, as disclosed in Table 4. In some embodiments, an antigen of the plurality of antigens comprises the extracellular domain of the antigen. In some embodiments, an antigen of the plurality of antigens further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of any one of SEQ ID NOS: 43-63 or 130-150. In some embodiments, the transmembrane domain comprises the sequence of any one of SEQ ID NOS: 43-63. In some embodiments, the transmembrane domain may be coupled to an extracellular domain of the antigen. In some embodiments, the vaccine composition comprises -16- WO 2024 / 220936 PCT / US2024 / 025583 nucleic acid sequences encoding any one of SEQ ID NOS: 85-105. In some embodiments, the vaccine composition comprises one or more nucleic acids. In some embodiments, each nucleic acid of the nucleic acid vaccine may encode a signal peptide of an influenza hemagglutinin. In some embodiments, each nucleic acid may encode an extracellular domain of an influenza hemagglutinin. In some embodiments, each nucleic acid may encode a transmembrane domain of an influenza hemagglutinin. In some embodiments, each nucleic acid may encode a signal peptide, an extracellular domain, and a transmembrane domain, wherein the signal peptide, the extracellular domain, and the transmembrane domain are each operably linked with one another. In some embodiments, each nucleic acid may encode an open reading frame coding for a signal peptide, extracellular domain, and transmembrane domain. In some embodiments, each nucleic acid encodes only a signal peptide and an extracellular domain of an antigen. In some embodiments, the nucleic acid encodes an antigen extracellular domain that is not connected to a signal peptide. In some embodiments, the nucleic acid encodes an antigen extracellular domain that is not connected to a transmembrane domain. In some embodiments, the nucleic acid encodes an antigen extracellular domain that is not connected to a signal peptide or a transmembrane domain. In some embodiments, a nucleic acid of the vaccine composition may comprise any of SEQ ID NOs 64-84. In some embodiments, the antigen extracellular domain may have 1-5 amino acid mutations relative to the wild type sequence to increase the stability of the antigen. In some embodiments, the antigen extracellular domain may have 3 amino acid mutations relative to the wild type sequence to increase the stability of the antigen. Table 1. Amino acid sequences of antigens and corresponding transmembrane domains for a vaccine composition Strain Amino Acid Sequence of Antigen Extracellular Domain SEQ ID NO: Amino Acid Sequence of Antigen Transmembrane Domain SEQ ID NO: A / New_Jersey / 8 / 1976 A_ / _H1N1 ADTLCIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDRHNGKLCKLGGIAPLHLGKCNIAGWLLG NPECELLLTVSSWSYIVETSNSDNGTCYPGDF INYEELREQLSSVSSFERFEIFPKTSSWPDHE TNRGVTAACPYAGANSFYRNLIWLVEKGNSYP KLSKSYVNNKGKEVLVLWGIHHPPTSTDQQSL YQNADAYVFVGSSKYNRKFKPEIAARPKVRGQ AGRMNYYWT LIE PGDTITFEAT GNLVVPRYAF AMNRGSGSGIIISDAPVHDCNTKCQTPKGAIN TSLPFQNIHPVTIGECPKYVKSTKLRMATGLR NIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGY HHQNEQGSGYAADQRSTQNAIDGITNKVNSVI EKMNTQFTAVGKEFNHLEKRIENLNKKVDDGF LDIWTYNAELLVLLENERTLDFHDSNVKNLYE 1 TRIYQILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQCR ICI 130 -17- WO 2024 / 220936 PCT / US2024 / 025583 KVRSQLRNNAKEIGNGCFEFYHKCDDTCMESV KNGTYDYPKYSEESKLNREEIDGVKLES A / New_York / 1 / 1918 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDSHNGKLCKLKGIAPLQLGKCNIAGWLLG NPECDLLLTASSWSYIVETSNSENGTCYPGDF IDYEELREQLSSVSSFEKFEIFPKTSSWPNHE TTKGVTAACSYAGASSFYRNLLWLTKKGSSYP KLSKSYVNNKGKEVLVLWGVHHPPTGTDQQSL YQNADAYVSVGSSKYNRRFTPEIAARPKVRDQ AGRMNYYWT LLE PGDTIT FEAT GNLIAPWYAF ALNRGS GS GIITSDAPVHDCNTKCQT PHGAIN SSLPFQNIHPVTIGECPKYVRSTKLRMATGLR NIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGY HHQNEQGSGYAADRKSTQNAIDGITNKVNSVI EKMNTQFTSVGKEFNHLEKRIENLNRKVDDGF LDVWTYNAELLVLLENERTLDYHDSNVKNLYE KVRSQLKNNAKEIGNGCFE FYHKCDDS CME SV KNGTYDYPKYSEESKLNREEIDGVKLES 2 MGVYQILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQCR ICI 43 A / Wisconsin / 5 88 / 2019 A_ / _H1N1 ADTLCIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDKHNGKLCKLRGVAPLHLGKCNIAGWILG NPECESLSTARSWSYIVETSNSDNGTCYPGDF INYEELREQLSSVSSFERFEIFPKTSSWPNHD SDNGVTAACPHAGAKSFYKNLIWLVKKGKSYP KINQTYINDKGKEVLVLWGIHHPPTIADQQSL YQNADAYVFVGTSRYSKKFKPEIATRPKVRDQ EGRMNYYWTLVEPGDKITFEATGNLVAPRYAF TMERDAGSGIIISDTPVHDCNTTCQTPEGAIN TSLPFQNVHPITIGKCPKYVKSTKLRLATGLR NVPSIQSRGLFGAIAGFIEGGWTGMVDGWYGY HHQNEQGSGYAADLKSTQNAIDKITNKVNSVI EKMNTQFTAVGKEFNHLEKRIENLNKKVDDGF LDIWTYNAELLVLLENERTLDYHDSNVKNLYE KVRNQLKNNAKEIGNGCFE FYHKCDNTCME SV KNGTYDYPKYSEEAKLNREKIDGVKLDS 3 TRIYQILAIYSTV ASSLVLVVSLGAI SFWMCSNGSLQCR ICI 44 A / Brisbane / 59 / 2007 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVN LLENSHNGKLCLLKGIAPLQLGNCSVAGWILG NPECELLISKESWSYIVEKPNPENGTCYPGHF ADYEELREQLSSVSSFERFEIFPKESSWPNHT VT GVSAS CS HNGE S S FYRNLLWLT GKNGLY PN LSKSYANNKEKEVLVLWGVHHPPNIGNQKALY HTENAYVSVVSSHYSRKFTPEIAKRPKVRDQE GRINYYWTLLE PGDTIIFEANGNLIAPRYAFA LSRGFGSGIINSNAPMDKCDAKCQTPQGAINS S L P FQNVH PVTIGE C PKYVRSAKLRMVT GLRN IPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYH HQNEQGSGYAADQKSTQNAINGITNKVNSVIE KMNTQFTAVGKEFNKLERRMENLNKKVDDGFI DIWTYNAELLVLLENERTLDFHDSNVKNLYEK VKSQLKNNAKEIGNGCFE FYHKCNDECMESVK NGTYDYPKYSEESKLNREKIDGVKLES 4 MGVYQILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQCR ICI 45 -18- WO 2024 / 220936 PCT / US2024 / 025583 A / Wisconsin / 2 8 / 2011.2011 / 1 2 A_ / _H1N1 ADTLCIGYHANNSTDTVDTVLEKNVTVTHSVN LLENRHNGKLCKLRGVAPLHLGKCNIAGWLLG NPECESLSTASSWSYIVETSNSDNGTCYPGDF INYEELREQLSSVSSFERFEIFPKTSSWPNHD TNRGVTAACPHDGTNSFYRNLIWLVKKGNSYP KINKSYINNKEKEILVLWAIHHPSTSADQQSL YQNADAYVFVGSSRYSRKFEPEVATRPKVRDQ AGRMNYYWTLVEPGDKITFEATGNLVVPRYAF ALKRNSGSGIIISDTSVHDCDTNCQTPNGAIN TSLPFQNIHPVTIGECPKYVKSTKLRMATGLR NIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGY HHQNEQGSGYAADLKSTQNAIDGITNKVNSVI EKMNTQFTAVGKEFSHLERRIENLNKKVDDGF LDIWTYNAELLVLLENERTLDYHDSNVKNLYE KVRSQLKNNAKEIGNGCFE FYHKCDDMCME SV KNGTYDYPKYSEEAKLNREEIDGVKLES 5 TRIYQILAIYSTV ASSLVLVVSLGAI SFWMCSNGSLQCR ICI 46 A / Denver / 57 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDSHNGKLCRLKGKAPLQLGNCNIAGWVLG NPECESLLSNRSWSYIAETPNSENGTCYPGDF ADYEELREQLSSVSSFERFEIFPKERSWPNHT TRGVTAACPHARKSSFYKNLVWLTEANGSYPN LSRSYVNNQEKEVLVLWGVHHPSNIEEQRALY RKDNAYVSVVSSNYNRRFTPEIAKRPKVRDQS GRMNYYWTLLE PGDTIIFEATGNLIAPWYAFA LSRGPGSGIITSNAPLDECDTKCQTPQGAINS SLPFQNIHPVTIGECPKYVRSTKLRMVTGLRN IPSVQSRGLFGAIAGFIEGGWTGMMDGWYGYH HQNEQGSGYAADQKSTQNAINGITNKVNSVIE KMNTQFTAVGKEFNKLEKRMENLNKKVDDGFM DIWTYNAELLVLLENERTLDFHDSNVKNLYEK VKNQLRNNAKE LGNGCFE FYHKCDNE CME SVK NGTYDYPKYSEESKLNREKIDGVKLES 6 MGVYRILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQCR ICI 47 A / Beij ing / 2 62 / 1995 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDSHNGKLCLLKGIAPLQLGNCSVAGWILG NPECESLISKESWSYIVETPNPENGTCYPGYF ADYEELREQLSSVSSFERFEIFPKESSWPNHT VTGVTASCSHNGKSSFYRNLLWLTEKNGLYPN LSNSYVNNKEKEVLVLWGVHHPSNIRDQRAIY HTENAYVSVVSSHYSRRFTPEIAKRPKVRGQE GRINYYWTLLE PGDTIIFEANGNLIAPWYAFA LSRGFGSGIITSNAPMNECDAKCQTPQGAINS SLPFQNVHPVTIGECPKYVRSTKLRMVTGLRN IPSIQSRGLFGAIAGFIEGGWTGMMDGWYGYH HQNEQGSGYAADQKSTQNAINGITNKVNSVIE KMNTQFTAVGKEFNKLERRMENLNKKVDDGFL DIWTYNAELLVLLENERTLDFHDSNVKNLYEK VKSQLKNNAKEIGNGCFEFYHKCNNECMESVK NGTYDYPKYSEESKLNREKIDGVKLES 7 MGVYQILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQCR ICI 48 -19- WO 2024 / 220936 PCT / US2024 / 025583 A / Puerto_Rico / 8 / 1934 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDSHNGKLCRLKGIAPLQLGKCNIAGWLLG NPECDPLLPVRSWSYIVETPNSENGICYPGDF IDYEELREQLSSVSSFERFEIFPKESSWPNHN TNKGVTAACSHEGKSSFYRNLLWLTEKEGSYP KLKNSYVNKKGKEVLVLWGIHHPPNSKEQQNL YQNENAYVSVVTSNYNRRFTPEIAERPKVRDQ AGRMNYYWTLLKPGDTIIFEANGNLIAPMYAF ALSRGFGSGIITSNASMHECNTKCQTPLGAIN SSLPYQNIHPVTIGECPKYVRSAKLRMVTGLR NIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGY HHQNEQGSGYAADQKSTQNAINGITNKVNTVI EKMNIQFTAVGKEFNKLEKRMENLNKKVDDGF LDIWTYNAELLVLLENERTLDFHDSNVKNLYE KVKSQLKNNAKEIGNGCFEFYHKCDNECMESV RNGTYDYPKYSEESKLNREKVDGVKLES 8 MGIYQILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQCR ICI 49 A / California / 07 / 2009 A_ / _H1N1 ADTLCIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDKHNGKLCKLRGVAPLHLGKCNIAGWILG NPECESLSTASSWSYIVETPSSDNGTCYPGDF IDYEELREQLSSVSSFERFEIFPKTSSWPNHD SNKGVTAACPHAGAKSFYKNLIWLVKKGNSYP KLSKSYINDKGKEVLVLWGIHHPSTSADQQSL YQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQ EGRMNYYWTLVEPGDKITFEATGNLVVPRYAF AMERNAGSGIIISDTPVHDCNTTCQTPKGAIN TSLPFQNIHPITIGKCPKYVKSTKLRLATGLR NIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGY HHQNEQGSGYAADLKSTQNAIDEITNKVNSVI EKMNTQFTAVGKEFNHLEKRIENLNKKVDDGF LDIWTYNAELLVLLENERTLDYHDSNVKNLYE KVRSQLKNNAKEIGNGCFEFYHKCDNTCMESV KNGTYDYPKYSEEAKLNREEIDGVKLES 9 TRIYQILAIYSTV ASSLVLVVSLGAI SFWMCSNGSLQCR ICI 50 swine / Denmark / 12813-1 / 2004 A_ / _H1N1 ADTICVGYHANNSTDTVDTILEKNVTVTHSVN LLESNHNGKLCSLNGKAPLQLGNCNVAGWILG NPECDLLLTANSWSYIIETSNSKNGACYPGEF ADYEELRELLSTVSSFERFEIFPKATSWPHHE TTKGTTVACPHSGVNSFYRNLLWIVKKGNSYP KLSKSYTNSKGKEVLVIWGVHHPPTDSDQQTL YQNNHTYVSVGTSKYYRRFTPEIVARPKIREQ AGRMNYYWTLLDQGDTITLEATGNLIVPWHAF ALNKGSNSGIMISDADFHNCTTKCQTPHGALK SNLPFQNVHPITIGECPKYVKSTQLRMATGLR NVPSIQSRGLFGAIAGFIEGGWTGMIDGWYGY HHQNEQGSGYAADQKSTQIAIDGISNKVNSVI EKMNIQFASVGKEFNDLEKRIENLNKKVDDGF VDVWTYNAELLILLENERTLDFHDFNVKNLYE KVKSQLRNNAKEIGNGCFEFYHKCDNECMESV KNGTYNYPKYSEESKLNREEIDGVKLES 10 MGVHQILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQCR VC I 131 -20- WO 2024 / 220936 PCT / US2024 / 025583 A / swine / Eire / 89 / 1996.1996 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVN LLENNHNGKLCNLNGIAPLQLGKCNVAGWLLG NPECGLLLNANAWSYIIETSDSKNGTCYPGDF IDYEELREQLGSVSSFEKFEIFPKASSWPDHE TTKGTTAACPYSGVESFYRNLLWIIKKGNSYP KISKSYTNNRGKEVLVLWGVHHPPTTSDQQTL YQNIDAYVSVGSSKYNRRFTPEIATRPKVRGL AGRMNYYWTLLDQGDTIMFEATGNLIAPWYAF ALNKGSDSGIITSDTPVHDCDTKCQTPYGALN SSLPFQNVHPITIGECPKYVKSTKLRMATGLR NVPSIQSKGLFGAIAGFIEGGWTGMIDGWYGY HHQNEQGSGYSADQKSTQNAIDGITNKVNSVI EKMNTQFTAVGKEFNNLERRIENLNKKVDDGF LDVWTYNAELLVLLENERTLDFHDSNVRDLYE RVKSQLRNNAKEIGNGCFE FYHKCDDE CMENV KNGTYDYPKYSEEAKLNREKIDGVKIES 11 MGVYQILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQCR TCI 132 A / Thailand / 27 1 / 2005.2005 / 0 7 A_ / _H1N1 ADTLCIGYHANNSTDTVDTILEKNVTVTHSVN LLEDRHNGKLCNLRGEAPLHLGKCNIAGWLLG NPECELLFAVNSWSYIVETSNSDNGTCYPGDF TSYEELREQLSSVSSFERFEIFPKASSWPNHE TNRGVTAACPYAGTNSFYRNLIWLVKKGNSYP KLSKSYVNNKKKEVLVLWGIHHPPTNADQQSL YQNADAYVFVGSSKYNKKFKPEIAKRPKVRGQ AGRMNYYWT LVE PGDTIT FEAT GNLVAPRYAF AMNRDPGSGIITSDAPIHDCNATCQTPKGAIN TSLPFQNIHPITIGECPKYVKSTRLRMATGLR NIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGY HHQNGQGSGYAADQKSTQNAIDRITNKVNSVI EKMNIQFTAVGKEFNHLERRIENLNKKVDDGF LDVWTYNAELLVLLENERTLDFHDSNVKTLYE KVKTQLRNNAKEIGNGCFE FYHKCDDTCME SI KNGTYDYPKYSKESKLNREEIDGVQLES 12 TRLYQILAIYSTA ASSLVLLVSLGAI GFWMCSNGSLQCR ICI 133 A / Hawaii / 7 0 / 2 019 A_ / _H1N1 ADTLCIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDKHNGKLCKLRGVAPLHLGKCNIAGWILG NPECESLSTARSWSYIVETSNSDNGTCYPGDF INYEELREQLSSVSSFERFEIFPKTSSWPNHD SDKGVTAACPHAGAKSFYKNLIWLVKKGNSYP KLNQTYINDKGKEVLVLWGIHHPPTIAAQESL YQNADAYVFVGTSRYSKKFKPEIATRPKVRDQ EGRMNYYWTLVEPGDKITFEATGNLVVPRYAF TMERDAGSGIIISDTPVHDCNTTCQTPEGAIN TSLPFQNVHPITIGKCPKYVKSTKLRLATGLR NVPSIQSRGLFGAIAGFIEGGWTGMVDGWYGY HHQNEQGSGYAADLKSTQNAIDKITNKVNSVI EKMNTQFTAVGKEFNHLEKRIENLNKKVDDGF LDIWTYNAELLVLLENERTLDYHDSNVKNLYE KVRNQLKNNAKEIGNGCFE FYHKCDNTCME SV KNGTYDYPKYSEEAKLNREKIDGVKLES 13 TRIYQILAIYSTV ASSLVLVVSLGAI SFWMCSNGSLQCR ICI 134 -21- WO 2024 / 220936 PCT / US2024 / 025583 A / USSR / 90 / 197 7 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDSHNGKLCRLKGIAPLQLGKCNIAGWILG NPECESLFSKKSWSYIAETPNSENGTCYPGYF ADYEELREQLSSVSSFERFEIFPKERSWPKHN VTRGVTASCSHKGKSSFYRNLLWLTEKNGSYP NLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTI YRKENAYVSVVSSNYNRRFTPEIAERPKVRGQ AGRINYYWTLLE PGDTIIFEANGNLIAPWHAF ALNRGFGSGIITSNASMDECDTKCQTPQGAIN SSLPFQNIHPVTIGECPKYVRSTKLRMVTGLR NIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGY HHQNEQGSGYAADQKSTQNAINGITNKVNSVI EKMNTQFTAVGKEFNKLEKRMENLNKKVDDGF LDIWTYNAELLVLLENERTLDFHDSNVKNLYE KVKSQLKNNAKEIGNGCFEFYHKCNNECMESV KNGTYDYPKYSEESKLNREKIDGVKLES 14 MGVYQILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQCR ICI 135 A / Minnesota / 1 4 / 2012.2012 / 1 2 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDSHNGKLCLLKGIAPLQLGNCSVAGWILG NPECESLISKKSWSYIVETPNPENGACYPGEF ADYEELREQLSSVSSFERFEIFPKESSWPNHT ATGESASCSHNGKKSFYRNLIWLTVKNGLYPN LSKSYENDKEKEVLILWGVHHPPNIENQRTLY HTENAYVSVVSSHYSGRFTPEITKRPKVRDQE GRINYYWTLLE PGDTIIFEANGNLIAPWYAFA LSRGLGSGIITSNAPMDECDSKCQTPQGAINS S L P FQNVH PVTIGE C PKYVRS AKLRMVT GLRN IPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYH HQNEQGSGYAADQESTQNAINGITNKVNSVIE KMNTQFTAVGKEFNKLERRMENLNKKVDDGFL DIWTYNAELLVLLENERTLDFHDSNVKSLYEK VKSQLKNNAKEIGNGCFEFYHKCNNECMESVK NGTYDYPKYYEESKLNREKIDGVKLDS 15 MGVYRILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQ CRICI 136 A / Indiana / 11 / 2018 A_ / _H3N2 TATLCLGHHAVPNGTIVKTITNDRIEVTNATE LVQNS SIGEICDS PHQILDGENCTLIDALLGD PQCDGFQNKKWDLFVERSKAYSNCYPYDVPDY AS LRS LVAS S GT LE FNNE S FNWT GVKQNGT S S ACIRKSSSSFFSRLNWLTHLNYTYPALNVTMP NNEQFDKLYIWGVHHPGTDKDQIFLYAQSSGR ITVSTKRSQQAVIPNIGSRPRIRDIPSRISIY WTIVKPGDILLINSTGNLIAPRGYFKIQSGKS SIMRSDAPIGKCKSECITPNGSIPNDKPFQNV NRITYGACPRYVKHSTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGR GQAADLKSTQAAIDQINGKLNRLIGKTNEKFH QIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFEKTKKQLRE NAEDMGNGCFKIYHKCDNACIGSIRNGTYDHN VYRDEALNNRFQIKGVELKS 16 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 51 -22- WO 2024 / 220936 PCT / US2024 / 025583 A / California / 07 / 2004 A_ / _H3N2 TATLCLGHHAVPNGTIVKTITNDQIEVTNATE LVQSSSTGGICDSPHQILDGENCTLIDALLGD PQCDGFQNKKWDLFVERSKAYSNCYPYDVPDY AS LRS LVAS S GT LE FNNE S FNWT GVTQNGT S S SCKRRSNNSFFSRLNWLTHLKFKYPALNVTMP NNEKFDKLYIWGVHHPGTNNDQISLYTQASGR ITVSTKRSQQTVIPNIGSRPRVRDIPSRISIY WTIVKPGDILLINSTGNLIAPRGYFKIRSGKS SIMRSDAPIGKCNSECITPNGSIPNDKPFQNV NRITYGACPRYVKQNTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGI GQAADLKSTQAAINQINGKLNRLIGKTNEKFH QIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFERTKKQLRE NAEDMGNGCFKIYHKCDNACIGSIRNGTYDHD VYRDEALNNRFQIKGVELKS 17 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 52 A / Alaska / 01 / 2 021 A_ / _H3N2 TATLCLGHHAVPNGTIVKTITNDRIEVTNATE LVQNS SIGEICNS PHQILDGGNCTLIDALLGD PQCDGFQNKEWDLFVERSRANSSCYPYDVPDY AS LRS LVAS S GT LE FKNE S FNWT GVKQNGT S S ACIRGSSSSFFSRLNWLTSLNNIYPAQNVTMP NKEQFDKLYIWGVHHPDTDKNQFSLFAQSSGR ITVSTKRSQQAVIPNIGSRPRIRDIPSRISIY WTIVKPGDILLINSTGNLIAPRGYFKIRSGKS SIMRSDAPIGKCKSECITPNGSIPNDKPFQNV NRITYGACPRYVKQSTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGR GQAADLKSTQAAIDQISGKLNRLIGKTNEKFH QIEKEFSEVEGRVQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFEKTKKQLRE NAEDMGNGCFKIYHKCDNACIGSIRNETYDHN VYRDEALNNRFQIKGVELKS 18 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 53 A / Cambodia / eO 826360 / 2020 A_ / _H3N2 TATLCLGHHAVPNGTIVKTITNDRIEVTNATE LVQNS SIGEICDS PHQILDGGNCTLIDALLGD PQCDGFQNKEWDLFVERSRANSNCYPYDVPDY AS LRS LVAS S GT LE FKNE S FNWT GVKQNGT S S ACIRGSSSSFFSRLNWLTHLNYTYPALNVTMP NNEQFDKLYIWGVHHPSTDKDQISLFAQPSGR ITVSTKRSQQAVIPNIGSRPRIRDIPSRISIY WTIVKPGDILLINSTGNLIAPRGYFKIRSGKS SIMRSDAPIGKCKSECITPNGSIPNDKPFQNV NRITYGACPRYVKQSTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGR GQAADLKSTQAAIDQINGKLNRLIGKTNEKFH QIEKEFSEVEGRVQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFEKTKKQLRE NAEDMGNGCFKIYHKCDNACIGSIRNETYDHN VYRDEALNNRFQIKGVELKS 19 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 54 -23- WO 2024 / 220936 PCT / US2024 / 025583 A / Nanchang / 93 3 / 1995 A_ / _H3N2 TATLCLGHHAVPNGTLVKTITNDQIEVTNATE LVQSSSTGRICDSPHRILDGKNCTLIDALLGD PHCDGFQNKEWDLFVERSKAYSNCYPYDVPDY ASLRSLVASSGTLEFTNEGFNWTGVAQDGTSY ACKRGSVKSFFSRLNWLHKLEYKYPALNVTMP NNDKFDKLYIWGVHHPSTDSDQTSLYVQASGR VTVSTKRSQQTVIPNIGSRPWVRGISSRISIY WTIVKPGDILLIKSTGNLIAPRGYFKIRSGKS SIMRSDAPIGNCNSECITPNGSIPNDKPFQNV NRITYGACPRYVKQNTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGT GQAADLKSTQAAINQINGKLNRLIEKTNEKFH QIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFERTRKQLRE NAEDMGNGCFKIYHKCDNACIGSIRNGTYDHD VYRDEALNNRFQIKGVELKS 20 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 55 A / Memphi s / 1 / 1 980 A_ / _H3N2 TATLCLGHHAVPNGTLVKTITNDQIEVTNATE LVQSSSTGRICDSPHRILDGKNCTLVDALLGD PHCDGFQNEKWDLFVERSKAFSNCYPYDVPDY ASLRSLVASSGTLEFINESFNWTGVTQSGGSY ACKRGSDNSFFSRLNWLYESESKYPVLNVTMP NNGNFDKLYIWGVHHPSTDKEQTNLYVRASGR VTVSTKRSQQTIIPNIGSRPWVRGLSSRISIY WTIVKPGDILLINSNGNLIAPRGYFKIRTGKS SIMRSDAPIGTCSSECITPNGSIPNDKPFQNV NKITYGACPKYVKQNTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGT GQAADLKSTQAAIDQINGKLNRVIEKTNEKFH QIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFEKTRRQLRE NAEDMGNGCFKIYHKCDNACIGSIRNGTYDHD VYRDEALNNRFQIKGVELKS 21 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 56 A / Hong_Kong / 1 / 1968 A_ / _H3N2 TATLCLGHHAVPNGTLVKTITDDQIEVTNATE LVQSSSTGKICNNPHRILDGIDCTLIDALLGD PHCDVFQNETWDLFVERSKAFSNCYPYDVPDY AS LRS LVAS S GTLE FITE GFTWTGVTQNGGSN ACKRGPGSGFFSRLNWLTKSGSTYPVLNVTMP NNDNFDKLYIWGVHHPSTNQEQTSLYVQASGR VTVSTRRSQQTIIPNIGSRPWVRGLSSRISIY WTIVKPGDVLVINSNGNLIAPRGYFKMRTGKS SIMRSDAPIDTCISECITPNGSIPNDKPFQNV NKITYGACPKYVKQNTLKLATGMRNVPEKQTR GLFGAIAGFIENGWEGMIDGWYGFRHQNSEGT GQAADLKSTQAAIDQINGKLNRVIEKTNEKFH QIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFEKTRRQLRE NAEDMGNGCFKIYHKCDNACIESIRNGTYDHD VYRDEALNNRFQIKGVELKS 22 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 57 -24- WO 2024 / 220936 PCT / US2024 / 025583 A / Indiana / 08 / 2011 A_ / _H3N2 ATLCLGHHAVPNGTLVKTITDDQIEVTNATEL VQSSSTGGICNSPHQILDGKNCTLIDALLGDP HCDDFQNKEWDLFVERSTAYSNCYPYYVPDYA TLRSLVASSGNLEFTQESFNWTGVAQGGSSYA CRRGSVNSFFSRLNWLYNLNYKYPEQNVTMPN NDKFDKLYIWGVHHPGTDKDQTNLYVQASGRV IVSTKRSQQTVIPNIGSRPWVRGVSSIISIYW TIVKPGDILLINSTGNLIAPRGYFKIQSGKSS IMRSDAHIDECNSECITPNGSIPNDKPFQNVN KITYGACPRYVKQNTLKLATGMRNVPEKQTRG IFGAIAGFIENGWEGMVDGWYGFRHQNSEGTG QAADLKSTQAAINQITGKLNRVIKKTNEKFHQ IEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAE ILVALENQHTIDLTDSEMSKLFERTRRQLREN AEDMGNGCFKIYHKCDNACIGSIRNGTYDHDI YRNEALNNRFQIKGVQLKS 23 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 137 A / Bilthoven / 1 761 / 1976 A_ / _H3N2 TATLCLGHHAVPNGTLVKTITNDQIEVTNATE LVQSSSTGKICDNPHRILDGINCTLIDALLGD PHCDGFQNEKWDLFVERSKAFSNCYPYDVPDY AS LRS LVAS S GT LE FINE GFNWT GVTQNGGS S ACKRGPDNGFFSRLNWLYKSGSTYPVQNVTMP NNDNSDKLYIWGVHHPSTDKEQTDLYVQASGK VTVSTKRSQQTVIPNVGSRPWVRGLSSRVSIY WTIVKPGDILVINSNGNLIAPRGYFKMRTGKS SIMRSDAPIGTCSSECITPNGSIPNDKPFQNV NKITYGACPKYVKQNTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMIDGWY GFRHQNS E GT GQAADLKSTQAAIDQINGKLNRVIEKTNEKFH QIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFEKTRRQLRE NAEDMGNGCFKIYHKCDNACIGSIRNGTYDHD VYRDEALNNRFQIKGVELKS 24 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 58 A / Victoria / 36 1 / 2011 A_ / _H3N2 TATLCLGHHAVPNGTIVKTITNDQIEVTNATE LVQNS SIGEICDS PHQILDGENCTLIDALLGD PQCDGFQNKKWDLFVERSKAYSNCYPYDVPDY AS LRS LVAS S GT LE FNNE S FNWT GVTQNGT S S ACIRRSNNSFFSRLNWLTHLNFKYPALNVTMP NNEQFDKLYIWGVHHPGTDKDQIFLYAQSSGR ITVSTKRSQQAVIPNIGSRPRIRNIPSRISIY WTIVKPGDILLINSTGNLIAPRGYFKIRSGKS SIMRSDAPIGKCNSECITPNGSIPNDKPFQNV NRITYGACPRYVKQSTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGR GQAADLKSTQAAIDQINGKLNRLIGKTNEKFH QIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFEKTKKQLRE NAEDMGNGCFKIYHKCDNACIGSIRNGTYDHD VYRDEALNNRFQIKGVELKS 25 GYKDWILWISFAI SCFLLCVALLGFI MWACQKGNI RCNICI 138 -25- WO 2024 / 220936 PCT / US2024 / 025583 A / Brisbane / 10 / 2007 A_ / _H3N2 TATLCLGHHAVPNGTIVKTITNDQIEVTNATE LVQSSSTGEICDSPHQILDGENCTLIDALLGD PQCDGFQNKKWDLFVERSKAYSNCYPYDVPDY AS LRS LVAS S GT LE FNNE S FNWT GVTQNGT S S ACIRRSNNSFFSRLNWLTHLKFKYPALNVTMP NNEKFDKLYIWGVHHPGTDNDQIFLYAQASGR ITVSTKRSQQTVIPNIGSRPRVRNIPSRISIY WTIVKPGDILLINSTGNLIAPRGYFKIRSGKS SIMRSDAPIGKCNSECITPNGSIPNDKPFQNV NRITYGACPRYVKQNTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGI GQAADLKSTQAAIDQINGKLNRLIGKTNEKFH QIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFEKTKKQLRE NAEDMGNGCFKIYHKCDNACIGSIRNGTYDHD VYRDEALNNRFQIKGVELKS 26 GYKDWILWISFAI SCFLLCVALLGFI MWACQKGNIRCNI CI 139 A / Maryland / 02 / 2021 A_ / _H3N2 TATLCLGHHAVPNGTIVKTITNDRIEVTNATE LVQNS SIGEICGS PHQILDGGNCTLIDALLGD PQCDGFQNKEWDLFVERSRANSNCYPYDVPGY AS LRS LVAS S GT LE FKNE S FNWT GVKQNGT S S ACIRGSSSSFFSRLNWLTSINNIYPAQNVTMP NKEQFDKLYIWGVHHPDTDKNQISLFAQSSGR ITVSTKRSQQAVIPNIGSRPRIRDIPSRISIY WTIVKPGDILLINSTGNLIAPRGYFKIRNGKS SIMRSDAPIGRCKSECITPNGSIPNDKPFQNV NRITYGACPRYVKQSTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGR GQAADLKSTQAAIDQINGKLNRLIGKTNEKFH QIEKEFSEVEGRVQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFEKTKKQLRE NAEDMGNGCFKIYHKCDNACIGSIRNETYDHN VYRDEALNNRFQIKGVELKS 27 GYKDWILWISFAM SCFLLCIALLGFI MWACQKGNIRCNI CI 140 A / Sydney / 5 / 19 97 A_ / _H3N2 TATLCLGHHAVPNGTLVKTITNDQIEVTNATE LVQSSSTGRICDSPHRILDGENCTLIDALLGD PHCDGFQNKEWDLFVERSKAYSNCYPYDVPDY ASLRSLVASSGTLEFNNESFNWTGVAQNGTSY ACKRSSIKSFFSRLNWLHQLKYKYPALNVTMP NNDKFDKLYIWGVHHPSTDSDQTSIYAQASGR VTVSTKRSQQTVIPNIGSRPWVRGISSRISIH WTIVKPGDILLINSTGNLIAPRGYFKIRSGKS SIMRSDAPIGKCNSECITPNGSIPNDKPFQNV NRITYGACPRYVKQNTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGT GQAADLKSTQAAINQINGKLNRLIEKTNEKFH QIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFERTRKQLRE NAEDMGNGCFKIYHKCDNACIGSIRNGTYDHD VYRDEALNNRFQIKGVELKS 28 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 141 -26- WO 2024 / 220936 PCT / US2024 / 025583 B_ / _HAB B / Guangdong- Maonan / 316 / 20 21 ADRICTGITSSNSPHVVKTATQGEVNVTGVIP LTTTPTKSHFANLKGTETRGKLCPKCLNCTDL DVALGRPKCTGKIPSAKVSILHEVRPVTSGCF PIMHDRTKIRQLPNLLRGYEHVRLSTNNVINA EDAPGGPYEIGTSGSCPNITNGKGFFATMAWA VPKNKTATNPLTIEVPYICTEEEDQITVWGFH SDDETQMAKLYGDSKPQKFTSSANGMTTHYVS QIGGFPNQTEDGGLQQSGRIVVDYMVQKSGKT GTITYQRGILLPQKVWCASGKSKVIKGSLPLI GEADCLHEKYGGLNKSKPYYTGEHAKAIGNCP IWVKTPLKLANGTKYRPPAKLLKERGFFGAIA GFLEGGWEGMIAGWHGYTSHGAHGVAVAADLK STQEAINKITKNLNSLSELEVKNLQRLSGAMD E LHNEILE LDE KVDDLRADTIS S QIE LAVLLS NEGIINSEDEHLLALERKLKKMLGPSAVEIGN GCFETKHKCNQTCLDRIAAGTFDAGEFS 29 LPTFDSLNITAAS LNDDGLDNHTILL YYSTAASSLAVTL MIAIFVVYMVSRD NVSCSICL 142 B_ / _HAB B / Ann_Arbor / 1 / 1986 ADRICTGITSSNSPHVVKTATQGEVNVTGVIP LTTTPTKSHFANLKGTKTRGKLCPKCLNCTDL DVALGRPKCMGTIPSAKASILHEVKPVTSGCF PIMHDRTKIRQLPNLLRGYENIRLSTHNVINA EAAPGGPYIVGTSGSCPNVTNGNGFFATMAWA VPKNNNNKTATNPLTVEVPFICTEGEDQITVW GFHSDNEIQMVKLYGDSKPQKFTSSANGVTTH YVSQIGGFPKQAEDGGLPQSGRIVVDYMVQKS GKTGTITYQRGILLPQKVWCASGRSKVIKGSL PLIGEADCLHEKYGGLNKSKPYYTGEHAKAIG NCPIWVKTPLKLANGTKYRPPAKLLKERGFFG AIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAA DLKSTQEAINKITKNLNSLSELEVKNLQRLSG AMDE LHNEILE LDE KVDDLRADTIS S QIE LAV LLSNEGIINSEDEHLLALERKLKKMLGPSAVD IGNGCFETKHKCNQTCLDRIAAGTFNAGEF 30 LPTFDSLNITAAS LNDDGLDNHTILL YYSTAASSLAVTL MIAIFIVYMVSRD NVSCSICL 143 B_ / _HAB B / Utah / 02 / 201 2 ADRICTGITSSNSPHVVKTATQGEVNVTGVIP LTTTPTKSYFANLKGTRTRGKLCPDCLNCTDL DVALGRPMCVGTTPSAKASILHEVRPVTSGCF PIMHDRTKIRQLPNLLRGYEKIRLSTQNVIDA EKAPGGPYRLGTSGSCPNATSKIGFFATMAWA VPKDNYKNATNPLTVEVPYICTEGEDQITVWG FHSDNKTQMKSLYGDSNPQKFTSSANGVTTHY VSQIGDFPDQTEDGGLPQSGRIVVDYMMQKPG KTGTIVYQRGVLLPQKVWCASGRSKVIKGSLP LIGEADCLHEEYGGLNKSKPYYTGKHAKAIGN CPIWVKTPLKLANGTKYRPPAKLLKERGFFGA IAGFLEGGWEGMIAGWHGYTSHGAHGVAVAAD LKSTQEAINKITKNLNSLSELEVKNLQRLSGA MDELHNEILELDEKVDDLRADTISSQIELAVL LSNEGIINSEDEHLLALERKLKKMLGPSAVDI GNGCFETKHKCNQTCLDRIAAGTFNAGEF 31 LPTFDSLNITAAS LNDDGLDNHTILL YYSTAASSLAVTL MLAIFIVYMVSRD NVSCSICL 144 -27- WO 2024 / 220936 PCT / US2024 / 025583 B_ / _HAB B / Yamagata / 16 / 1988 ADRICTGITSSNSPHVVKTATQGEVNVTGVIP LTTTPTKSHFANLKGTKTRGKLCPNCLNCTDL DVALGR PMCMGTIPSAKASILHEVR PVT S GC F PIMHDRTKIRQLPNLLRGYENIRLSTHNVINA ERAPGGPYRLGTSGSCPNVTSRNGFFATMAWA VPRDNKTATNPLTVEVPYICTKGEDQITVWGF HSDDKTQMKNLYGDSNPQKFTSSANGVTTHYV SQIGDFPNQTEDGGLPQSGRIVVDYMVQKPGK TGTIVYQRGVLLPQKVWCASGRSKVIKGSLPL IGEADCLHEKYGGLNKSKPYYTGEHAKAIGNC PIWVKTPLKLANGTKYRPPAKLLKERGFFGAI AGFLEGGWEGMIAGWHGYTSHGAHGVAVAADL KSTQEAINKITKNLNSLSELEVKNLQRLSGAM DELHNEILELDEKVDDLRADTISSQIELAVLL SNEGIINSEDEHLLALERKLKKMLGPSAVDIG NGCFETKHKCNQTCLDRIAAGTFNAGEF 32 LPTFDSLNITAAS LNDDGLDNHTILL YYSTAASSLAVTL MIAIFIVYMVSRD NVSCSICL 145 B_ / _HAB B / Singapore / W UH0784 / 2021 ADRICTGITSSNSPHVVKTATQGEVNVTGVIP LTTTPTKSHFANLKGTETRGKLCPKCLNCTDL DVALGRPKCTGKIPSARVSILHEVRPVTSGCF PIMHDRTKIRQLPNLLRGYEHVRLSTHNVINT EDAPGGPYEIGTSGSCLNITNGKGFFATMAWA VPKNKTATNPLTIEVPYICTEEEDQITVWGFH SDDETQMVRLYGDSKPQKFTSSANGVTTHYVS QIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKT GTITYQRGILLPQKVWCASGKSKVIKGSLPLI GEADCLHEKYGGLNKSKPYYTGEHAKAIGNCP IWVKTPLKLANGTKYRPPAKLLKERGFFGAIA GFLEGGWEGMIAGWHGYTSHGAHGVAVAADLK STQEAINKITKNLNSLSELEVKNLQRLSGAMD E LHNE TLE LDE KVDDLRADTIS S QIE LAVLLS NEGIINSEDEHLLALERKLKKMLGPSAVEIGN GCFETKHKCNQTCLDRIAAGTFDAGEFS 33 LPTFDSLNITAAS LNDDGLDNHTILL YYSTAASSLAVTL MIAIFVVYMVSRD NVSCSICL 146 B_ / _HAB B / Colorado / 06 / 2017 ADRICTGITSSNSPHVVKTATQGEVNVTGVIP LTTTPTKSHFANLKGTETRGKLCPKCLNCTDL DVALGRPKCTGKIPSARVSILHEVRPVTSGCF PIMHDRTKIRQLPNLLRGYEHVRLSTHNVINA EGAPGGPYKIGTSGSCPNITNGNGFFATMAWA VPDKNKTATNPLTIEVPYVCTEGEDQITVWGF HSDNETQMAKLYGDSKPQKFTSSANGVTTHYV SQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGK TGTITYQRGILLPQKVWCASGRSKVIKGSLPL IGEADCLHEKYGGLNKSKPYYTGEHAKAIGNC PIWVKTPLKLANGTKYRPPAKLLKERGFFGAI AGFLEGGWEGMIAGWHGYTSHGAHGVAVAADL KSTQEAINKITKNLNSLSELEVKNLQRLSGAM DELHNEILELDEKVDDLRADTISSQIELAVLL SNEGIINSEDEHLLALERKLKKMLGPSAVEIG NGCFETKHKCNQTCLDKIAAGTFDAGEFS 34 LPTFDSLNITAAS LNDDGLDNHTILL YYSTAASSLAVTL MIAIFVVYMVSRD NVSCSICL 147 -28- WO 2024 / 220936 PCT / US2024 / 025583 B_ / _HAB B / Brisbane / 60 / 2008 ADRICTGITSSNSPHVVKTATQGEVNVTGVIP LTTTPTKSHFANLKGTETRGKLCPKCLNCTDL DVALGRPKCTGKIPSARVSILHEVRPVTSGCF PIMHDRTKIRQLPNLLRGYEHIRLSTHNVINA ENAPGGPYKIGTSGSCPNITNGNGFFATMAWA VPKNDKNKTATNPLTIEVPYICTEGEDQITVW GFHSDNETQMAKLYGDSKPQKFTSSANGVTTH YVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKS GKTGTITYQRGILLPQKVWCASGRSKVIKGSL PLIGEADCLHEKYGGLNKSKPYYTGEHAKAIG NCPIWVKTPLKLANGTKYRPPAKLLKERGFFG AIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAA DLKSTQEAINKITKNLNSLSELEVKNLQRLSG AMDE LHNEILE LDE KVDDLRADTIS S QIE LAV LLSNEGIINSEDEHLLALERKLKKMLGPSAVE IGNGCFETKHKCNQTCLDRIAAGTFDAGEFS 35 LPTFDSLNITAAS LNDDGLDNHTILL YYSTAASSLAVTL MIAIFVVYMVSRD NVSCSICL 148 B_ / _HAB B / Washington / 02 / 2019 ADRICTGITSSNSPHVVKTATQGEVNVTGVIP LTTTPTKSHFANLKGTETRGKLCPKCLNCTDL DVALGRPKCTGKIPSARVSILHEVRPVTSGCF PIMHDRTKIRQLPNLLRGYEHVRLSTHNVINA EDAPGRPYEIGTSGSCPNITNGNGFFATMAWA VPKNKTATNPLTIEVPYICTEGEDQITVWGFH SDNETQMAKLYGDSKPQKFTSSANGVTTHYVS QIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKT GTITYQRGILLPQKVWCASGRSKVIKGSLPLI GEADCLHEKYGGLNKSKPYYTGEHAKAIGNCP IWVKTPLKLANGTKYRPPAKLLKERGFFGAIA GFLEGGWEGMIAGWHGYTSHGAHGVAVAADLK STQEAINKITKNLNSLSELEVKNLQRLSGAMD E LHNEILE LDE KVDDLRADTIS S QIE LAVLLS NEGIINSEDEHLLALERKLKKMLGPSAVEIGN GCFETKHKCNQTCLDRIAAGTFDAGEFS 36 LPTFDSLNITAAS LNDDGLDNHTILL YYSTAASSLAVTL MIAIFVVYMVSRD NVSCSICL 149 B_ / _HAB B / Florida / 4 / 2 006 ADRICTGITSSNSPHVVKTATQGEVNVTGVIP LTTTPTKSYFANLKGTRTRGKLCPDCLNCTDL DVALGRPMCVGTTPSAKASILHEVKPVTSGCF PIMHDRTKIRQLPNLLRGYENIRLSTQNVIDA EKAPGGPYRLGTSESCPSATSKSGFFATMAWA VPKDNNKNATNPLTVEVPYICTEGEDQITVWG FHSDDKTQMKNLYGDSNPQKFTSSANGVTTHY VSQIGSFPDQTEDGGLPQSGRIVVDYMMQKPG KTGTIVYQRGVLLPQKVWCASGRSKVIKGSLP LIGEADCLHEKYGGLNKSKPYYTGEHAKAIGN CPIWVKTPLKLANGTKYRPPAKLLKERGFFGA IAGFLEGGWEGMIAGWHGYTSHGAHGVAVAAD LKSTQEAINKITKNLNSLSELEVKNLQRLSGA MDELHNEILELDEKVDDLRADTISSQIELAVL LSNEGIINSEDEHLLALERKLKKMLGPSAVEI GNGCFETKHKCNQTCLDRIAAGTFNAGEF 37 LPTFDSLNITAAS LNDDGLDNHTILL YYSTAASSLAVTL MLAIFIVYMVSRD NVSCSICL 150 -29- WO 2024 / 220936 PCT / US2024 / 025583 A / Roma / 1949 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDSHNGKLCRLKGIAPLQLGKCNIAGWILG NPECESLFSKKSWSYIAETPNSENGTCYPGYF ADYEELREQLSSVSSFERFEIFPKERSWPKHN VTRGVTAACSHKGKSSFYRNLLWLTEKDGSYP NLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTL YRKENAYVSVVSSNYNRRFTPEIAERPKVRGQ AGRINYYWTLLE PGDTIIFEANGNLIAPWHAF ALSRGFGSGIITSNASMDECDTKCQTPQGAIN SSLPFQNIHPVTIGECPKYVRSTKLRMVTGLR NIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGY HHQNEQGSGYAADQKSTQNAINGITNKVNSVI EKMNTQFTAVGKEFNKLEKRMENLNKKVDDGF LDIWTYNAELLVLLENERTLDFHDSNVKNLYE KVKSQLKNNAKEIGNGCFEFYHKCNNECMESV KNGTYDYPKYSEESKLNREKIDGVKLES 38 MGVYQILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQCR TCI 59 A / MD / 12 / 1991 ADTLCIGYHANNSTDTVDTVLEKNVTVTHSVN LLEDRHNGKLCKLRGVAPLHLGKCNIAGWLLG NPECELLFTASSWSYIVETSNSDNGTCYPGDF INYEELREQLSSVSSFERFEIFPKASSWPDHE TNRGVTAACPYAGANSFYRNLIWLVKKGNSYP KLSKSYVNNKEKEVLVLWGIHHPPTSTDQQSL YQNADAYVFVGSSKYNKKFKPEIATRPKVRGQ AGRMNYYWTLVEPGDTITFEATGNLVVPRYAF AMKRGSGSGIIISDTPVHDCNTTCQTPKGAIN TSLPFQNIHPVTIGECPKYVKSTKLRMATGLR NIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGY HHQNEQGSGYAADQKSTQNAIDGITNKVNSVI EKMNTQFTAVGKEFNHLEKRIENLNKKVDDGF LDVWTYNAELLVLLENERTLDYHDSNVKNLYE KVRSQLKNNAKEIGNGCFEFYHKCDDTCMESV KNGTYDYPKYSEESKLNREEIDGVKLES 39 TRIYQILAIYSTV ASSLVLLVSLGAI SFWMCSNGSLQCR ICI 60 A / Auckland / 58 8 / 2000 TATLCLGHHAVPNGTLVKTITNDQIEVTNATE LVQSSSTGGICDSPHQILDGENCTLIDALLGD PHCDGFQNKEWDLFVERSKAYSNCYPYDVPDY ASLRSLVASSGTLEFNNESFNWTGVAQNGTSS ACKRRSNKSFFSRLNWLHQLKYKYPALNVTMP NNEKFDKLYIWGVHHPSTDSDQISLYAQAPGR VTVSTKRSQQTVIPNIGSRPWVRGVSSRISIY WTIVKPGDILLINCTGNLIAPRGYFKIRSGKS SIMRSDASIGKCNSECITPNGSIPNDKPFQNV NRITYGACPRYVKQNTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGT GQAADLKSTQAAINQINGKLNRLIEKTNEKFH QIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFERTKKQLRE NAEDMGNGCFKIYHKCDNACIGSIRNGTYDHD VYRDEALNNRFQIKGVELKS 40 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 61 -30- WO 2024 / 220936 PCT / US2024 / 025583 A / Argentina / 2 8302 / 2010 TATLCLGHHAVPNGTIVKTITNDQIEVTNATE LVQSSSTGEICDSPHQILDGKNCTLIDALLGD PQCDGFQNKKWDLFVERSKAYSNCYPYDVPDY AS LR S LVAS S GT LE FNNE S FNWT GVT QD GT S S ACIRGSKNSFFSRLNWLTHLNFKYPALNVTMP NNEQFDKLYIWGVHHPGTDKDQIFLYAQASGR ITVSTKRSQQAAIPNIGSRPRVRNIPSRISIY WTIVKPGDILLINSTGNLIAPRGYFKIRSGKS SIMRSDAPIGKCNSECITPNGSIPNDKPFQNV NRITYGACPRYVKQNTLKLATGMRNVPEKQTR GIFGAIAGFIENGWEGMVDGWYGFRHQNSEGR GQAADLKSTQAAIDQINGKLNRLIGKTNEKFH QIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNA ELLVALENQHTIDLTDSEMNKLFEKTKKQLRE NAEDMGNGCFKIYHKCDNACIGSIRNGTYDHD VYRDEALNKRFQIKGIELKS 41 GYKDWILWISFAI SCFLLCVVLLGFI MWACQKGNIRCNI CI 62 B / Austria / 1359417 / 2021 ADRICTGITSSNSPHVVKTATQGEWVTGVIPLTTTPTKSHFANLKG TETRGKLCPKCLNCTDLDVALGRPKCTGKIPSARVSILHEVRPVTSG CFPIMHDRTKIRQLPNLLRGYEHVRLSTHNVINTEDAPGGPYEIGTS GSCLNITNGKGFFATMAWAVPKNKTATNPLTIEVPYICTEEEDQITV WGFHSDDETQMARLYGDSKPQKFTSSANGVTTHYVSQIGGFPNQT EDGGLPQSGRIVVDYMVQKSGKTGTITYQRGILLPQKVWCASGKS KVIKGSLPLIGEADCLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVK TPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGY TSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQRLSGA MDELHNE1LELDEKWDLRADTISSQIELAVLLSNEGIINSEDEHLLA LERKLKKMLGPSAVEIGNGCFETKHKCNQTCLDRIAAGTFDAGEFS LPTFDSLNITAASLNDDGLDNHT 42 ILLYYSTAASSLAVTLMIAIF VVYMVSRDNVSCSICL 63 Table 2. Nucleic acid sequences for a vaccine composition s E Q I D N O Nucleic Acid Sequence Strain 6 4 ATGAAAGTGAAGTTACTGGTCCTCCTTTGCACCTTTACCGCCACCTACGCTGACACCCTGTGCA A / Wisc onsin / 588 / 20 19 T T GGCTAT CAT GC CAACAACT C CACAGACAC C GT GGACACAGT GCT GGAGAAGAAC GT GACAGT GACCCACTCCGTGAACCTGCTGGAAGACAAGCACAACGGCAAACTGTGCAAGCTGAGAGGCGTG GCCCCTCTGCACCTGGGCAAGTGCAACATCGCCGGCTGGATCCTGGGCAACCCAGAGTGCGAGA GC CT GT C CACAGC C C GGT C CT GGT CT TACAT T GT GGAGACAT C CAACAGC GACAAC GGCAC CT G CTACCCTGGCGACTTCATCAATTACGAGGAGCTGAGAGAGCAGCTGAGCTCCGTGTCCAGCTTC GAGAGGT T C GAGAT CT T T C C CAAGACAAGCT C CT GGC C CAAC CAC GACAGC GACAAC GGGGT GA CAGCCGCCTGCCCTCACGCAGGCGCCAAGAGCTTCTACAAAAACCTGATCTGGCTCGTGAAGAA AGGAAAGAGCTAC C C CAAGAT CAAC CAGAC CTACAT CAAC GACAAGGGCAAGGAGGT GCT GGT G CT T T GGGGCAT C CAC CAC C CT C C CACAAT T GC C GAC CAGCAGT C C CT GTAC CAGAAC GCT GAC G CCTATGTCTTCGTGGGCACCTCTAGATACAGCAAGAAGTTCAAGCCTGAGATCGCCACAAGACC CAAGGT GC GGGAT CAGGAGGGC C GGAT GAAT TACTACT GGAC C CT GGT GGAGC CAGGC GACAAG AT CAC CT T C GAGGC CAC C GGCAAC CT GGT GGCTCCCC GATAC GC CT T CAC CAT GGAGC GGGAC G C C GGCAGC GGCAT CAT CAT CAGC GACACAC CT GT GCAC GACT GCAACAC CAC CT GC CAGAC C C C T GAAGGAGC CAT CAACAC CAGC CT GC C CT T C CAGAAT GT C CAC C C CAT CAC CAT C GGCAAAT GT C CAAAGTAC GT GAAGT C CAC CAAAC TGAGACTGGCCACCGGCCT GAGAAAC GT C C C C T CAAT C C AGAGCAGAGGCCTGTTTGGGGCCATTGCCGGCTTCATCGAGGGCGGATGGACCGGCATGGTCGA -31- WO 2024 / 220936 PCT / US2024 / 025583 C GGAT GGTAC GGATAT CAC11C CAGAAC GAACAGGGAAGC GGCTAC GC C GC C GAC CT GAAGT C C ACACAGAAC GC CAT C GACAAGAT CAC CAAC g c c GT GAACAGC GT GAT C GAGAAAAT GAACACAC AGT T CACAGC C GT GGGCAAGGAAT T CAAT CAC CT GGAGAAGAGGAT C GAGAAT CT GAACAAGAA GGTGGACGACGGCTTCCTGGACATCTGGACATACAACGCAGAGCTCCTGGTGCTGCTGgccAAT GAGC GGACACT GGACTAC CAC GACT C CAAC GT GAAGAAC CT GTAC GAGAAGGT GC GGAAT CAAC T GAAGAACAAC GC CAAGGAGAT T GGCAAC GGCTGCTTT GAGT T CTAC CACAAGT GC GACAACAC CT GTAT GGAGT C C GT GAAGAAC GGCACATAT GACTAC C C CAAGTACAGC GAAGAAGC CAAGCT G AACAGAGAGAAGAT T GAT GGAGT GAAACTGGACAGCACCCGGATCTACCAAATCCTCGCCATCT ACTCCACAGTGGCCTCTAGCCTGGTGCTCGTGGTTTCGCTGGGCGCTATCAGCTTCTGGATGTG TTCCAACGGCTCCCTGCAATGCCGGATCTGCATCtga 6 5 ATGAAAGTGAAGTTACTGGTCCTCCTTTGCACCTTTACCGCCACCTACGCCGACACCATCTGCA A / Roma / 1949T T GGCTAC CAT GC CAACAACAGCAC C GACAC C GT GGACACAGT GCT GGAAAAGAAC GT GAC C GT GACACACT CT GT GAACCT GCT GGAGGACAGCCACAACGGAAAACT GT GCAGACT GAAGGGCAT C GCCCCTCTGCAGCTGGGCAAGTGCAACATCGCCGGCTGGATCCTGGGCAATCCTGAGTGCGAGA GCCTGTTCTCTAAGAAGTCCTGGAGCTACATCGCCGAGACACCCAACAGCGAGAATGGCACCTG CTACCCTGGCTACTTCGCTGATTACGAAGAACTGAGAGAGCAGCTGAGCAGCGTCAGCTCCTTC GAAAGAT T C GAGAT CT T C C C CAAAGAAAGAAGCT GGC C CAAACACAAC GT GAC CAGGGGC GT GA CCGCCGCCTGCAGCCACAAGGGCAAGTCTTCCTTTTACCGGAACCTGCTCTGGCTGACAGAGAA GGAC GGCAGCTAC C C CAAC CT GT C CAAGAGCTAC GT GAACAACAAGGAGAAGGAGGT GCT GGT G CTCTGGGGGGT GCAC CAC C CT T CAAACAT C GAGGAT CAGAAGAC C CT GTAC C GGAAGGAGAAT G CCTATGTCTCCGTGGTGTCTTCCAACTACAATCGGAGATTCACCCCTGAGATCGCCGAGAGGCC CAAGGTGCGGGGCCAGGCCGGCAGAATCAACTACTACTGGACCCTGCTGGAACCTGGCGACACA ATCATCTTTGAGGCCAACGGCAATCTGATCGCCCCCTGGCATGCATTCGCCCTGTCCAGAGGCT T C GGCAGC GGCAT CAT TAG CAGCAAC GC CAGCAT GGAT GAGT GC GACAC CAAGT GC CAGAC C C C T CAGGGC GC CAT CAAT T CAAGC CT GC CT T T C CAGAACAT C CAT C CT GT GAC CAT T GGC GAGT GT C C CAAGTAC GT GAGAAGCACAAAGCT GAGAAT GGT GAC C GGACT GAGAAACAT C C CT T C CAT T C AGAGC CGGGGCCTGTTTGGCGC CAT CGCCGGCTT CAT C GAGGGC GGCT GGAC C GGCAT GAT C GA C GGCT GGTAC GGCTAC CAT 11C CAGAAC GAACAGGGCAGC GGCTAC GC C GCT GAT CAGAAGT C C ACACAGAAC GC CAT CAAC GGCAT CAC CAAC g c c GT GAACAGC GT GAT C GAGAAGAT GAACACAC AGT T CAC C GC C GT GGGCAAGGAGT T CAACAAACT GGAGAAGAGAAT GGAGAAT CT GAACAAGAA GGTGGACGACGGCTTCCTGGACATCTGGACCTACAATGCTGAGCTGCTGGTGCTGCTGgccAAC GAAAGAAC CCTCGACTTCCACGACTC CAAC GT GAAGAAC C T GTAC GAGAAGGT GAAGT CACAGC T GAAAAACAAC GC CAAGGAGAT C GGCAAC GGCTGCTTC GAGT T CTAC CACAAGT GCAACAAC GA GT GTAT GGAGT C C GT GAAGAAT GGCAC CTAC GAT TAG C C CAAGTACAGC GAGGAGAGCAAGCT G AACAGAGAAAAGAT C GAC GGAGT GAAGCTGGAGAGCATGGGCGTGTATCAAATCCTCGCCATCT ACTCCACAGTGGCCTCTAGCCTGGTGCTCCTGGTTTCGCTGGGCGCTATCAGCTTCTGGATGTG TTCCAACGGCTCCCTGCAATGCCGGATCTGCATCtga 6 6 ATGAAAGTGAAGTTACTGGTCCTCCTTTGCACCTTTACCGCCACCTACGCCGACACCCTGTGCA A / MD / 1 2 / 1991T T GGCTAC CAT GC CAACAACT CAACAGACAC C GT GGACACAGT GCT GGAGAAGAAC GT GAC C GT GACACACAGC GT GAAT CT GCT GGAGGAC C GGCACAAC GGCAAACT GT GCAAGCT GAGAGGC GT G GCTCCCCTGCACCTGGGCAAGTGCAACATCGCCGGATGGCTGCTGGGAAACCCAGAGTGCGAAC TACTGTTCACCGCCAGCTCCTGGAGCTACATCGTGGAAACCTCCAACAGCGACAACGGCACATG CTACCCTGGCGACTTCATCAATTACGAAGAACTGCGGGAACAGCTGTCCTCAGTGAGCAGCTTC GAAAGATTTGAGATCTTCCCAAAGGCCTCCTCTTGGCCCGACCACGAAACCAACCGGGGCGTGA CCGCCGCCTGTCCCTACGCCGGAGCCAACAGCTTCTACAGAAATCTGATTTGGCTGGTGAAGAA AGGCAACTCCTACCCCAAACTGAGCAAGAGCTACGTGAACAACAAAGAAAAGGAGGTGCTGGTG CTCTGGGGCATCCACCACCCTCCGACCTCCACAGACCAGCAAAGCCTGTACCAGAATGCTGACG C CTAC GT CT T C GT GGGCAGCT C CAAGTACAACAAGAAGT T CAAGC C C GAGAT C GC CAC C C GGC C AAAGGTGCGGGGCCAGGCCGGCAGAATGAACTACTACTGGACACTGGTGGAGCCTGGCGACACC AT CACAT T C GAGGC CAC C GGCAAC CT GGT GGT GC C CAGATAC GCCTTCGC CAT GAAGAGAGGCT CT GGAT C C GGCAT CAT CAT CAGC GACAC C C CT GT GCAC GACT GCAACAC CACAT GC CAGAC C C C CAAGGGC GC CAT CAACAC CAGCT TAC CT T T C CAGAACAT C CAC C CT GT GAC CAT C GGAGAAT GT C C CAAGTAC GT GAAGT CAACAAAGCT GC GGAT GGC CACAGGACT GAGAAACAT C C C CAGCAT C C AGTCCAGAGGACTGTTTGGCGCCATCGCCGGCTTCATCGAGGGCGGCTGGACCGGAATGATCGA T GGAT GGTAC GGCTAC CAC 11C CAGAAT GAGCAGGGCAGC GGCTAC GC C GCT GAT CAGAAGT C C -32- WO 2024 / 220936 PCT / US2024 / 025583 AC C CAGAAT GC CAT C GAC GGCAT CAC CAAC g c c GT GAACT CT GT GAT C GAGAAGAT GAACAC C C AGT T TAG C GC C GT GGGAAAGGAGT T CAAT CAC CT GGAGAAGAGAAT C GAAAAC CT GAACAAGAA GGTGGACGACGGCTTCCTGGACGTGTGGACCTACAACGCTGAACTGCTGGTGCTGCTGgccAAT GAGAGAAC C CT GGACTAC CAC GACT C CAAC GT GAAGAAC CT GTAC GAGAAAGT GC GGAGC CAGC T GAAAAACAAC GC CAAGGAGAT T GGAAAT GGCTGCTTC GAAT T CTAC CACAAGT GC GAC GACAC AT GTAT GGAGT C C GT GAAAAAC GGCAC CTAC GACTAC C C CAAGTACAGC GAGGAAAGCAAGCT G AACAGAGAGGAGAT C GAT GGGGT GAAACTGGAGAGCACCCGGATCTACCAAATCCTCGCCATCT ACTCCACAGTGGCCTCTAGCCTGGTGCTCCTGGTTTCGCTGGGCGCTATCAGCTTCTGGATGTG TTCCAACGGCTCCCTGCAATGCCGCATCTGCATCtga 6 7 ATGAAAGTGAAGTTACTGGTCCTCCTTTGCACCTTTACCGCCACCTACGCCGACACCATCTGCA A / Denv er / 57T T GGATAC CAT GC CAACAACAGCAC C GACAC C GT GGACACAGT GCT GGAAAAGAAC GT GAC C GT GAC C CACAGC GT GAAC CT GCT GGAAGACAGC CACAAC GGCAAACT GT GCAGACT GAAGGGCAAG GCCCCCCTGCAGCTGGGAAACTGCAACATCGCCGGATGGGTGCTGGGAAATCCCGAGTGCGAGA GCCTGCTGAGCAACAGGAGCTGGAGCTACATCGCTGAAACCCCCAACAGCGAGAACGGCACCTG CTATCCTGGCGACTTCGCTGACTACGAGGAACTGCGGGAGCAGCTGTCCTCCGTGTCCTCCTTT GAAAGATTTGAGATCTTCCCCAAGGAGCGGAGCTGGCCCAACCACACAACCAGGGGCGTGACCG CCGCCTGCCCTCATGCCAGAAAGAGCAGCTTCTACAAGAATCTGGTCTGGCTGACCGAGGCCAA TGGCAGCTATCCCAACCTGTCCAGAAGCTACGTGAACAACCAGGAGAAGGAGGTGCTGGTCCTG T GGGGGGT GCAC CAC C C CAGCAACAT C GAGGAGCAGAGAGC C CT GTACAGAAAGGACAAC GC CT AT GT CAGC GT GGT GT C CAGCAACTACAACAGAC GGT T CAC C C C C GAAAT TGC CAAGC GGC C CAA GGTGCGGGATCAGAGCGGCCGGATGAACTACTACTGGACCCTGCTGGAGCCTGGAGACACCATC ATCTTCGAGGCCACCGGCAACCTGATCGCCCCTTGGTACGCCTTCGCCCTGAGCAGAGGCCCTG GCAGC GGCAT CAT CAC CAGCAAT GC C C C C CT GGAC GAGT GC GACACAAAGT GT CAGAC C C C C CA GGGC GC CAT CAACAGCT C CCTGCCCTTT CAGAACAT C CAC C CT GT GACAAT C GGGGAGT GC C C C AAGTAC GT GAGAAGCAC CAAGCT GC GGAT GGT GAC CGGCCTGC GGAACAT TCCCTCTGT GCAGT CCCGGGGCCTGTTTGGGGC CAT CGCCGGCTT CAT C GAGGGC GGCT GGAC C GGCAT GAT GGAC GG CTGGTACGGCTACCACttCCAGAACGAACAAGGCTCCGGCTACGCCGCTGACCAAAAGTCCACC CAGAAT GCAAT CAAC GGCAT CAC CAAC g c c GT GAAT T C C GT GAT C GAGAAGAT GAACAC C CAGT T CACAGC C GT GGGCAAGGAGT T CAACAAGCT GGAAAAGC GGAT GGAGAAC CT GAACAAGAAAGT GGACGACGGCTTCATGGACATCTGGACCTACAACGCTGAACTGCTGGTGCTGCTGgccAATGAA AGAACAC TGGACTTCCACGACTC CAAC GT GAAGAAC C T GTAT GAGAAGGT GAAGAAT CAGC T CA GAAACAAC GC CAAAGAGCT GGGCAAC GGCTGCTTC GAGT T CTAC CACAAGT GC GACAAC GAGT G TAT GGAGT C C GT GAAGAAC GGCACATAC GACTAC C C CAAGTACAGC GAGGAGAGCAAGCT GAAC AGGGAGAAGAT C GAT GGC GT GAAGCT GGAGT C CATGGGCGTCTACAGAATCCTCGCCATCTACT CCACAGTGGCCTCTAGCCTGGTGCTCCTGGTTTCGCTGGGCGCTATCAGCTTCTGGATGTGTTC CAACGGCTCCCTGCAATGCCGGATCTGCATCtga 6 8 ATGAAAGTGAAGTTACTGGTCCTCCTTTGCACCTTTACCGCCACCTACGCTGACACCATCTGCA A / Puer to_Ric 0 / 8 / 19 34 T T GGCTAC CAT GC CAACAACT C CAC C GACAC C GT GGACACAGT GCT GGAGAAGAAC GT GAC C GT GACACATTCCGTGAACCTGCTGGAGGATTCTCACAACGGCAAGCTCTGTCGGCTGAAGGGCATC GCCCCTCTGCAGCTGGGCAAGTGCAACATCGCCGGCTGGCTGCTGGGCAACCCCGAGTGCGACC CTCTGCTGCCCGTGAGATCCTGGTCCTACATTGTGGAAACCCCTAACAGCGAGAACGGCATCTG CTACCCTGGCGACTTCATTGATTACGAGGAGCTGCGGGAGCAGCTGTCCTCAGTGAGCAGCTTC GAGAGGT T T GAGAT CT T C C C CAAGGAGT CCTCTTGGCC CAAC CACAACACAAACAAGGGC GT CA CCGCCGCCTGCAGCCATGAGGGAAAGAGCAGCTTCTACAGAAACCTGCTGTGGCTGACAGAGAA GGAGGGCTCCTACCCCAAGCTGAAGAATTCCTACGTGAACAAGAAAGGCAAAGAGGTGCTGGTG CT GT GGGGGAT C CAC CAC C CT C C CAAT T C CAAGGAACAGCAGAAC CT GTAC CAGAAC GAAAAC G CCTACGTCTCTGTGGTGACCTCCAACTACAACAGAAGATTCACCCCTGAGATCGCAGAGCGGCC CAAGGTGCGGGACCAAGCCGGCAGAATGAACTACTACTGGACCCTGCTGAAGCCTGGCGACACA ATCATCTTCGAGGCCAATGGAAACCTGATCGCCCCAATGTACGCCTTCGCCCTGTCCCGGGGCT T C GGAAGC GGCAT CAT CACAAGCAAC GC CT C CAT GCAC GAGT GCAACAC CAAGT GC CAGAC C C C ACTGGGCGCCATCAATTCCTCTCTCCCTTACCAGAACATCCACCCTGTGACCATCGGGGAATGC C C CAAGTAC GT GAGAT C C GC CAAGCT GC GGAT GGT GAC C GGC CT GAGAAACAT C C C CAGCAT T C AGAGCAGGGGCCTGTTTGGAGCCATCGCTGGCTTCATCGAGGGCGGATGGACCGGCATGATCGA C GGCT GGTAC GGCTAC CAC 11C CAGAAT GAACAGGGCT C C GGCTAC GCAGC C GAT CAGAAAAGC ACACAGAAT GC CAT CAAC GGCAT CAC CAAC g c c GT GAACAC C GT GAT C GAAAAGAT GAACAT C C -33- WO 2024 / 220936 PCT / US2024 / 025583 AGT T CAC C GC C GT GGGCAAGGAGT T CAACAAGCT GGAGAAGAGAAT GGAGAAC CT GAACAAGAA GGTGGACGACGGCTTTCTGGACATTTGGACATACAATGCTGAGCTGCTGGTGCTGCTGgccAAT GAGAGGAC C CT GGACT T T CAC GACT C CAAC GT GAAAAAC CT GTAC GAAAAGGT CAAGAGC CAGC T GAAGAACAAT GC CAAGGAGAT C GGCAAC GGCTGCTTC GAGT T CTAC CACAAGT GC GACAAC GA GTGTATGGAGTCCGTGAGAAACGGCACCTATGACTACCCCAAGTACTCTGAGGAGTCCAAACTG AACAGAGAGAAGGT GGACGGAGT GAAGCTGGAGTCTATGGGCATCTACCAAATCCTCGCCATCT ACTCCACAGTGGCCTCTAGCCTGGTGCTCCTGGTTTCGCTGGGCGCTATCAGCTTCTGGATGTG TTCCAACGGCTCCCTGCAATGCCGCATCTGCATCtga 6 9 ATGAAAGTGAAGTTACTGGTCCTCCTTTGCACCTTTACCGCCACCTACGCCGACACCATCTGCA A / Bris bane / 5 9 / 2007 T T GGCTAT CAT GC CAACAAT T C CACAGACAC C GT GGACACAGT GCT GGAGAAGAAC GT GAC C GT GACCCACTCTGTGAACCTGCTGGAGAACTCTCACAACGGCAAACTGTGCCTGCTGAAGGGCATC GCCCCTCTGCAGCTCGGCAACTGCAGCGTGGCCGGCTGGATCCTGGGCAACCCAGAGTGCGAAC TGCTGATCTCCAAGGAAAGCTGGAGCTACATCGTGGAGAAGCCCAACCCCGAGAACGGCACCTG TTACCCTGGCCACTTTGCCGACTACGAGGAGCTGCGGGAACAGCTGTCTTCCGTGTCCTCCTTC GAAAGAT T C GAGAT CT T T C C CAAGGAGAGCT C CT GGC C CAAC CACACAGT GACAGGC GT CT C C G CCAGCTGCTCCCACAATGGCGAGTCCTCTTTCTACAGAAACCTGCTGTGGCTGACCGGCAAGAA CGGCCTGTATCCCAACCTGAGCAAGAGCTACGCCAACAACAAGGAGAAGGAAGTGCTGGTGCTG T GGGGGGT GCAC CAC C CT C C GAACAT C GGCAAT CAGAAGGC C CT GTAT CACACAGAAAAC GC CT AC GT CAGC GT GGT GT C CT C C CACTACAGCAGAAAGT T CAC C C CT GAGAT C GC CAAGC GGC C CAA AGT GC GGGAT CAGGAGGGC C GGAT CAAT TACTACT GGAC C CT GCT GGAAC CAGGC GACACAAT C ATCTTTGAGGCCAACGGCAACCTGATCGCCCCAAGATACGCCTTCGCCCTGAGCAGAGGCTTCG GCT CT GGCAT CAT CAACAGCAAT GC C C C GAT GGACAAGT GC GAT GC CAAGT GC CAGAC C C CACA GGGC GC CAT CAACAGCAGC CT GC CT T T C CAGAAT GT C CAC C C C GT GACAAT T GGC GAGT GT C C C AAGTAC GT GAGAAGC GC CAAGCT GC GGAT GGT GAC CGGCCTGC GGAACAT C C CT T C CAT T CAGA GCAGAGGC CT GT T T GGC GC CAT C GC C GGAT T CAT T GAAGGC GGCT GGAC C GGCAT GGT GGAC GG CTGGTACGGCTACCACttCCAGAACGAACAGGGCTCTGGCTACGCCGCTGACCAAAAGTCCACC CAGAAT GC CAT CAAC GGCAT CAC CAAC g c c GT CAACAGC GT GAT C GAGAAGAT GAACAC C CAGT TCACCGCTGTGGGCAAAGAGTTCAACAAGCTGGAGCGGCGGATGGAAAACCTGAACAAAAAGGT GGACGACGGCTTCATCGACATTTGGACATACAACGCAGAGCTGCTGGTGCTGCTGgccAATGAG AGAAC C CT GGAT T T C CAC GACAGCAAC GT GAAGAAC CT GTAC GAGAAGGT CAAAT C C CAGC T GA AAAACAAC GC CAAGGAGAT C GGCAAT GGCTGCTTC GAGT T CTAC CACAAGT GCAAC GAT GAGT G TAT GGAGT C C GT GAAAAAC GGCAC CTAC GACTAC C C GAAGTACAGC GAGGAAAGCAAGCT CAAT C GGGAGAAGAT C GAC GGAGT GAAGCTGGAGAGCATGGGCGTGTATCAAATCCTCGCCATCTACT CCACAGTGGCCTCTAGCCTGGTGCTCCTGGTTTCGCTGGGCGCTATCAGCTTCTGGATGTGTTC CAACGGCTCCCTGCAATGCCGGATCTGCATCtga 7 0 ATGAAAGTGAAGTTACTGGTCCTCCTTTGCACCTTTACCGCCACCTACGCTGACACCCTGTGCA A / Cali fornia / 07 / 20 09 T T GGCTAT CAT GC CAACAACAGCAC C GACACAGT GGACACAGT GCT GGAAAAGAAC GT GAC C GT GACACACT CCGT GAACCT GCT GGAGGACAAGCACAACGGCAAACT GT GCAAGCT GAGAGGC GT G GCCCCTCTGCACCTGGGCAAGTGCAACATCGCCGGCTGGATCCTGGGCAACCCAGAGTGCGAGA GCCTGAGCACCGCCAGCTCCTGGTCTTACATCGTGGAGACACCCAGCTCCGACAACGGCACATG CTACCCTGGCGACTTCATCGACTACGAGGAACTGAGAGAGCAGCTGAGCTCCGTGTCCTCTTTC GAGAGGT T C GAGAT CT T C C C CAAGAC CT CAT CT T GGC C CAAC CAC GACAGCAACAAGGGC GT GA CCGCCGCCTGTCCTCACGCTGGCGCAAAGAGCTTCTACAAGAACCTGATCTGGCTCGTGAAGAA GGGAAACAGCTACCCCAAGCT GAGCAAGAGCTACAT CAAT GACAAAGGCAAGGAGGT GCT GGT G CTAT GGGGCAT C CAT CAC C C CAGCACAAGC GCT GAC CAGCAGAGC CT GTAT CAGAAC GCT GAC G C CTAC GT CT T C GT C GGCAGCT C C C GGTACAGCAAGAAAT T CAAGC C C GAGAT C GC CAT C C GGC C CAAGGTGCGGGACCAAGAGGGCAGAATGAACTACTACTGGACCCTGGTGGAGCCTGGCGACAAG AT CAC CT T T GAGGC CACAGGCAAT CT GGT GGT GC C CAGATAC GCCTTTGC CAT GGAGAGAAAT G CCGGCTCC GGCAT CAT CAT CAGC GACACAC CT GT GCAC GACT GCAACAC CAC CT GT CAGACAC C CAAGGGC GC CAT CAACACAAGC CT GC CT TTT CAGAACATT CACCCCAT CACCATT GGCAAGT GC C C CAAGTAC GT CAAGAGCAC CAAACT GC GGCT GGC CACAGGACT GC GGAACAT C C C CAGCAT T C AGAGCCGGGGCCTGTTTGGAGCCATCGCTGGCTTCATCGAGGGCGGCTGGACCGGCATGGTGGA CGGCTGGTACGGCTACCATttCCAGAATGAACAGGGCAGCGGCTACGCCGCTGACCTGAAGTCC ACCCAGAACGCCAT CGACGAAAT CACCAACc t gGT CAACT CT GT GAT CGAAAAGAT GAACACCC AGT T CAC C GC C GT GGGAAAAGAGT T CAAC CAC CT GGAGAAGAGGAT C GAAAAT CT GAACAAAAA -34- WO 2024 / 220936 PCT / US2024 / 025583 7 1 GGTGGACGACGGCTTTCTGGACATCTGGACCTACAACGCAGAGCTCCTGGTGCTGCTGctgAAT GAAAGAACACT GGACTAC CAC GACT C CAAC GT CAAGAAC CT GTAC GAGAAGGT GC GGAGC CAGC T GAAGAACAAC GC CAAGGAGAT C GGCAAC GGCTGCTTC GAGT T CTAC CACAAGT GC GACAACAC CTGTATGGAGTCCGTGAAGAACGGCACATACGACTACCCCAAGTACTCTGAAGAGGCCAAGCTG AACAGAGAGGAGAT T GAT GGAGT GAAGCT GGAGT C CACCCGGATCTACCAAATCCTCGCCATCT ACTCCACAGTGGCCTCTAGCCTGGTGCTCGTGGTTTCGCTGGGCGCTATCAGCTTCTGGATGTG TTCCAACGGCTCCCTGCAATGCCGGATCTGCATCtga ATGAAAGTGAAGTTACTGGTCCTCCTTTGCACCTTTACCGCCACCTACGCCGACACCAT CT GCA T T GGCTAC CAT GC CAACAACAGCAC C GACAC C GT GGACACAGT GCT GGAGAAGAAC GT GACAGT GACACACTCTGTGAACCTGCTGGAGGACTCCCACAACGGAAAGCTGTGCCTGCTGAAGGGAATC GCCCCTCTGCAGCTGGGCAACTGTTCCGTCGCCGGCTGGATCCTGGGCAATCCTGAGTGCGAGA GCCTGATCTCCAAAGAATCTTGGTCCTACATCGTGGAGACACCCAACCCAGAGAACGGCACCTG CTACCCCGGATACTTTGCCGACTACGAGGAGCTGCGGGAGCAACTGTCCTCAGTGAGCAGCTTC GAAAGAT T C GAGAT CT T C C C CAAAGAGAGCT CT T GGC C CAAC CACACAGT GACAGGC GT GACAG CCTCCTGCAGCCACAACGGAAAGAGCAGCTTCTACAGAAATCTGCTGTGGCTCACCGAGAAGAA TGGCCTGTATCCCAACCTCTCCAACAGCTACGTGAACAACAAGGAGAAGGAAGTGCTGGTGCTA T GGGGGGT GCAC CAC C C CAGCAACAT C C GGGAC CAGC GGGC CAT CTAC CACACAGAGAAC GC CT ACGTCAGCGTGGTGTCCTCCCACTACTCTCGGAGATTCACTCCCGAGATCGCCAAGCGGCCCAA GGTGCGGGGC CAGGAGGGC C GGAT CAAT TACTACT GGAC C CT GCT GGAAC CAGGC GACAC CAT C ATCTTCGAGGCCAACGGCAATCTCATCGCCCCCTGGTACGCTTTCGCCCTGTCTCGGGGCTTCG GCT C C GGCAT CAT CACAAGCAAC GC C C C CAT GAAT GAGT GC GAT GC CAAGT GC CAGACAC C C CA GGGCGCCATCAACAGCTCCCTGCCCTTCCAGAACGTCCACCCTGTGACCATCGGAGAGTGTCCC AAGTAC GT GAGAT C CAC CAAGCT GAGAAT GGT GAC C GGC CT GAGAAACAT T C C CAGCAT C CAGA GCAGAGGCCTGTTCGGAGCCATCGCCGGATTCATTGAGGGAGGATGGACCGGCATGATGGACGG CT GGTAC GGCTAC CAC 11C CAGAAT GAGCAGGGAAGC GGCTAC GC C GCT GAC CAGAAAT C CACA CAGAAC GC CAT CAAC GGCAT CAC CAAC c t g GT GAACAGC GT GAT C GAAAAGAT GAACAC C CAGT T CAC C GC C GT GGGCAAAGAGT T CAACAAGCT GGAAAGAAGAAT GGAGAAC CT GAACAAGAAAGT GGACGACGGCTTCCTGGACATCTGGACATACAACGCAGAGCTGCTGGTGCTGCTGctgAATGAG AGAACACT GGACT T C CAC GACAGCAAC GT CAAAAAC CT GTAC GAGAAGGT GAAGT CACAGC T GA AAAACAAC GC CAAGGAGAT C GGCAAT GGCTGCTTC GAAT T CTAC CACAAGT GCAACAAC GAGT G TATGGAATCCGTGAAGAACGGCACCTACGACTACCCGAAGTACTCTGAGGAGAGCAAACTGAAC AGAGAGAAAAT C GAC GGGGT GAAGCTGGAGAGCATGGGCGTGTATCAAATCCTCGCCATCTACT CCACAGTGGCCTCTAGCCTGGTGCTCCTGGTTTCGCTGGGCGCTATCAGCTTCTGGATGTGTTC CAACGGCTCCCTGCAATGCCGGATCTGCATCtga 7 ATGAAAGTGAAGTTACTGGTCCTCCTTTGCACCTTTACCGCCACCTACGCCGACACAATCTGCA 2 T T GGCTAC CAT GC CAACAACAGCACAGACAC C GT GGACAC C GT C CT GGAGAAAAAC GT GACAGT GACCCACAGCGTGAACCTGCTGGAAGACTCCCACAATGGAAAACTGTGCAAGCTGAAGGGCATC GCCCCTCTGCAGCTGGGCAAGTGCAACATCGCCGGCTGGCTGCTGGGCAACCCAGAGTGCGACC T GCT GCT GACAGC CAGTAGCT GGAGCTACAT C GT GGAAAC CAGCAACAGC GAAAAT GGCACAT G CTACCCTGGCGACTTCATCGATTACGAGGAGCTGCGGGAGCAGCTGAGCAGCGTCAGCTCTTTC GAGAAGT T T GAGAT CT T C C C CAAAAC CT CAAGCT GGC C CAAC CAC GAAAC CACAAAGGGC GT GA CCGCCGCCTGCAGCTACGCAGGCGCCAGCTCTTTCTACAGAAACCTGCTGTGGCTGACAAAGAA GGGGAGCAGCTACCCCAAGCTCTCCAAAAGCTACGTGAACAACAAGGGCAAGGAGGTGCTGGTG CTAT GGGGGGT GCAT CAC C CT C CAAC C GGCAC C GAC CAGCAGAGC CT GTAC CAGAAC GC C GAC G CCTACGTCTCCGTGGGCTCCTCCAAGTACAACAGAAGATTCACCCCTGAGATCGCTGCTCGGCC CAAGGTGCGGGACCAGGCCGGAAGGATGAACTACTACTGGACCCTGCTGGAGCCTGGCGACACA ATCACCTTCGAGGCCACAGGCAACCTGATCGCCCCTTGGTACGCCTTCGCTCTCAACAGAGGCT C C GGCAGC GGCAT CAT CAC CT C C GAC GC C C CT GT GCAC GACT GCAACACAAAGT GC CAGAC C C C T CAC GGGGC CAT CAACT C CAGC CT GC CT T T C CAGAACAT C CAC C CT GT GAC CAT C GGAGAAT GC C C CAAGTACGT GAGAAGCACCAAGCT GAGAAT GGCCACAGGCCT GAGAAACATCCCTT CCAT CC AGAGCAGGGGCCT GTTT GGGGCCAT CGCCGGCTT CAT CGAGGGCGGCT GGACCGGCAT GAT CGA C GGCT GGTAC GGCTAC CAC 11C CAGAAC GAACAGGGCT C C GGCTAC GC C GC C GACAGAAAGT C C AC C CAGAAT GC CAT T GAC GGCAT CAC CAAC c t g GT GAAT T C C GT GAT C GAGAAGAT GAACAC C C AGT T CAC CAGC GT GGGAAAAGAGT T CAAC CAC CT GGAGAAGAGAAT C GAGAAC CT GAACAGGAA GGTGGATGACGGCTTCCTGGACGTGTGGACATACAACGCTGAACTGCTGGTGCTGCTGctgAAC A / Beij ing / 2 6 2 / 1995 A / New_ York / 1 / 1918 -35- WO 2024 / 220936 PCT / US2024 / 025583 GAAAGAAC C CT GGACTAC CAC GACAGCAAC GT GAAGAAC CT GTAC GAGAAGGT GC GGAGC CAGC T GAAGAACAAC GC CAAGGAAAT C GGCAAT GGCTGTTTC GAAT T CTAC CACAAGT GC GAC GACAG CT GTAT GGAAT C C GT GAAAAAC GGCACATAC GACTAG C C CAAGTACAGC GAGGAGAGCAAGCT G AACAGAGAGGAAAT C GAT GGC GT GAAACT GGAGT C CATGGGCGTGTATCAAATCCTCGCCATCT ACTCCACAGTGGCCTCTAGCCTGGTGCTCCTGGTTTCGCTGGGCGCTATCAGCTTCTGGATGTG TTCCAACGGCTCCCTGCAATGCCGGATCTGCATCtga 7 3 ATGAAAGTGAAGTTACTGGTCCTCCTTTGCACCTTTACCGCCACCTACGCTGACACCCTGTGCA A / Wisc onsin / 28 / 201 1.2011 / 12 T T GGCTAC CAT GC CAACAACAGCAC C GACAC C GT C GACACAGT C CT GGAAAAGAAC GT GACAGT GACCCACTCCGTGAATCTGCTGGAAAACAGACACAACGGCAAACTGTGCAAGCTGCGGGGCGTG GCCCCTCTGCACCTGGGCAAATGCAACATCGCCGGATGGCTGCTGGGCAACCCAGAGTGCGAAA GC CT GAGCAC C GC CAGCT CT T GGT C CTACAT C GT C GAAAC CAGCAACAGC GACAAT GGCACAT G CTACCCTGGCGACTTCATCAACTACGAGGAACTGAGAGAGCAGCTGAGCTCTGTGTCCTCCTTC GAGAGGT T T GAGAT CT T C C C CAAGAC CT CAAGCT GGC C CAAT CAC GACACAAACAGAGGAGT GA CCGCCGCCTGTCCTCACGATGGAACCAACAGCTTCTACAGAAATCTGATCTGGCTCGTGAAGAA GGGCAACT CT TAC C C CAAGAT CAACAAGT CT TACAT CAACAACAAAGAGAAGGAAAT T CT GGT G CTGTGGGCCATCCACCACCCCAGCACCTCCGCTGACCAGCAAAGCCTGTACCAGAACGCTGACG C CTAC GT CT T C GT GGGCAGCT C C C GGTACAGCAGAAAGT T C GAAC CT GAAGT GGC CAC C C GGC C CAAGGTGCGGGACCAGGCCGGCAGAATGAACTACTACTGGACCCTGGTCGAACCTGGCGACAAG ATCACCTTCGAAGCCACCGGAAACCTGGTGGTGCCCAGATACGCCTTCGCCCTGAAGAGAAATT C GGGCAGC GGCAT CAT CAT CAGC GACACAT C C GT C CAC GACT GC GACAC CAACT GT CAGAC C C C AAAT GGGGC CAT CAACAC CAGC CT GC CT T T C CAGAACAT C CAC C CT GT CAC CAT C GGAGAGT GC C C CAAGTAC GT GAAGT C CACAAAGCT GAGAAT GGC CAC CGGCCTGC GGAACAT C C C CAGCAT C C AGAGCCGGGGACTGTTTGGCGCCATCGCCGGCTTCATCGAGGGCGGCTGGACCGGCATGATCGA CGGCTGGTACGGCTACCACttCCAGAATGAGCAGGGCAGCGGCTACGCCGCTGACCTGAAGTCC ACACAGAAC GC CAT C GAC GGCAT CAC CAAC c t g GT GAACAGC GT GAT C GAGAAAAT GAACAC C C AGT T CAC C GC C GT GGGCAAGGAAT T CT C C CAC CT GGAGAGAC GGAT T GAGAAC CT GAACAAGAA GGTGGACGACGGCTTTCTGGACATCTGGACCTACAACGCTGAACTGCTGGTGCTGCTGctgAAT GAGAGAACACT GGACTAC CAC GAT T C CAAT GT CAAAAAC CT GTAT GAGAAAGT GC GGAGC CAGC T GAAGAACAAT GC CAAGGAAAT T GGCAAC GGCTGTTTC GAGT T CTAC CACAAGT GC GAT GATAT GT GTAT GGAGT C C GT GAAGAAT GGAACATAC GACTAC C C CAAGTACAGC GAAGAGGC CAAGCT G AACAGAGAGGAGAT C GAC GGGGT GAAGCTGGAGTCTACCCGGATCTACCAAATCCTCGCCATCT ACTCCACAGTGGCCTCTAGCCTGGTGCTCGTGGTTTCGCTGGGCGCTATCAGCTTCTGGATGTG TTCCAACGGCTCCCTGCAATGCCGGATCTGCATCtga 7 4 ATGAAAACGATCATCGCCCTATCCTACATCCTATGCCTCGTCTTCGCCCAAAAACTCCCCGGCA A / Alas ka / 01 / 2021 AC GACAACAGCACAGCCACACT GT GCCTGGGCCAT CACGCT GT GCCCAACGGAACCAT CGT GAA GAC CAT TAG CAAC GACAGAAT C GAAGT GACAAAT GC CACAGAGCT GGT GCAGAACAGCAGCAT T GGCGAGATCTGCAACAGCCCTCACCAGATCCTGGACGGAGGCAACTGCACACTGATCGATGCCC TGCTCGGCGACCCTCAGTGCGATGGCTTCCAGAACAAGGAGTGGGACCTGTTCGTGGAAAGAAG CAGAGCCAACAGCTCCTGCTACCCCTACGACGTCCCTGACTACGCCAGCCTGCGGAGCCTGGTG GC CT C CAGC GGCAC C CT GGAGT T CAAAAAC GAAAGCT T CAAT T GGAC C GGAGT GAAACAGAAC G GCACCTCCAGCGCCTGTATCAGAGGCTCCAGCAGCTCTTTCTTCAGCAGACTGAACTGGCTGAC AAGC CT GAACAACAT T TAG C C C GC C CAGAAC GT GACAAT GC C CAACAAGGAGCAGT T T GACAAA CTGTACATCTGGGGAGTGCACCACCCTGATACCGACAAAAACCAGTTCTCCCTGTTCGCCCAGT CT T C C GGCAGAAT CAC C GT GT CTAC CAAGC GGAGC CAGCAGGC C GT GAT C C C CAACAT C GGCAG CCGGCCCCGGATTCGGGACATCCCTTCCCGGATCAGCATTTACTGGACCATCGTGAAGCCTGGA GACATTCTCCTGATCAACAGCACCGGCAACCTGATCGCCCCTCGGGGCTACTTCAAGATCAGAA GC GGCAAGT C CAGCAT CAT GAGAT CT GAC GC C C CTAT C GGCAAGT GCAAGT CT GAGT GTAT CAC AC C CAAC GGCAGCAT C C C CAAC GACAAGC C CT T T CAGAAC GT GAACAGAAT CAC CTAT GGC GC C T GT C C CAGGTAC GT GAAGCAGAGCAC C CT GAAGCT GGC CACAGGGAT GAGAAAC GT C C C C GAAA AGCAGAC C C GGGGCAT CT T T GGC GCTAT CGCCGGCTT CAT C GAGAAC GGCT GGGAGGGCAT GGT GGAC GGCT GGTAC GGCT T C C GGt t CCAGAACAGCGAGGGCAGAGGCCAGGCCGCT GACCT GAAG T C CAC C CAGGCT GC CAT C GAC CAGAT CAGC GGAc t g CT GAACAGACT GAT C GGCAAAACAAAC G AAAAGT T C CAT CAGAT C GAGAAGGAGT T CT C C GAGGT GGAAGGC C GGGT GCAGGAC CT GGAAAA GTACGTGGAAGACACCAAGATCGACCTGTGGTCCTACAACGCTGAACTGCTGGTCGCCCTGctg -36- WO 2024 / 220936 PCT / US2024 / 025583 AAT CAGCACAC CAT C GAC CT GAC C GACAGC GAGAT GAACAAACT GT T C GAGAAGAC CAAGAAGC AGCTGCGGGAAAACGCCGAGGATATGGGCAACGGATGCTTCAAGATTTACCACAAGTGCGACAA C GC CT GCAT T GGCAGCAT CAGAAAT GAGACATAC GAC CACAAT GT T TAG C GGGAT GAGGC C CT G AACAACAGAT T C CAGAT CAAGGGAGT GGAGCT GAAGT C CGGCTACAAGGACTGGATCTTGTGGA TCAGCTTCGCCATCTCCTGCTTCCTGCTCTGTGTGGTCCTGCTCGGCTTCATTATGTGGGCCTG T CAGAAGGGCAACAT C C GAT GCAACAT CT GCAT T t g a 7 5 ATGAAAACGATCATCGCCCTATCCTACATCCTATGCCTCGTCTTCGCCCAAAAACTCCCCGGCA A / Indi ana / 11 / 2018 AC GACAACAGCACCGCCACCCT GT GCCT GGGGCACCACGCT GT GCCAAAT GGCACCATT GT GAA GAC CAT TAG CAAT GACAGAAT C GAGGT GAC CAAT GC CAC C GAACT GGT GCAGAAT T C CAGCAT T GGCGAGATCTGCGACAGCCCTCACCAGATCCTGGATGGCGAGAACTGCACCCTGATCGATGCTC TGCTGGGCGACCCTCAGTGCGATGGCTTCCAGAACAAGAAATGGGACCTGTTCGTGGAGCGGAG CAAGGCCTACAGCAACTGCTACCCCTACGACGTCCCCGATTACGCCAGCCTGCGGAGCCTGGTG GCCTCCTCCGGCACACTGGAGTTCAACAACGAAAGCTTCAACTGGACAGGAGTGAAGCAGAACG GCACATCCAGCGCCTGCATCAGAAAAAGCTCCAGCAGCTTCTTCTCTCGACTGAACTGGCTGAC C CAC C T GAAC TACACCTACCCCGCCCT GAAC GT GAC CAT GC CAAACAAT GAGCAGT T T GACAAA CT GTACAT T T GGGGAGT GCAC CAC C C C GGCACAGACAAGGAC CAGAT CT T T CT GTAC GC C CAGA GCAGC GGCAGGAT CAC C GT GT CTAC CAAGAGAAGC CAGCAGGC C GT GAT C C C CAACAT C GGCAG CAGACCTCGGATCAGAGACATCCCCTCCAGAATCTCCATCTACTGGACAATTGTGAAGCCTGGA GACATTCTGCTGATCAACAGCACCGGCAACCTGATCGCCCCTCGAGGATACTTCAAGATCCAGA GC GGCAAAAGCAGCAT CAT GAGAT CT GAC GC C C C CAT C GGCAAAT GCAAAAGC GAGT GTAT CAC C C C CAAC GGCAGCAT C C C CAAC GACAAGC C CT T T CAGAAC GT GAACAGAAT CAC CTAT GGC GC C T GT C C CAGGTAC GT GAAGCACAGCAC C CT GAAGCT GGC CACAGGAAT GAGAAAC GT C C C C GAGA AGCAAACCCGGGGCATCTTTGGCGCTATTGCCGGCTTCATCGAGAACGGCTGGGAAGGGATGGT GGAC GGCT GGTAC GGCTTCCGGttC CAGAACAGC GAGGGAAGAGGC CAGGC C GCT GAC CT GAAG T C CAC C CAGGC C GC CAT T GAT CAGAT CAAC GGC c t g CT GAACAGACT GAT C GGCAAGAC CAAC G AAAAAT T C CAC CAGAT C GAAAAGGAAT T CAGC GAAGT GGAGGGCAGAAT T CAGGAC CT GGAAAA GTACGTGGAGGACACAAAGATCGACCTGTGGTCCTACAACGCTGAACTGCTGGTGGCCCTGctg AAT CAGCACAC CAT C GAC CT GAC C GACAGC GAGAT GAACAAACT GT T T GAAAAGAC CAAGAAGC AGCT GAGAGAAAAC GC C GAGGACAT GGGCAAT GGAT GCT T CAAAAT CTAC CACAAGT GC GACAA C GC CT GTAT T GGCAGCAT CAGAAAT GGCAC CTAC GAC CACAAC GT CTACAGGGAC GAGGC C CT G AACAACAGAT T T CAAAT CAAGGGC GT GGAGCTGAAGTCTGGCTACAAGGACTGGATCTTGTGGA TCAGCTTCGCCATCTCCTGCTTCCTGCTCTGTGTGGTCCTGCTCGGCTTCATTATGTGGGCCTG T CAGAAGGGCAACAT C C GAT GCAACAT CT GCAT T t g a 7 6 ATGAAAACGATCATCGCCCTATCCTACATCCTATGCCTCGTCTTCGCCCAAAAACTCCCCGGCA A / Cali fornia / 07 / 20 04 AC GACAACAGCACAGCCACACT CT GT CT GGGCCAT CACGCT GT GCCAAACGGCACAAT CGT GAA GACAAT CAC CAAC GAC CAGAT T GAGGT GACAAAT GC CACAGAGCT GGT GCAGAGCT C CAGCACA GGCGGCATCTGCGACAGCCCTCATCAGATCCTGGATGGCGAGAACTGCACACTGATCGATGCCC TGCTGGGCGACCCTCAGTGCGACGGCTTCCAGAACAAGAAATGGGACCTGTTCGTGGAGCGGAG CAAGGCTTACAGCAACTGTTACCCCTACGACGTCCCTGACTACGCCTCCCTGCGGAGCCTGGTG GCCTCCTCCGGCACCCTGGAGTTTAACAATGAATCCTTTAACTGGACAGGCGTCACCCAGAACG GCACATCTTCCAGCTGCAAGAGAAGAAGCAACAACTCCTTCTTCAGCAGACTGAATTGGCTGAC C CAC C T GAAGT T CAAGTAC CCTGCCCT GAAC GT GAC CAT GC CAAACAAT GAGAAGT T C GACAAG CT GTACAT CT GGGGGGT T CAC CAC C CT GGCACAAACAAC GAC CAGAT CAGC CT GTACAC C CAGG C CAGC GGC C GGAT CAC C GT GT CTACAAAGC GGAGC CAGCAGACAGT GAT C C C CAACAT C GGCT C CAGAC CT C GGGT GAGAGACAT C C C CT C CAGAAT CAGCAT CTACT GGAC CAT C GT GAAGC CAGGC GACATCCTGCTCATCAACAGCACCGGAAACCTGATTGCACCCAGAGGCTACTTCAAGATCAGAA GC GGCAAGAGCAGCAT CAT GAGAAGC GAT GC C C C CAT C GGCAAGT GCAACAGC GAGT GTAT CAC C C C CAAC GGCAGCAT C C C CAAT GACAAGC C CT T C CAGAAC GT GAACAGAAT CAC CTAT GGC GC C T GC C C CAGGTAC GT CAAGCAGAACAC C CT GAAGCT GGC CAC C GGAAT GAGAAAC GT C C C C GAGA AGCAGACCAGGGGGATCTTTGGAGCCATCGCCGGCTTCATCGAGAACGGCTGGGAGGGAATGGT GGAC GGAT GGTAC GGCTTCCGGttC CAGAACT CT GAGGGCAT T GGC CAGGC C GCAGAT CT GAAG T C CAC C CAGGC C GC CAT CAAC CAGAT CAAC GGC c t g CT GAACAGACT GAT C GGCAAGACAAAT G AAAAAT T C CAC CAGAT C GAGAAAGAAT T CAGC GAGGT GGAAGGC C GGAT T CAGGAC CT GGAGAA GTACGTGGAGGACACCAAGATCGACCTGTGGAGCTACAACGCTGAACTGCTCGTGGCCCTGctg AAC CAGCACACAAT C GAC CT GACAGACAGC GAGAT GAACAAGCT GT T C GAAAGAACAAAGAAAC -37- WO 2024 / 220936 PCT / US2024 / 025583 AGCTGAGAGAAAACGCCGAGGACATGGGCAACGGCTGCTTCAAGATCTACCACAAGTGCGACAA C GC CT GCAT T GGCAGCAT CAGAAAC GGCAC CTAC GAC CAT GAC GT T TAC C GGGAC GAGGC C CT G AACAAC C GGT T C CAGAT CAAGGGC GT GGAACT GAAGT C CGGCTACAAGGACTGGATCTTGTGGA TCAGCTTCGCCATCTCCTGCTTCCTGCTCTGTGTGGTCCTGCTCGGCTTCATTATGTGGGCCTG T CAGAAGGGCAACAT C C GAT GCAACAT CT GCAT T t g a 7 7 ATGAAAACGATCATCGCCCTATCCTACATCCTATGCCTCGTCTTCGCCCAAAAACTCCCCGGCA A / Nanc hang / 9 33 / 199 5 AC GACAACAGCACAGCCACCCT GT GCCT GGGACACCACGCT GT GCCAAAT GGCACCCT GGT GAA GACAAT CAC CAAC GAC CAGAT C GAAGT GACAAAT GC CACAGAGCT GGT GCAGAGCT C CT C CAC C GGCAGAATCTGCGACTCTCCTCACAGAATCCTGGACGGCAAGAACTGCACCCTGATCGATGCCC TGCTGGGCGACCCTCACTGCGACGGCTTCCAGAACAAGGAGTGGGACCTGTTCGTGGAGAGAAG CAAGGCCTACTCCAACTGTTACCCTTACGACGTCCCTGATTACGCCTCCCTGAGAAGCCTGGTG GCCTCCTCTGGCACCCTGGAGTTCACCAATGAGGGCTTCAACTGGACCGGAGTGGCCCAGGATG GCACCTCCTACGCCTGCAAGAGAGGCTCCGTGAAAAGCTTCTTCAGCAGACTGAACTGGCTCCA CAAGCT GGAGTACAAGTAC C C C GC C CT GAAC GT GAC CAT GC CAAACAAC GACAAGT T C GACAAG CTCTACATCTGGGGCGTCCACCACCCCAGCACCGACAGCGACCAGACATCTCTCTATGTCCAGG C CAGC GGCAGAGT GACAGT CAGCAC CAAGAGAAGC CAGCAAACAGT GAT C C C CAACAT C GGCAG CAGACCTTGGGTGCGGGGCATCTCTTCCAGAATCAGCATCTACTGGACAATCGTGAAGCCTGGC GATATCCTGCTGATCAAGAGCACCGGCAACCTGATCGCCCCCAGAGGCTACTTCAAGATCAGAA GCGGAAAGAGCTCCATCATGAGAAGCGATGCTCCTATCGGCAACTGCAACTCTGAGTGTATCAC C C C CAAC GGCT C CAT T C C CAAC GACAAGC CT T T T CAGAAC GT GAACAGAAT CAC CTAC GGGGC C T GC C C CAGGTAC GT GAAGCAGAACAC C CT GAAGCT GGC CAC C GGAAT GAGAAAC GT C C C C GAGA AGCAGACAC GGGGCAT CT T T GGC GC CAT CGCCGGCTT CAT C GAGAAC GGCT GGGAGGGGAT GGT GGAT GGCT GGTAC GGCT T C C GGt t CCAGAATT CGGAGGGCACCGGCCAGGCCGCCGACTT GAAA T C CAC C CAGGC CGC CAT CAAC CAGAT CAAC GGC c t g CT GAACAGACT GAT C GAGAAGACAAAT G AGAAGT T C CAC CAGAT C GAGAAGGAGT T CAGC GAAGT GGAGGGAAGAAT C CAGGAC CT GGAGAA GTACGTGGAAGACACCAAGATCGACCTGTGGTCCTACAACGCAGAACTGCTGGTGGCCCTGctg AAC CAACACACAAT C GAC C T GACAGACAGC GAAAT GAACAAAC T GT T C GAGAGAAC CAGAAAAC AGCT GAGAGAGAAC GC C GAGGACAT GGGCAAC GGCT GT T T CAAGAT CTAC CACAAGT GC GACAA C GC CT GCAT T GGCT C CAT CAGAAAC GGCAC CTAC GAT CAC GAT GT T TAC C GGGAC GAGGC C CT G AACAAT C GT T T C CAGAT CAAGGGAGT GGAGCTGAAGTCTGGCTACAAGGACTGGATCTTGTGGA TCAGCTTCGCCATCTCCTGCTTCCTGCTCTGTGTGGTCCTGCTCGGCTTCATTATGTGGGCCTG T CAGAAGGGCAACAT C C GAT GCAACAT CT GCAT T t q a 7 8 ATGAAAACGATCATCGCCCTATCCTACATCCTATGCCTCGTCTTCGCCCAAAAACTCCCCGGCA A / Bilt hoven / 1761 / 1 976 AC GACAACAGCAC CGC CAC CCTGTGCCTC GGGCAC CAC GCT GT GC CAAAC GGCAC C CT GGT GAA GAC CAT CAC CAAC GAT CAGAT C GAAGT GAC CAAT GC CAC C GAACT GGT GCAGAGCT C CT C CAC C GGCAAGATCTGCGACAACCCTCACAGAATCCTGGACGGCATCAACTGCACCCTGATCGATGCCC TGCTGGGCGACCCTCACTGCGATGGCTTCCAGAATGAGAAGTGGGACCTGTTCGTCGAGAGAAG CAAGGCCTTTTCCAACTGTTACCCTTACGACGTCCCCGATTACGCCAGCCTGAGATCCCTGGTG GC CT C CAGC GGAACACT GGAGT T CAT CAAC GAGGGCT T CAACT GGACAGGC GT GAC C CAGAAC G GCGGCTCCTCTGCCTGCAAGAGAGGCCCCGACAATGGCTTTTTCAGCAGACTGAACTGGCTGTA CAAGAGC GGCAGCAC CTAC C CAGT C CAGAAC GT GAC CAT GC CAAACAAC GACAACT C C GACAAG CT GTACAT CT GGGGC GT C CAC CAC C C CAGCACAGACAAGGAGCAGACAGAC CT CTAC GT C CAAG C CT C C GGCAAGGT CAC C GT GT C CAC CAAGC GGAGC CAGCAGAC C GT GAT C C C CAAC GT GGGCAG CCGGCCCTGGGTGAGAGGCCTGAGCTCCCGGGTGTCCATCTACTGGACCATCGTGAAACCAGGC GACATCCTGGTGATCAACAGCAACGGCAACCTGATCGCCCCTCGGGGCTACTTCAAGATGAGAA C C GGCAAGAGCAGCAT CAT GAGAAGC GAT GC C C CAAT C GGAACAT GCT C CT CT GAAT GCAT TAC AC C CAAC GGAAGCAT C C C CAAC GACAAAC C CT T C CAGAAC GT GAACAAGAT TACATAT GGC GC C T GC C C CAAGTAC GT GAAGCAGAACACACT GAAGCT GGC CACAGGAAT GAGAAAC GT C C CT GAGA AGCAGACAAGAGGCATCTTTGGCGCTATCGCCGGATTCATCGAAAACGGCTGGGAGGGAATGAT CGACGGCTGGTACGGATTTAGAttCCAAAACAGCGAGGGCACCGGCCAGGCCGCTGACCTGAAG T CAAC C CAGGC CGC CAT C GAC CAGAT CAAC GGC c t g CT GAACAGAGT GAT C GAAAAGAC CAAT G AGAAGT T C CAT CAGAT C GAGAAGGAGT T CAGC GAAGT GGAGGGCAGAAT C CAGGAC CT GGAGAA GTACGTGGAGGATACCAAGATCGACCTGTGGAGCTACAACGCAGAGCTGCTGGTGGCCCTGctg AAC CAGCACAC CAT C GAC CT GACAGACAGC GAGAT GAACAAGCT GT T C GAGAAGACAAGAAGAC AGCT GAGAGAGAAC GC C GAGGATAT GGGCAAC GGCT GT T T CAAGAT CTAT CACAAGT GC GACAA -38- WO 2024 / 220936 PCT / US2024 / 025583 CGCCTGCATTGGCAGCATCAGAAACGGCACCTACGACCACGATGTCTACAGAGACGAGGCTCTG AACAACAGAT T C CAGAT CAAGGGC GT GGAGCT GAAGT C CGGCTACAAGGACTGGATCTTGTGGA TCAGCTTCGCCATCTCCTGCTTCCTGCTCTGTGTGGTCCTGCTCGGCTTCATTATGTGGGCCTG T CAGAAGGGCAACAT C C GAT GCAACAT CT GCAT T t q a 7 9 ATGAAAACGATCATCGCCCTATCCTACATCCTATGCCTCGTCTTCGCCCAAAAACTCCCCGGCA A / Camb odia / e 082636 0 / 2020 -4 AC GACAACAGCACCGCCACACT GT GCCT GGGACACCACGCT GT GCCAAACGGCACAAT CGT GAA GACAAT CAC CAAT GACAGAAT C GAGGT GAC CAAT GC CACAGAGCT GGT GCAGAACAGCT CTAT C GGCGAAATCTGCGACAGCCCCCACCAGATCCTGGACGGCGGCAATTGCACCCTGATCGATGCCC TGCTGGGCGACCCTCAGTGCGACGGCTTCCAGAACAAGGAATGGGACCTGTTCGTGGAGCGGAG CAGAGCCAATTCAAACTGCTACCCCTACGACGTCCCCGACTACGCCAGCCTGCGGAGCCTGGTG GC CT C CAGC GGCACACT GGAGT T CAAGAAC GAGT CT T T CAACT GGACAGGC GT CAAGCAGAAC G GCACCTCCAGCGCCTGCATCAGGGGCTCCAGCAGCAGCTTCTTCAGCAGACTGAACTGGCTGAC C CAC C T GAAT TACACCTACCCCGCCCT GAAC GT GAC CAT GC CAAACAAC GAACAGT T C GACAAG CT GTACAT CT GGGGAGT GCAT CAC C C CAGCACAGACAAGGAC CAGAT CAGC CT GT T C GCT CAGC C CT C C GGCAGAAT TAG C GT GT C CAC CAAGAGAAGC CAGCAAGC C GT GAT C C CAAACAT C GGCAG CCGGCCTCGGATCCGGGACATCCCTTCCAGAATCTCCATCTACTGGACCATCGTGAAGCCTGGC GACATCCTGCTGATCAACAGCACAGGCAATCTGATCGCCCCCAGGGGCTACTTCAAGATCAGAA GC GGCAAGAGCAGCAT CAT GAGAAGC GAT GC C C C CAT C GGCAAGT GCAAGAGC GAGT GTAT CAC C C CTAAC GGCAGCAT C C CAAAC GACAAGC CT T T C CAGAAC GT GAACAGAAT CACATAT GGAGC C T GC C C CAGGTAC GT CAAGCAGAGCACACT GAAGCT GGC CACAGGGAT GAGAAAC GT C C CT GAGA AGCAGAC C C GGGGCAT CT T T GGC GC CAT CGCCGGCTT TAT C GAGAAC GGCT GGGAGGGAAT GGT GGATGGCTGGTATGGCTTCCGGTTCCAGAACAGCGAGGGAAGAGGCCAGGCCGCTGACCTGAAG T CTAC C CAGGC C GC CAT C GAC CAGAT CAAT GGC CT GCT CAAT C GC CT GAT T GGCAAGAC CAAT G AAAAGT T T CAC CAGAT C GAGAAGGAGT T CT C C GAAGT C GAGGGC C GGGT GCAGGAC CT GGAGAA GTACGTGGAAGACACCAAGATCGACCTGTGGTCTTACAACGCTGAACTGCTGGTGGCCCTGCTG AAC CAACACACAAT C GAC CT GAC C GACAGC GAGAT GAACAAGCT GT T T GAGAAGAC CAAGAAGC AGCT GAGAGAGAAC GC C GAGGACAT GGGCAAC GGCTGCTT CAAGAT CTAC CACAAGT GC GACAA T GC CT GCAT T GGCAGCAT C C GGAAC GAAAC CTAC GAC CACAAT GT CTACAGAGAC GAGGC C CT G AACAACAGAT T C CAGAT CAAAGGC GT GGAGCT GAAAT C CGGCTACAAGGACTGGATCTTGTGGA TCAGCTTCGCCATCTCCTGCTTCCTGCTCTGTGTGGTCCTGCTCGGCTTCATTATGTGGGCCTG T CAGAAGGGCAACAT C C GAT GCAACAT CT GCAT T t q a 8 0 ATGAAAACGATCATCGCCCTATCCTACATCCTATGCCTCGTCTTCGCCCAAAAACTCCCCGGCA A / Arge ntina / 28302 / 2010 AC GACAACAGCACAGCAACCCT GT GCCT GGGACACCACGCAGT CCCCAACGGCACAAT CGT GAA GACAAT CAC CAAC GAC CAGAT T GAGGT GACAAAT GC CACAGAGCT GGT GCAGAGCT C CAGCACA GGCGAGATCTGCGACAGCCCTCACCAGATCCTGGATGGCAAGAACTGCACCCTGATCGATGCCC TGCTGGGCGACCCCCAGTGCGACGGCTTCCAGAACAAAAAGTGGGACCTGTTCGTGGAGAGAAG CAAGGCCTACAGCAACTGCTACCCTTACGATGTCCCTGACTACGCCAGCCTGCGGAGCCTGGTG GC CT C CAGC GGCAC C CT GGAGT T CAACAAC GAGAGCT T CAAT T GGACAGGC GT GAC C CAGGAT G GAACAAGCAGCGCCTGCATCCGGGGCTCCAAGAATTCCTTCTTCAGCAGACTGAACTGGCTGAC ACAC C T GAAC T T CAAGTAC CCTGCCCT GAAC GT GACAAT GC CAAACAAC GAACAAT T C GACAAG CT GTACAT CT GGGGAGT GCAC CAC C C C GGCAC C GACAAGGAT CAGAT CT T T CT GTAT GC C CAGG C CAGC GGC C GGAT CAC C GT GT C CAC CAAAAGAAGC CAGCAGGC C GCTAT C C C CAATAT C GGCAG CCGGCCTCGGGTGAGAAACATCCCTTCCAGAATCTCAATCTACTGGACAATCGTGAAGCCTGGC GACATCCTGCTGATCAATAGCACCGGCAACCTGATCGCCCCCAGAGGCTACTTCAAGATCAGAA GC GGAAAGAGCAGCAT CAT GAGAAGC GAT GC C C C CAT C GGCAAGT GCAAT T CT GAAT GCAT CAC CCCCAACGGCTCCATTCCCAACGACAAGCCTTTCCAGAACGTGAATCGGATCACCTATGGCGCC T GC C C CAGGTAC GT GAAGCAGAACACACT GAAGCT GGC CAC C GGGAT GAGAAAT GT C C C C GAGA AGCAGAC CAGGGGCAT CT T T GGC GC CAT CGCCGGCTT CAT C GAGAAC GGCT GGGAAGGCAT GGT GGAC GGCT GGTAT GGCT T CAGGt t C CAGAACAGC GAAGGCAGAGGC CAGGC C GCT GAC CT GAAA T C CAC C CAGGCT GC CAT C GAC CAGAT CAAT GGAc t g CT GAATAGGCT GAT C GGCAAGACAAAC G AGAAAT T C CAC CAGAT C GAGAAGGAGT T CAGC GAAGT GGAGGGC C GGAT T CAGGAC CT GGAGAA GTACGTGGAGGACACAAAGATTGACCTGTGGAGCTACAACGCAGAGCTGCTGGTGGCCCTGctg AAC CAGCACAC CAT C GAC CT GACAGACAGC GAGAT GAACAAGCT GT T T GAGAAGACAAAAAAGC AGCT GAGAGAGAAT GC C GAGGACAT GGGAAAC GGCT GT T T CAAGAT CTAC CACAAGT GC GACAA C GC CT GCAT T GGCAGCAT C C GGAAC GGCAC CTAC GAT CAC GAT GT T TAG C GGGAC GAAGC C CT G -39- WO 2024 / 220936 PCT / US2024 / 025583 AACAAAAGAT T C CAGAT CAAGGGGAT C GAACT GAAAT C CGGCTACAAGGACTGGATCTTGTGGA TCAGCTTCGCCATCTCCTGCTTCCTGCTCTGTGTGGTCCTGCTCGGCTTCATTATGTGGGCCTG T CAGAAGGGCAACAT C C GAT GCAACAT CT GCAT T t q a 8 1 ATGAAAACGATCATCGCCCTATCCTACATCCTATGCCTCGTCTTCGCCCAAAAACTCCCCGGCA A / Auck land / 5 88 / 200 0 AC GACAACAGCACCGCCACCCT GT GCCT GGGACACCACGCT GT GCCAAAT GGCACCCT GGT GAA GAC CAT CACAAAC GAC CAGAT C GAGGT CACAAAT GC CAC C GAACT GGT C CAGT CT T CTAGCACA GGCGGCATCTGCGACAGCCCCCACCAAATTCTGGATGGCGAGAACTGCACCCTGATCGATGCCC TGCTGGGAGATCCCCACTGCGACGGCTTCCAGAACAAAGAATGGGACCTGTTCGTGGAGCGGAG CAAAGCCTACTCCAACTGCTACCCCTACGATGTCCCCGACTACGCCTCCCTGAGAAGCCTGGTG GCCAGCTCTGGCACCCTGGAGTTCAACAATGAGTCCTTCAACTGGACAGGCGTGGCCCAGAATG GCACATCCTCCGCCTGCAAGCGGAGATCTAACAAGAGCTTCTTTAGCAGACTGAATTGGCTGCA C CAGC T GAAGTACAAGTAC CCTGCCCT GAAC GT GAC CAT GC CAAACAAT GAGAAGT T C GACAAG CT GTACAT CT GGGGC GT C CAT CAC C C CT C CAC C GACAGC GAC CAGAT CAGC CT GTAC GC C CAAG C C C CT GGCAGAGT GACAGT GAGCACAAAGC GGAGC CAGCAGACAGT GAT C C C GAACAT C GGCAG CCGGCCTTGGGT GAGAGGC GT GT C CAGCAGAAT CAGCAT CTACT GGACAAT C GT GAAGC CT GGC GACATCCTGCTGATCAACTGCACAGGCAACCTGATCGCCCCAAGAGGCTACTTCAAGATCCGGT C C GGCAAGAGCAGCAT CAT GAGAAGC GAT GC CAGCAT C GGAAAGT GCAACAGC GAGT GTAT CAC C C C CAAC GGCAGCAT C C C CAAC GACAAGC CT T T C CAGAAC GT GAAT C GGAT CAC CTAT GGC GC C T GC C C CAGGTAC GT GAAGCAGAACAC C CT GAAACT C GC CAC C GGGAT GAGAAAC GT C C C C GAGA AACAGACAAGAGGCATCTTTGGAGCCATCGCCGGCTTCATCGAGAACGGCTGGGAGGGGATGGT GGAC GGCT GGTAC GGAT T C C GGt t CCAGAACAGCGAGGGCACCGGCCAGGCCGCT GACCT GAAA AGCAC C CAGGC C GC CAT CAAT CAAAT CAAT GGC c t g CT GAACAGACT GAT C GAAAAGACAAAT G AGAAGT T C CAC CAGAT C GAAAAGGAAT T CAGC GAGGT GGAAGGCAGAAT C CAGGAC CT GGAGAA GTACGTGGAGGATACCAAGATCGACCTGTGGAGCTACAACGCTGAACTGCTGGTGGCCCTGctg AAC CAGCACACAAT C GAC CT GAC C GACAGC GAGAT GAACAAGCT GT T C GAGAGAAC CAAGAAGC AGCT GAGAGAGAAC GC C GAGGACAT GGGCAAT GGT T GCT T CAAGAT CTAC CACAAGT GC GACAA C GC CT GCAT T GGAAGCAT CAGAAAC GGCACATAC GAC CAC GAT GT CTACAGAGAC GAGGCT CT G AACAAT C GGT T T CAGAT CAAGGGC GT GGAGCTGAAGTCTGGCTACAAGGACTGGATCTTGTGGA TCAGCTTCGCCATCTCCTGCTTCCTGCTCTGTGTGGTCCTGCTCGGCTTCATTATGTGGGCCTG T CAGAAGGGCAACAT C C GAT GCAACAT CT GCAT T t g a 8 2 ATGAAAACGATCATCGCCCTATCCTACATCCTATGCCTCGTCTTCGCCCAAAAACTCCCCGGCA A / Memp his / 1 / 1980 AC GACAACAGCAC C GC CAC CCTGTGCCTGGGC CAC CAC GCT GT GC CAAAC GGCAC C CT GGT GAA GAC CAT CAC CAAC GAT CAGAT T GAAGT GAC CAAT GC CACAGAGCT GGT GCAGAGCT C CT C CACT GGCAGAATCTGCGACTCCCCTCACAGAATCCTGGATGGCAAAAACTGCACACTCGTGGATGCCC TGCTGGGCGACCCCCACTGCGACGGCTTCCAGAATGAGAAGTGGGACCTGTTCGTGGAGAGAAG CAAGGCCTTCAGCAACTGCTACCCTTACGACGTCCCTGACTACGCCAGCCTGAGAAGCCTGGTG GCCTCCAGCGGCACACTGGAGTTCATCAATGAGTCCTTCAACTGGACAGGCGTGACACAGTCTG GCGGCTCTTACGCCTGCAAGCGGGGCAGCGACAACAGCTTCTTCTCCCGGCTGAATTGGCTGTA C GAGAGC GAGAGCAAGTAC C CT GT GCT GAAC GT GAC CAT GC CAAACAAT GGCAAT T T C GACAAA CT GTACAT CT GGGGAGT GCAC CAC C C CAGCAC C GACAAGGAGCAGAC CAAC CT CTAC GT GAGAG C CAGC GGCAGAGT GAC C GT GT C CACAAAGC GGAGC CAGCAGAC CAT CAT C C C CAACAT C GGCAG CCGGCCCTGGGTGAGAGGCCTGAGCTCCCGGATCAGCATCTACTGGACAATCGTGAAACCCGGA GACATCCTGCTGATCAACAGCAACGGCAACCTGATCGCCCCCAGAGGCTACTTTAAGATCAGAA CAGGCAAGAGCT C CAT CAT GAGAAGC GAT GC C C C CAT C GGCACAT GCAGCAGC GAGT GTAT CAC C C C CAAC GGCT CAAT C C C CAAC GACAAGC CT T T C CAGAAC GT GAACAAGAT TAG CTAT GGC GC C T GC C C CAAGTAC GT GAAGCAGAACACACT GAAGCT GGC CACAGGGAT GAGGAAT GT C C C C GAAA AGCAGACAAGAGGCATCTTTGGGGCCATCGCCGGCTTCATCGAGAACGGCTGGGAAGGAATGGT GGAC GGCT GGTAC GGCT T CAGGt t C CAGAACAGC GAGGGCAC C GGC CAGGC C GCT GAC CT GAAG T C CAC C CAGGC C GC CAT C GAC CAGAT CAAT GGAc t g CT GAACAGAGT GAT C GAGAAGACAAAC G AAAAGT T C CAC CAGAT C GAAAAGGAAT T CT C C GAGGT GGAAGGAC GGAT T CAGGAC CT GGAAAA GTACGTGGAAGACACCAAGATCGACCTGTGGAGCTACAACGCAGAGCTGCTGGTGGCTCTGctg AAC CAGCACACAAT C GAC CT GACAGACAGC GAGAT GAACAAACT GT T C GAAAAGACAC GGAGAC AGCTGAGGGAGAACGCTGAAGACATGGGAAACGGCTGCTTTAAGATTTAGCACAAGTGCGACAA T GC CT GCAT T GGCAGCAT T C GGAAC GGCACATAC GAC CAT GAT GT CTACAGAGAC GAGGCT CT G AACAAC C GGT T C CAGAT CAAGGGC GT GGAGCTGAAGTCTGGCTACAAGGACTGGATCTTGTGGA -40- WO 2024 / 220936 PCT / US2024 / 025583 TCAGCTTCGCCATCTCCTGCTTCCTGCTCTGTGTGGTCCTGCTCGGCTTCATTATGTGGGCCTG T CAGAAGGGCAACAT C C GAT GCAACAT CT GCAT T t g a 8 3 ATGAAAACGATCATCGCCCTATCCTACATCCTATGCCTCGTCTTCGCCCAAAAACTCCCCGGCA A / Hong _Kong / 1 / 1968 AC GACAACAGCACAGC CAC CCTGTGCCTGGGC CAC CAC GCT GT GC CAAAC GGCACACT GGT GAA GACAAT CAC C GAC GAC CAGAT C GAGGT GAC CAAT GCAACAGAGCT GGT GCAGAGT T C CAGCAC C GGAAAGATCTGCAACAACCCTCACCGGATCCTGGACGGCATCGACTGCACCCTGATTGATGCCC TGCTCGGC GAC C CT CACT GC GAC GT GT T C CAGAAC GAAACAT GGGAC CT GT T C GT GGAGC GGT C CAAGGCCTTTAGCAACTGCTACCCCTACGACGTCCCCGATTACGCCAGCCTGAGATCTCTCGTG GC CT C CAGC GGCAC C CT GGAGT T CAT TACAGAGGGCT T CACAT GGACAGGC GT GACACAGAAC G GCGGCAGCAACGCCTGCAAGAGAGGCCCTGGCTCTGGCTTCTTCAGCAGGCTGAATTGGCTGAC AAAGAGC GGAAGCAC CTAC C CT GT GCT GAAC GT GAC CAT GC CAAACAAC GACAAT T T C GACAAG CT GTACAT CT GGGGC GT C CAC CAC C C CAGCAC CAAC CAGGAGCAGAC CAGC CT CTAT GT C CAGG C CAGC GGCAGAGT GACAGT GAGCAC CAGAC GGT C C CAGCAGAC CAT CAT C C CTAACAT C GGAT C CAGACCTTGGGTGCGGGGCCTGAGCAGCAGAATCTCCATCTACTGGACCATCGTGAAACCTGGC GATGTCCTGGTGATCAACTCCAACGGCAACCTGATCGCCCCTCGGGGCTACTTCAAGATGCGGA CAGGCAAGAGCT CAAT CAT GAGAAGC GAT GCT C CTAT C GACAC CT GCAT CAGC GAGT GTAT CAC AC C CAAC GGCT CTAT C C C CAAC GACAAGC C CT T C CAGAAC GT GAACAAGAT CACATAT GGAGC C T GC C C CAAGTAC GT GAAACAGAACAC C CT GAAGCT GGC CAC C GGGAT GAGAAAC GT C C CT GAGA AGCAGACCCGGGGCCTGTTTGGAGCCATCGCCGGCTTCATCGAGAACGGCTGGGAAGGCATGAT C GAC GGCT GGTAC GGAT T C C GGt t CCAGAACAGCGAAGGCACCGGCCAGGCT GCT GACCT GAAG T C CACACAGGC C GC CAT C GAC CAGAT CAAT GGC c t g CT GAACAGAGT GAT C GAAAAGACAAAC G AAAAGT T C CAC CAGAT C GAAAAGGAGT T CAGC GAAGT GGAGGGCAGAAT C CAGGAC CT GGAGAA GTACGTGGAGGACACCAAGATCGACCTGTGGAGCTACAACGCAGAACTGCTGGTCGCCCTGctg AAC CAGCACAC CAT C GAC CT GACAGAT T C GGAGAT GAACAAGCT GT T C GAGAAAAC C C GGAGAC AGCT GAGAGAGAAC GC C GAGGACAT GGGAAAC GGCTGCTT CAAGAT T TAG CACAAGT GC GACAA C GC CT GCAT T GAAT C CAT T C GGAAC GGCAC CTAC GAC CAC GAT GT CTACAGAGAC GAGGC C CT G AACAAC C GGT T T CAGAT CAAGGGC GT GGAGCT GAAGT C CGGCTACAAGGACTGGATCTTGTGGA TCAGCTTCGCCATCTCCTGCTTCCTGCTCTGTGTGGTCCTGCTCGGCTTCATTATGTGGGCCTG T CAGAAGGGCAACAT C C GAT GCAACAT CT GCAT T t g a 8 4 AT GAAGGC GAT CAT C GT C CT C CT GAT GGTAGT GACAAGCAAT GC C GACAGAAT T T GCAC C GGCA B / Aust ria / 13 59417 / 2021 T TAG CAGCAGCAACAGC C CT CAC GT GGT CAAGAC C GC CAC C CAGGGC GAGGT GAAC GT GACAGG C GT GAT T C C C CT GACAAC CAC C C C CAC CAAGAGC CACT T C GC CAAC CT GAAAGGCAC C GAGACA CGGGGCAAACTGTGCCCCAAGTGCCTCAACTGTACCGACCTGGACGTGGCCCTGGGCAGACCCA AGT GCAC C GGCAAAAT C C CAAGC GC CAGAGT GAGCAT C CT GCAC GAGGT GCGGCCCGT GAC CAG CGGCTGCTTCCCCATTATGCACGATAGAACCAAGATCAGACAGCTGCCAAATCTGCTGAGAGGC TAG GAACAC GT CAGACT GT C CAC C CACAAC GT GAT CAACACAGAGGAC GCCCCTGGCGGCCCTT ACGAGATCGGCACAAGCGGCTCCTGCCTGAACATTACAAACGGCAAAGGCTTCTTCGCCACCAT GGCTTGGGCCGTCCC CAAGAACAAGACAGC CAC CAAT C CT CT GAC CAT C GAGGT C C CT TAGAT C T GCAC C GAAGAGGAGGAT CAGAT CACAGT GTGGGGCTTC CACAGC GAT GAC GAGACACAGAT GG C CAGACT GTAC GGC GACAGCAAGC CT CAGAAGT T CAC CAGCAGC GC CAAC GGC GT GAC CAC C CA CTACGTCAGCCAGATTGGCGGCTTTCCTAACCAGACCGAGGACGGCGGCCTGCCTCAGAGCGGC AGAAT T GT GGT GGACTACAT GGT T CAGAAAAGC GGCAAGACAGGCACAAT CAC CTAC CAGC GGG GCATCCTGCTGCCTCAGAAGGTGTGGTGCGCCTCCGGCAAATCTAAGGTGATCAAGGGCTCCCT GCCTCTGATCGGAGAGGCCGACTGCCTGCACGAGAAGTACGGAGGCCTGAACAAGAGCAAACCC TACTACACAGGC GAACAT GC CAAGGC CAT C GGCAACT GC C C CAT CT GGGT CAAGAC C C CT C T GA AGCTGGCCAATGGAACAAAGTACAGACCTCCTGCCAAGCTGCTGAAGGAGAGAGGCTTCTTTGG CGCCATCGCCGGCTTCCTGGAAGGCGGCTGGGAGGGCATGATCGCCGGCTGGTACGGATACACC T CT CAT GGAGCACACGGCGTGGCCGTGGCCGCT GACCT CAAGAGCACCCAGGAGGCCATTAACA AGAT CACAAAGAACCT GAACT CCCT GAGCGAACT GGAGGT GAAGAAT CT GCAGAGACT GT CAGG CGCCATGGACGAACTGCACAATGAGATCCTGGAGCTGGACGAGAAGGTGGACGACCTGCGGGCC GACACCATCTCCTCCCAGATCGAACTGGCAGTCCTGCTGAGCAACGAGGGCATCATCAACTCCG AGGACGAGCACCTGCTGGCCCTGGAGAGAAAGCTGAAGAAGATGCTGGGCCCCTCTGCCGTGGA GAT C GGCAAC GGCTGCTTC GAAAC CAAGCACAAAT GCAAC CAGAC CT GT CT GGAC C GGAT T GCA GCCGGCACCTTTGACGCCGGGGAATTCAGCCTGCCTACCTTCGACTCCCTGAACATCACCGCCG C T T C T C T GAAC GACGACGGCCTC GACAAT CACAC CATCCTGCTCTACTACTCCACCGCCGCCTC -41- WO 2024 / 220936 PCT / US2024 / 025583 Table 2 depicts nucleic acid sequences of the invention. Each nucleic acid sequence encodes for a signaling peptide sequence (denoted with single underlining), a stabilized extracellular sequence, and a transmembrane domain sequence (denoted with double underlining). In some embodiments, a vaccine composition comprises nucleic acids comprising any one of (or all of) the sequences in Table 2. CAGC CT GGC C GT GAC C CT GAT GAT C GC CAT CT T C GT GGT GTACAT GGT T T C CAGAGACAAC GT C TCCTGCAGCATCTGCCTGtcfa Table 3. Example Composition A with amino acid sequences for antigens comprising signal peptide, stabilized extracellular domain, and transmembrane domain Strain Amino Acid Sequence of Antigen SEQ ID NO: A / New_York / 1 / 191 8 A_ / _H1N1 MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLE DSHNGKLCKLKGIAPLQLGKCNIAGWLLGNPECDLLLTASSWSYIVETSNS ENGTCYPGDFIDYEELREQLSSVSSFEKFEIFPKTSSWPNHETTKGVTAAC SYAGASSFYRNLLWLTKKGSSYPKLSKSYVNNKGKEVLVLWGVHHPPTGTD QQSLYQNADAYVSVGSSKYNRRFTPEIAARPKVRDQAGRMNYYWTLLEPGD TITFEATGNLIAPWYAFALNRGSGSGIITSDAPVHDCNTKCQTPHGAINSS LPFQNIHPVTIGECPKYVRSTKLRMATGLRNIPSIQSRGLFGAIAGFIEGG WTGMIDGWYGYHFQNEQGSGYAADRKSTQNAIDGITNLVNSVIEKMNTQFT SVGKEFNHLEKRIENLNRKVDDGFLDVWTYNAELLVLLLNERTLDYHDSNV KNLYEKVRSQLKNNAKEIGNGCFEFYHKCDDSCMESVKNGTYDYPKYSEES KLNRE EIDGVKLE SMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQ CRICI 85 A / Wisconsin / 5 8 8 / 2019 A_ / _H1N1 MKVKLLVLLCTFTATYADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLE DKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTARSWSYIVETSNS DNGTCYPGDFINYEELREQLSSVSSFERFEIFPKTSSWPNHDSDNGVTAAC PHAGAKSFYKNLIWLVKKGKSYPKINQTYINDKGKEVLVLWGIHHPPTIAD QQSLYQNADAYVFVGTSRYSKKFKPEIATRPKVRDQEGRMNYYWTLVEPGD KITFEATGNLVAPRYAFTMERDAGSGIIISDTPVHDCNTTCQTPEGAINTS LPFQNVHPITIGKCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFIEGG WTGMVDGWYGYHFQNEQGSGYAADLKSTQNAIDKITNAVNSVIEKMNTQFT AVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLANERTLDYHDSNV KNLYEKVRNQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEA KLNREKIDGVKLDSTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQ CRICI 86 A / Brisbane / 59 / 20 07 A_ / _H1N1 MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLE NSHNGKLCLLKGIAPLQLGNCSVAGWILGNPECELLISKESWSYIVEKPNP ENGTCYPGHFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTGVSASCS HNGESSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLVLWGVHHPPNIGNQ KALYHTENAYVSVVSSHYSRKFTPEIAKRPKVRDQEGRINYYWTLLEPGDT IIFEANGNLIAPRYAFALSRGFGSGIINSNAPMDKCDAKCQTPQGAINSSL PFQNVHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGW TGMVDGWYGYHFQNEQGSGYAADQKSTQNAINGITNAVNSVIEKMNTQFTA VGKEFNKLERRMENLNKKVDDGFIDIWTYNAELLVLLANERTLDFHDSNVK NLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESK 87 -42- WO 2024 / 220936 PCT / US2024 / 025583 LNREKIDGVKLE SMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQC RICI A / Wisconsin / 2 8 / 2 011.2011 / 12 A_ / _H1N1 MKVKLLVLLCTFTATYADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLE NRHNGKLCKLRGVAPLHLGKCNIAGWLLGNPECESLSTASSWSYIVETSNS DNGTCYPGDFINYEELREQLSSVSSFERFEIFPKTSSWPNHDTNRGVTAAC PHDGTNSFYRNLIWLVKKGNSYPKINKSYINNKEKEILVLWAIHHPSTSAD QQSLYQNADAYVFVGSSRYSRKFEPEVATRPKVRDQAGRMNYYWTLVEPGD KITFEATGNLVVPRYAFALKRNSGSGIIISDTSVHDCDTNCQTPNGAINTS LPFQNIHPVTIGECPKYVKSTKLRMATGLRNIPSIQSRGLFGAIAGFIEGG WTGMIDGWYGYHFQNEQGSGYAADLKSTQNAIDGITNLVNSVIEKMNTQFT AVGKEFSHLERRIENLNKKVDDGFLDIWTYNAELLVLLLNERTLDYHDSNV KNLYEKVRSQLKNNAKEIGNGCFEFYHKCDDMCMESVKNGTYDYPKYSEEA KLNRE ΕIDGVKLE STRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLO CRICI 88 A / Denver / 57 A_ / _H1N1 MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLE DSHNGKLCRLKGKAPLQLGNCNIAGWVLGNPECESLLSNRSWSYIAETPNS ENGTCYPGDFADYEELREQLSSVSSFERFEIFPKERSWPNHTTRGVTAACP HARKSSFYKNLVWLTEANGSYPNLSRSYVNNQEKEVLVLWGVHHPSNIEEQ RALYRKDNAYVSVVSSNYNRRFTPEIAKRPKVRDQSGRMNYYWTLLEPGDT IIFEATGNLIAPWYAFALSRGPGSGIITSNAPLDECDTKCQTPQGAINSSL PFQNIHPVTIGECPKYVRSTKLRMVTGLRNIPSVQSRGLFGAIAGFIEGGW TGMMDGWYGYHFQNEQGSGYAADQKSTQNAINGITNAVNSVIEKMNTQFTA VGKEFNKLEKRMENLNKKVDDGFMDIWTYNAELLVLLANERTLDFHDSNVK NLYEKVKNQLRNNAKELGNGCFEFYHKCDNECMESVKNGTYDYPKYSEESK LNREKIDGVKLE SMGVYRILAIYSTVASSLVLLVSLGAISFWMCSNGSLQC RICI 89 A / Beij ing / 2 62 / 19 95 A_ / _H1N1 MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLE DSHNGKLCLLKGIAPLQLGNCSVAGWILGNPECESLISKESWSYIVETPNP ENGTCYPGYFADYEELREQLSSVSSFERFEIFPKESSWPNHTVTGVTASCS HNGKSSFYRNLLWLTEKNGLYPNLSNSYVNNKEKEVLVLWGVHHPSNIRDQ RAIYHTENAYVSVVSSHYSRRFTPEIAKRPKVRGQEGRINYYWTLLEPGDT IIFEANGNLIAPWYAFALSRGFGSGIITSNAPMNECDAKCQTPQGAINSSL PFQNVHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGW TGMMDGWYGYHFQNEQGSGYAADQKSTQNAINGITNLVNSVIEKMNTQFTA VGKEFNKLERRMENLNKKVDDGFLDIWTYNAELLVLLLNERTLDFHDSNVK NLYEKVKSQLKNNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESK LNREKIDGVKLE SMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQC RICI 90 A / Puerto_Rico / 8 / 1934 A_ / _H1N1 MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLE DSHNGKLCRLKGIAPLQLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNS ENGICYPGDFIDYEELREQLSSVSSFERFEIFPKESSWPNHNTNKGVTAAC SHEGKSSFYRNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKE QQNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGD ΤΙIFEANGNLIAPMYAFALSRGFGSGIITSNASMHECNTKCQTPLGAINSS LPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGG WTGMIDGWYGYHFQNEQGSGYAADQKSTQNAINGITNAVNTVIEKMNIQFT AVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLANERTLDFHDSNV KNLYEKVKSQLKNNAKEIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEES KLNRE KVDGVKLE SMGIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQ CRICI 91 A / California / 07 / 2009 A_ / _H1N1 MKVKLLVLLCTFTATYADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLE DKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSS DNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAAC PHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSAD QQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGD 92 -43- WO 2024 / 220936 PCT / US2024 / 025583 KITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTS LPFQNIHPITIGKCPKYVKSTKLRLATGLRNIPSIQSRGLFGAIAGFIEGG WTGMVDGWYGYHFQNEQGSGYAADLKSTQNAIDEITNLVNSVIEKMNTQFT AVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLLNERTLDYHDSNV KNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEA KLNRE EIDGVKLE STRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQ CRICI A / Indiana / 11 / 2 01 8 A_ / _H3N2 MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTIVKTITNDRIE VTNATE LVQNS SIGEICDS PHQILDGENCTLIDALLGDPQCDGFQNKKWDL FVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNESFNWTGVKQNGTSS ACIRKSSSSFFSRLNWLTHLNYTYPALNVTMPNNEQFDKLYIWGVHHPGTD KDQIFLYAQSSGRITVSTKRSQQAVIPNIGSRPRIRDIPSRISIYWTIVKP GDILLINSTGNLIAPRGYFKIQSGKSSIMRSDAPIGKCKSECITPNGSIPN DKPFQNVNRITYGACPRYVKHSTLKLATGMRNVPEKQTRGIFGAIAGFIEN GWEGMVDGWYGFRFQNSEGRGQAADLKSTQAAIDQINGLLNRLIGKTNEKF HQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALLNQHTIDLTDSE MNKLFEKTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHNVYRDE ALNNR FQIKGVE LKSGYKDWILWIS FAIS CFLLCVVLLGFIMWACQKGNIR CNICI 93 A / California / 07 / 2004 A_ / _H3N2 MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTIVKTITNDQIE VTNATELVQSSSTGGICDSPHQILDGENCTLIDALLGDPQCDGFQNKKWDL FVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNESFNWTGVTQNGTSS SCKRRSNNSFFSRLNWLTHLKFKYPALNVTMPNNEKFDKLYIWGVHHPGTN NDQISLYTQASGRITVSTKRSQQTVIPNIGSRPRVRDIPSRISIYWTIVKP GDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCNSECITPNGSIPN DKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIEN GWEGMVDGWYGFRFQNSEGIGQAADLKSTQAAINQINGLLNRLIGKTNEKF HQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALLNQHTIDLTDSE MNKLFERTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDE ALNNR FQIKGVE LKSGYKDWILWISFAISCFLLCVVLLGFIMWACQKGNIR CNICI 94 A / Alaska / 01 / 2021 A_ / _H3N2 MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTIVKTITNDRIE VTNATELVQNSSIGEICNS PHQILDGGNCTLIDALLGDPQCDGFQNKEWDL FVE RS RANS S CY PYDVPDYAS LRS LVAS S GT LE FKNE S FNWT GVKQNGT S S ACIRGSSSSFFSRLNWLTSLNNIYPAQNVTMPNKEQFDKLYIWGVHHPDTD KNQFSLFAQSSGRITVSTKRSQQAVIPNIGSRPRIRDIPSRISIYWTIVKP GDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCKSECITPNGSIPN DKPFQNVNRITYGACPRYVKQSTLKLATGMRNVPEKQTRGIFGAIAGFIEN GWEGMVDGWYGFRFQNSEGRGQAADLKSTQAAIDQISGLLNRLIGKTNEKF HQIEKEFSEVEGRVQDLEKYVEDTKIDLWSYNAELLVALLNQHTIDLTDSE MNKLFEKTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNETYDHNVYRDE ALNNR FQIKGVE LKSGYKDWILWISFAISCFLLCVVLLGFIMWACQKGNIR CNICI 95 A / Cambodia / e0826 360 / 2020 A_ / _H3N2 MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTIVKTITNDRIE VTNATELVQNSSIGEICDS PHQILDGGNCTLIDALLGDPQCDGFQNKEWDL FVERSRANSNCYPYDVPDYASLRSLVASSGTLEFKNESFNWTGVKQNGTSS ACIRGSSSSFFSRLNWLTHLNYTYPALNVTMPNNEQFDKLYIWGVHHPSTD KDQISLFAQPSGRITVSTKRSQQAVIPNIGSRPRIRDIPSRISIYWTIVKP GDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCKSECITPNGSIPN DKPFQNVNRITYGACPRYVKQSTLKLATGMRNVPEKQTRGIFGAIAGFIEN GWEGMVDGWYGFRFQNSEGRGQAADLKSTQAAIDQINGLLNRLIGKTNEKF HQIEKEFSEVEGRVQDLEKYVEDTKIDLWSYNAELLVALLNQHTIDLTDSE MNKLFEKTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNETYDHNVYRDE ALNNR FQIKGVE LKSGYKDWILWISFAISCFLLCVVLLGFIMWACQKGNIR CNICI 96 -44- WO 2024 / 220936 PCT / US2024 / 025583 A / Nanchang / 933 / 1 995 A_ / _H3N2 MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTLVKTITNDQIE VTNATELVQSSSTGRICDSPHRILDGKNCTLIDALLGDPHCDGFQNKEWDL FVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFTNEGFNWTGVAQDGTSY ACKRGSVKSFFSRLNWLHKLEYKYPALNVTMPNNDKFDKLYIWGVHHPSTD SDQTSLYVQASGRVTVSTKRSQQTVIPNIGSRPWVRGISSRISIYWTIVKP GDILLIKSTGNLIAPRGYFKIRSGKSSIMRSDAPIGNCNSECITPNGSIPN DKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIEN GWEGMVDGWYGFRFQNSEGTGQAADLKSTQAAINQINGLLNRLIEKTNEKF HQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALLNQHTIDLTDSE MNKLFERTRKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDE ALNNR FQIKGVE LKSGYKDWILWI S FAIS CFLLCVVLLGFIMWACQKGNIR CNICI 97 A / Memphi s / 1 / 1980 A_ / _H3N2 MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTLVKTITNDQIE VTNATELVQSSSTGRICDSPHRILDGKNCTLVDALLGDPHCDGFQNEKWDL FVERSKAFSNCYPYDVPDYASLRSLVASSGTLEFINESFNWTGVTQSGGSY ACKRGSDNSFFSRLNWLYESESKYPVLNVTMPNNGNFDKLYIWGVHHPSTD KEQTNLYVRASGRVTVSTKRSQQTIIPNIGSRPWVRGLSSRISIYWTIVKP GDILLINSNGNLIAPRGYFKIRTGKSSIMRSDAPIGTCSSECITPNGSIPN DKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIEN GWEGMVDGWYGFRFQNSEGTGQAADLKSTQAAIDQINGLLNRVIEKTNEKF HQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALLNQHTIDLTDSE MNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDE ALNNR FQIKGVE LKSGYKDWILWIS FAIS CFLLCVVLLGFIMWACQKGNIR CNICI 98 A / Hong_Kong / l / 19 68 A_ / _H3N2 MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGT LVKTITDDQIE VTNATELVQSSSTGKICNNPHRILDGIDCTLIDALLGDPHCDVFQNETWDL FVERSKAFSNCYPYDVPDYASLRSLVASSGTLEFITEGFTWTGVTQNGGSN ACKRGPGSGFFSRLNWLTKSGSTYPVLNVTMPNNDNFDKLYIWGVHHPSTN QEQTSLYVQASGRVTVSTRRSQQTIIPNIGSRPWVRGLSSRISIYWTIVKP GDVLVINSNGNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITPNGSIPN DKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGLFGAIAGFIEN GWEGMIDGWYGFRFQNSEGTGQAADLKSTQAAIDQINGLLNRVIEKTNEKF HQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALLNQHTIDLTDSE MNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIESIRNGTYDHDVYRDE ALNNR FQIKGVE LKSGYKDWILWISFAISCFLLCVVLLGFIMWACQKGNIR CNICI 99 A / Bilthoven / 1761 / 1976 A_ / _H3N2 MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTLVKTITNDQIE VTNATELVQSSSTGKICDNPHRILDGINCTLIDALLGDPHCDGFQNEKWDL FVERSKAFSNCYPYDVPDYASLRSLVASSGTLEFINEGFNWTGVTQNGGSS ACKRGPDNGFFSRLNWLYKSGSTYPVQNVTMPNNDNSDKLYIWGVHHPSTD KEQTDLYVQASGKVTVSTKRSQQTVIPNVGSRPWVRGLSSRVSIYWTIVKP GDILVINSNGNLIAPRGYFKMRTGKSSIMRSDAPIGTCSSECITPNGSIPN DKPFQNVNKITYGACPKYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIEN GWEGMIDGWYGFRFQNSEGTGQAADLKSTQAAIDQINGLLNRVIEKTNEKF HQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALLNQHTIDLTDSE MNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDE ALNNR FQIKGVE LKSGYKDWILWISFAISCFLLCVVLLGFIMWACQKGNIR CNICI 100 A / Roma / 1949 MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLE DSHNGKLCRLKGIAPLQLGKCNIAGWILGNPECESLFSKKSWSYIAETPNS ENGTCYPGYFADYEELREQLSSVSSFERFEIFPKERSWPKHNVTRGVTAAC SHKGKSSFYRNLLWLTEKDGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIED QKTLYRKENAYVSVVSSNYNRRFTPEIAERPKVRGQAGRINYYWTLLEPGD ΤΙIFEANGNLIAPWHAFALSRGFGSGIITSNASMDECDTKCQTPQGAINSS LPFQNIHPVTIGECPKYVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGG 101 -45- WO 2024 / 220936 PCT / US2024 / 025583 WTGMIDGWYGYHFQNEQGSGYAADQKSTQNAINGITNAVNSVIEKMNTQFT AVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLANERTLDFHDSNV KNLYEKVKSQLKNNAKEIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEES KLNREKIDGVKLE SMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQ CRICI A / MD / 12 / 1991 MKVKLLVLLCTFTATYADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLE DRHNGKLCKLRGVAPLHLGKCNIAGWLLGNPECELLFTASSWSYIVETSNS DNGTCYPGDFINYEELREQLSSVSSFERFEIFPKASSWPDHETNRGVTAAC PYAGANSFYRNLIWLVKKGNSYPKLSKSYVNNKEKEVLVLWGIHHPPTSTD QQSLYQNADAYVFVGSSKYNKKFKPEIATRPKVRGQAGRMNYYWTLVEPGD TITFEATGNLVVPRYAFAMKRGSGSGIIISDTPVHDCNTTCQTPKGAINTS LPFQNIHPVTIGECPKYVKSTKLRMATGLRNIPSIQSRGLFGAIAGFIEGG WTGMIDGWYGYHFQNEQGSGYAADQKSTQNAIDGITNAVNSVIEKMNTQFT AVGKEFNHLEKRIENLNKKVDDGFLDVWTYNAELLVLLANERTLDYHDSNV KNLYEKVRSQLKNNAKEIGNGCFEFYHKCDDTCMESVKNGTYDYPKYSEES KLNRE EIDGVKLE STRIYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQ CRICI 102 A / Auckland / 588 / 2 000 MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTLVKTITNDQIE VTNATELVQSSSTGGICDSPHQILDGENCTLIDALLGDPHCDGFQNKEWDL FVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNESFNWTGVAQNGTSS ACKRRSNKSFFSRLNWLHQLKYKYPALNVTMPNNEKFDKLYIWGVHHPSTD SDQISLYAQAPGRVTVSTKRSQQTVIPNIGSRPWVRGVSSRISIYWTIVKP GDILLINCTGNLIAPRGYFKIRSGKSSIMRSDASIGKCNSECITPNGSIPN DKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIEN GWEGMVDGWYGFRFQNSEGTGQAADLKSTQAAINQINGLLNRLIEKTNEKF HQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALLNQHTIDLTDSE MNKLFERTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDE ALNNR FQIKGVE LKSGYKDWILWI S FAIS CFLLCVVLLGFIMWACQKGNIR CNICI 103 A / Argentina / 2 8 3 0 2 / 2010 MKTIIALSYILCLVFAQKLPGNDNSTATLCLGHHAVPNGTIVKTITNDQIE VTNATELVQSSSTGEICDSPHQILDGKNCTLIDALLGDPQCDGFQNKKWDL FVERSKAYSNCYPYDVPDYASLRSLVASSGTLEFNNESFNWTGVTQDGTSS ACIRGSKNSFFSRLNWLTHLNFKYPALNVTMPNNEQFDKLYIWGVHHPGTD KDQIFLYAQASGRITVSTKRSQQAAIPNIGSRPRVRNIPSRISIYWTIVKP GDILLINSTGNLIAPRGYFKIRSGKSSIMRSDAPIGKCNSECITPNGSIPN DKPFQNVNRITYGACPRYVKQNTLKLATGMRNVPEKQTRGIFGAIAGFIEN GWEGMVDGWYGFRFQNSEGRGQAADLKSTQAAIDQINGLLNRLIGKTNEKF HQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALLNQHTIDLTDSE MNKLFEKTKKQLRENAEDMGNGCFKIYHKCDNACIGSIRNGTYDHDVYRDE ALNKR FQIKGIE LKSGYKDWILWIS FAIS CFLLCVVLLGFIMWACQKGNIR CNICI 104 B / Austria / 135941 7 / 2021 MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIPLTTTP TKSHFANLKGTETRGKLCPKCLNCTDLDVALGRPKCTGKIPSARVSILHEV RPVTSGCFPIMHDRTKIRQLPNLLRGYEHVRLSTHNVINTEDAPGGPYEIG TSGSCLNITNGKGFFATMAWAVPKNKTATNPLTIEVPYICTEEEDQITVWG FHSDDETQMARLYGDSKPQKFTSSANGVTTHYVSQIGGFPNQTEDGGLPQS GRIVVDYMVQKSGKTGTITYQRGILLPQKVWCASGKSKVIKGSLPLIGEAD CLHEKYGGLNKSKPYYTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLK ERGFFGAIAGFLEGGWEGMIAGWYGYTSHGAHGVAVAADLKSTQEAINKIT KNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAV LLSNEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKCNQTCLDR IAAGT FDAGE FS LPT FDS LNITAAS LNDDGLDNHTILLYYSTAASSLAVTL MIAIFVVYMVSRDNVSCSICL 105 -46- WO 2024 / 220936 PCT / US2024 / 025583 Table 3 depicts antigen amino acid sequences which may be encoded by nucleic acids of a vaccine composition of the invention. The amino acid sequences comprise a signaling peptide sequence (denoted with single underlining), an extracellular sequence, and a transmembrane domain sequence (denoted with double underlining). In some embodiments, a vaccine composition comprises nucleic acids encoding any one of (or all of) the sequences in Table 3. Table 4 - Stabilized amino acid sequences of antigen extracellular domains Strain Amino Acid Sequence of Antigen SEQ ID NO: A / New_York / 1 / 191 8 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCKLKGIAPL QLGKCNIAGWLLGNPECDLLLTASSWSYIVETSNSENGTCYPGDFIDYEEL REQLSSVSSFEKFEIFPKTSSWPNHETTKGVTAACSYAGASSFYRNLLWLT KKGSSYPKLSKSYVNNKGKEVLVLWGVHHPPTGTDQQSLYQNADAYVSVGS SKYNRRFTPEIAARPKVRDQAGRMNYYWTLLEPGDTITFEATGNLIAPWYA FALNRGSGSGIITSDAPVHDCNTKCQTPHGAINSSLPFQNIHPVTIGECPK YVRSTKLRMATGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHFQNE QGSGYAADRKSTQNAIDGITNLVNSVIEKMNTQFTSVGKEFNHLEKRIENL NRKVDDGFLDVWTYNAELLVLLLNERTLDYHDSNVKNLYEKVRSQLKNNAK EIGNGCFEFYHKCDDSCMESVKNGTYDYPKYSEESKLNREEIDGVKLES 108 A / Wisconsin / 5 8 8 / 2019 A_ / _H1N1 ADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPL HLGKCNIAGWILGNPECESLSTARSWSYIVETSNSDNGTCYPGDFINYEEL REQLSSVSSFERFEIFPKTSSWPNHDSDNGVTAACPHAGAKSFYKNLIWLV KKGKSYPKINQTYINDKGKEVLVLWGIHHPPTIADQQSLYQNADAYVFVGT SRYSKKFKPEIATRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVAPRYA FTMERDAGSGIIISDTPVHDCNTTCQTPEGAINTSLPFQNVHPITIGKCPK YVKSTKLRLATGLRNVPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHFQNE QGSGYAADLKSTQNAIDKITNAVNSVIEKMNTQFTAVGKEFNHLEKRIENL NKKVDDGFLDIWTYNAELLVLLANERTLDYHDSNVKNLYEKVRNQLKNNAK EIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREKIDGVKLDS 109 A / Brisbane / 59 / 20 07 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENSHNGKLCLLKGIAPL QLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEEL REQLSSVSSFERFEIFPKESSWPNHTVTGVSASCSHNGESSFYRNLLWLTG KNGLYPNLSKSYANNKEKEVLVLWGVHHPPNIGNQKALYHTENAYVSVVSS HYSRKFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEANGNLIAPRYAF ALSRGFGSGIINSNAPMDKCDAKCQTPQGAINSSLPFQNVHPVTIGECPKY VRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHFQNEQ GSGYAADQKSTQNAINGITNAVNSVIEKMNTQFTAVGKEFNKLERRMENLN KKVDDGFIDIWTYNAELLVLLANERTLDFHDSNVKNLYEKVKSQLKNNAKE IGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLNREKIDGVKLES 110 A / Wisconsin / 2 8 / 2 011.2011 / 12 A_ / _H1N1 ADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLENRHNGKLCKLRGVAPL HLGKCNIAGWLLGNPECESLSTASSWSYIVETSNSDNGTCYPGDFINYEEL REQLSSVSSFERFEIFPKTSSWPNHDTNRGVTAACPHDGTNSFYRNLIWLV KKGNSYPKINKSYINNKEKEILVLWAIHHPSTSADQQSLYQNADAYVFVGS SRYSRKFEPEVATRPKVRDQAGRMNYYWTLVEPGDKITFEATGNLVVPRYA FALKRNSGSGIIISDTSVHDCDTNCQTPNGAINTSLPFQNIHPVTIGECPK YVKSTKLRMATGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHFQNE QGSGYAADLKSTQNAIDGITNLVNSVIEKMNTQFTAVGKEFSHLERRIENL NKKVDDGFLDIWTYNAELLVLLLNERTLDYHDSNVKNLYEKVRSQLKNNAK EIGNGCFEFYHKCDDMCMESVKNGTYDYPKYSEEAKLNREEIDGVKLES 111 -47- WO 2024 / 220936 PCT / US2024 / 025583 A / Denver / 57 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGKAPL QLGNCNIAGWVLGNPECESLLSNRSWSYIAETPNSENGTCYPGDFADYEEL REQLSSVSSFERFEIFPKERSWPNHTTRGVTAACPHARKSSFYKNLVWLTE ANGSYPNLSRSYVNNQEKEVLVLWGVHHPSNIEEQRALYRKDNAYVSVVSS NYNRRFTPEIAKRPKVRDQSGRMNYYWTLLEPGDTIIFEATGNLIAPWYAF ALSRGPGSGIITSNAPLDECDTKCQTPQGAINSSLPFQNIHPVTIGECPKY VRSTKLRMVTGLRNIPSVQSRGLFGAIAGFIEGGWTGMMDGWYGYHFQNEQ GSGYAADQKSTQNAINGITNAVNSVIEKMNTQFTAVGKEFNKLEKRMENLN KKVDDGFMDIWTYNAELLVLLANERTLDFHDSNVKNLYEKVKNQLRNNAKE LGNGCFEFYHKCDNECMESVKNGTYDYPKYSEESKLNREKIDGVKLES 112 A / Beij ing / 2 62 / 19 95 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCLLKGIAPL QLGNCSVAGWILGNPECESLISKESWSYIVETPNPENGTCYPGYFADYEEL REQLSSVSSFERFEIFPKESSWPNHTVTGVTASCSHNGKSSFYRNLLWLTE KNGLYPNLSNSYVNNKEKEVLVLWGVHHPSNIRDQRAIYHTENAYVSVVSS HYSRRFTPEIAKRPKVRGQEGRINYYWTLLEPGDTIIFEANGNLIAPWYAF ALSRGFGSGIITSNAPMNECDAKCQTPQGAINSSLPFQNVHPVTIGECPKY VRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMMDGWYGYHFQNEQ GSGYAADQKSTQNAINGITNLVNSVIEKMNTQFTAVGKEFNKLERRMENLN KKVDDGFLDIWTYNAELLVLLLNERTLDFHDSNVKNLYEKVKSQLKNNAKE IGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKIDGVKLES 113 A / Puerto_Rico / 8 / 1934 A_ / _H1N1 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPL QLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFIDYEEL REQLSSVSSFERFEIFPKESSWPNHNTNKGVTAACSHEGKSSFYRNLLWLT EKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKEQQNLYQNENAYVSVVT SNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYA FALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPK YVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHFQNE QGSGYAADQKSTQNAINGITNAVNTVIEKMNIQFTAVGKEFNKLEKRMENL NKKVDDGFLDIWTYNAELLVLLANERTLDFHDSNVKNLYEKVKSQLKNNAK EIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLES 114 A / California / 07 / 2009 A_ / _H1N1 ADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPL HLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEEL REQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLV KKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVFVGS SRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYA FAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITIGKCPK YVKSTKLRLATGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHFQNE QGSGYAADLKSTQNAIDEITNLVNSVIEKMNTQFTAVGKEFNHLEKRIENL NKKVDDGFLDIWTYNAELLVLLLNERTLDYHDSNVKNLYEKVRSQLKNNAK EIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREEIDGVKLES 115 A / Indiana / 11 / 2 01 8 A_ / _H3N2 TATLCLGHHAVPNGTIVKTITNDRIEVTNATELVQNSSIGEICDSPHQILD GENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSL VASSGTLEFNNESFNWTGVKQNGTSSACIRKSSSSFFSRLNWLTHLNYTYP ALNVTMPNNEQFDKLYIWGVHHPGTDKDQIFLYAQSSGRITVSTKRSQQAV IPNIGSRPRIRDIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIQSGK SSIMRSDAPIGKCKSECITPNGSIPNDKPFQNVNRITYGACPRYVKHSTLK LATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRFQNSEGRGQAAD LKSTQAAIDQINGLLNRLIGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTK IDLWSYNAELLVALLNQHTIDLTDSEMNKLFEKTKKQLRENAEDMGNGCFK IYHKCDNACIGSIRNGTYDHNVYRDEALNNRFQIKGVELKS 116 A / California / 07 / 2004 A_ / _H3N2 TATLCLGHHAVPNGTIVKTITNDQIEVTNATELVQSSSTGGICDSPHQILD GENCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSL VASSGTLEFNNESFNWTGVTQNGTSSSCKRRSNNSFFSRLNWLTHLKFKYP ALNVTMPNNEKFDKLYIWGVHHPGTNNDQISLYTQASGRITVSTKRSQQTV IPNIGSRPRVRDIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGK 117 -48- WO 2024 / 220936 PCT / US2024 / 025583 SSIMRSDAPIGKCNSECITPNGSIPNDKPFQNVNRITYGACPRYVKQNTLK LATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRFQNSEGIGQAAD LKSTQAAINQINGLLNRLIGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTK IDLWSYNAELLVALLNQHTIDLTDSEMNKLFERTKKQLRENAEDMGNGCFK IYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKS A / Alaska / 01 / 2021 A_ / _H3N2 TATLCLGHHAVPNGTIVKTITNDRIEVTNATELVQNSSIGEICNSPHQILD GGNCTLIDALLGDPQCDGFQNKEWDLFVERSRANSSCYPYDVPDYASLRSL VASSGTLEFKNESFNWTGVKQNGTSSACIRGSSSSFFSRLNWLTSLNNIYP AQNVTMPNKEQFDKLYIWGVHHPDTDKNQFSLFAQSSGRITVSTKRSQQAV IPNIGSRPRIRDIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGK SSIMRSDAPIGKCKSECITPNGSIPNDKPFQNVNRITYGACPRYVKQSTLK LATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRFQNSEGRGQAAD LKSTQAAIDQISGLLNRLIGKTNEKFHQIEKEFSEVEGRVQDLEKYVEDTK IDLWSYNAELLVALLNQHTIDLTDSEMNKLFEKTKKQLRENAEDMGNGCFK IYHKCDNACIGSIRNETYDHNVYRDEALNNRFQIKGVELKS 118 A / Cambodia / e0826 360 / 2020 A_ / _H3N2 TATLCLGHHAVPNGTIVKTITNDRIEVTNATELVQNSSIGEICDSPHQILD GGNCTLIDALLGDPQCDGFQNKEWDLFVERSRANSNCYPYDVPDYASLRSL VASSGTLEFKNESFNWTGVKQNGTSSACIRGSSSSFFSRLNWLTHLNYTYP ALNVTMPNNEQFDKLYIWGVHHPSTDKDQISLFAQPSGRITVSTKRSQQAV IPNIGSRPRIRDIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGK SSIMRSDAPIGKCKSECITPNGSIPNDKPFQNVNRITYGACPRYVKQSTLK LATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRFQNSEGRGQAAD LKSTQAAIDQINGLLNRLIGKTNEKFHQIEKEFSEVEGRVQDLEKYVEDTK IDLWSYNAELLVALLNQHTIDLTDSEMNKLFEKTKKQLRENAEDMGNGCFK IYHKCDNACIGSIRNETYDHNVYRDEALNNRFQIKGVELKS 119 A / Nanchang / 933 / 1 995 A_ / _H3N2 TATLCLGHHAVPNGTLVKTITNDQIEVTNATELVQSSSTGRICDSPHRILD GKNCTLIDALLGDPHCDGFQNKEWDLFVERSKAYSNCYPYDVPDYASLRSL VASSGTLEFTNEGFNWTGVAQDGTSYACKRGSVKSFFSRLNWLHKLEYKYP ALNVTMPNNDKFDKLYIWGVHHPSTDSDQTSLYVQASGRVTVSTKRSQQTV IPNIGSRPWVRGISSRISIYWTIVKPGDILLIKSTGNLIAPRGYFKIRSGK SSIMRSDAPIGNCNSECITPNGSIPNDKPFQNVNRITYGACPRYVKQNTLK LATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRFQNSEGTGQAAD LKSTQAAINQINGLLNRLIEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTK IDLWSYNAELLVALLNQHTIDLTDSEMNKLFERTRKQLRENAEDMGNGCFK IYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKS 120 A / Memphi s / 1 / 1980 A_ / _H3N2 TATLCLGHHAVPNGTLVKTITNDQIEVTNATELVQSSSTGRICDSPHRILD GKNCTLVDALLGDPHCDGFQNEKWDLFVERSKAFSNCYPYDVPDYASLRSL VASSGTLEFINESFNWTGVTQSGGSYACKRGSDNSFFSRLNWLYESESKYP VLNVTMPNNGNFDKLYIWGVHHPSTDKEQTNLYVRASGRVTVSTKRSQQTI IPNIGSRPWVRGLSSRISIYWTIVKPGDILLINSNGNLIAPRGYFKIRTGK SSIMRSDAPIGTCSSECITPNGSIPNDKPFQNVNKITYGACPKYVKQNTLK LATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRFQNSEGTGQAAD LKSTQAAIDQINGLLNRVIEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTK IDLWSYNAELLVALLNQHTIDLTDSEMNKLFEKTRRQLRENAEDMGNGCFK IYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKS 121 A / Hong_Kong / l / 19 68 A_ / _H3N2 TATLCLGHHAVPNGTLVKTITDDQIEVTNATELVQSSSTGKICNNPHRILD GIDCTLIDALLGDPHCDVFQNETWDLFVERSKAFSNCYPYDVPDYASLRSL VASSGTLEFITEGFTWTGVTQNGGSNACKRGPGSGFFSRLNWLTKSGSTYP VLNVTMPNNDNFDKLYIWGVHHPSTNQEQTSLYVQASGRVTVSTRRSQQTI IPNIGSRPWVRGLSSRISIYWTIVKPGDVLVINSNGNLIAPRGYFKMRTGK SSIMRSDAPIDTCISECITPNGSIPNDKPFQNVNKITYGACPKYVKQNTLK LATGMRNVPEKQTRGLFGAIAGFIENGWEGMIDGWYGFRFQNSEGTGQAAD LKSTQAAIDQINGLLNRVIEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTK IDLWSYNAELLVALLNQHTIDLTDSEMNKLFEKTRRQLRENAEDMGNGCFK IYHKCDNACIESIRNGTYDHDVYRDEALNNRFQIKGVELKS 122 -49- WO 2024 / 220936 PCT / US2024 / 025583 A / Bilthoven / 1761 / 1976 A_ / _H3N2 TATLCLGHHAVPNGTLVKTITNDQIEVTNATELVQSSSTGKICDNPHRILD GINCTLIDALLGDPHCDGFQNEKWDLFVERSKAFSNCYPYDVPDYASLRSL VASSGTLEFINEGFNWTGVTQNGGSSACKRGPDNGFFSRLNWLYKSGSTYP VQNVTMPNNDNSDKLYIWGVHHPSTDKEQTDLYVQASGKVTVSTKRSQQTV IPNVGSRPWVRGLSSRVSIYWTIVKPGDILVINSNGNLIAPRGYFKMRTGK SSIMRSDAPIGTCSSECITPNGSIPNDKPFQNVNKITYGACPKYVKQNTLK LATGMRNVPEKQTRGIFGAIAGFIENGWEGMIDGWYGFRFQNSEGTGQAAD LKSTQAAIDQINGLLNRVIEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTK IDLWSYNAELLVALLNQHTIDLTDSEMNKLFEKTRRQLRENAEDMGNGCFK IYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKS 123 A / Roma / 1949 ADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPL QLGKCNIAGWILGNPECESLFSKKSWSYIAETPNSENGTCYPGYFADYEEL REQLSSVSSFERFEIFPKERSWPKHNVTRGVTAACSHKGKSSFYRNLLWLT EKDGSYPNLSKSYVNNKEKEVLVLWGVHHPSNIEDQKTLYRKENAYVSVVS SNYNRRFTPEIAERPKVRGQAGRINYYWTLLEPGDTIIFEANGNLIAPWHA FALSRGFGSGIITSNASMDECDTKCQTPQGAINSSLPFQNIHPVTIGECPK YVRSTKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHFQNE QGSGYAADQKSTQNAINGITNAVNSVIEKMNTQFTAVGKEFNKLEKRMENL NKKVDDGFLDIWTYNAELLVLLANERTLDFHDSNVKNLYEKVKSQLKNNAK EIGNGCFEFYHKCNNECMESVKNGTYDYPKYSEESKLNREKIDGVKLES 124 A / MD / 12 / 1991 ADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDRHNGKLCKLRGVAPL HLGKCNIAGWLLGNPECELLFTASSWSYIVETSNSDNGTCYPGDFINYEEL REQLSSVSSFERFEIFPKASSWPDHETNRGVTAACPYAGANSFYRNLIWLV KKGNSYPKLSKSYVNNKEKEVLVLWGIHHPPTSTDQQSLYQNADAYVFVGS SKYNKKFKPEIATRPKVRGQAGRMNYYWTLVEPGDTITFEATGNLVVPRYA FAMKRGSGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPVTIGECPK YVKSTKLRMATGLRNIPSIQSRGLFGAIAGFIEGGWTGMIDGWYGYHFQNE QGSGYAADQKSTQNAIDGITNAVNSVIEKMNTQFTAVGKEFNHLEKRIENL NKKVDDGFLDWTYNAELLVLLANERTLDYHDSNVKNLYEKVRSQLKNNAK EIGNGCFEFYHKCDDTCMESVKNGTYDYPKYSEESKLNREEIDGVKLES 125 A / Auckland / 588 / 2 000 TATLCLGHHAVPNGTLVKTITNDQIEVTNATELVQSSSTGGICDSPHQILD GENCTLIDALLGDPHCDGFQNKEWDLFVERSKAYSNCYPYDVPDYASLRSL VASSGTLEFNNESFNWTGVAQNGTSSACKRRSNKSFFSRLNWLHQLKYKYP ALNVTMPNNEKFDKLYIWGVHHPSTDSDQISLYAQAPGRVTVSTKRSQQTV IPNIGSRPWVRGVSSRISIYWTIVKPGDILLINCTGNLIAPRGYFKIRSGK SSIMRSDASIGKCNSECITPNGSIPNDKPFQNVNRITYGACPRYVKQNTLK LATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRFQNSEGTGQAAD LKSTQAAINQINGLLNRLIEKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTK IDLWSYNAELLVALLNQHTIDLTDSEMNKLFERTKKQLRENAEDMGNGCFK IYHKCDNACIGSIRNGTYDHDVYRDEALNNRFQIKGVELKS 126 A / Argentina / 2 8 3 0 2 / 2010 TATLCLGHHAVPNGTIVKTITNDQIEVTNATELVQSSSTGEICDSPHQILD GKNCTLIDALLGDPQCDGFQNKKWDLFVERSKAYSNCYPYDVPDYASLRSL VASSGTLEFNNESFNWTGVTQDGTSSACIRGSKNSFFSRLNWLTHLNFKYP ALNVTMPNNEQFDKLYIWGVHHPGTDKDQIFLYAQASGRITVSTKRSQQAA IPNIGSRPRVRNIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKIRSGK SSIMRSDAPIGKCNSECITPNGSIPNDKPFQNVNRITYGACPRYVKQNTLK LATGMRNVPEKQTRGIFGAIAGFIENGWEGMVDGWYGFRFQNSEGRGQAAD LKSTQAAIDQINGLLNRLIGKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTK IDLWSYNAELLVALLNQHTIDLTDSEMNKLFEKTKKQLRENAEDMGNGCFK IYHKCDNACIGSIRNGTYDHDVYRDEALNKRFQIKGIELKS 127 B / Austria / 135941 7 / 2021 DRICTGITSSNSPHVVKTATQGEVNVTGVIPLTTTPTKSHFANLKGTETRG KLCPKCLNCTDLDVALGRPKCTGKIPSARVSILHEVRPVTSGCFPIMHDRT KIRQLPNLLRGYEHVRLSTHNVINTEDAPGGPYEIGTSGSCLNITNGKGFF ATMAWAVPKNKTATNPLTIEVPYICTEEEDQITVWGFHSDDETQMARLYGD SKPQKFTSSANGVTTHYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKT 128 -50- WO 2024 / 220936 PCT / US2024 / 025583 GTITYQRGILLPQKVWCASGKSKVIKGSLPLIGEADCLHEKYGGLNKSKPY YTGEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGG WEGMIAGWYGYTSHGAHGVAVAADLKSTQEAINKITKNLNSLSELEVKNLQ RLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHL LALERKLKKMLGPSAVEIGNGCFETKHKCNQTCLDRIAAGTFDAGEFSLPT FDSLNITAASLNDDGLDNHT
[0018] In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 1 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 2 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 2 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 43, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 44, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 4 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 4 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 45, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 5 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 5 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 46, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 6 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 6 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 47, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 7 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 7 or a sequence at least 70% identical thereto further -51- WO 2024 / 220936 PCT / US2024 / 025583 comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 48, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 8 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 8 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 49, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 9 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 9 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 50, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 10 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 11 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 12 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 13 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 14 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 15 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 51, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 17 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 17 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 52, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical thereto further -52- WO 2024 / 220936 PCT / US2024 / 025583 comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 53, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 54, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 20 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 20 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 55, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 56, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 22 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 22 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 57, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 23 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 58, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 25 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 26 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 27 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 28 or a sequence at -53- WO 2024 / 220936 PCT / US2024 / 025583 least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 29 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 30 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 31 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 32 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 33 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 34 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 35 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 36 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 37 or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 38 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 38 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 59, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 39 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 39 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 60, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 40 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 40 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 61, or a sequence at least 70% identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 41 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 41 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 62, or a sequence at least 70% -54- WO 2024 / 220936 PCT / US2024 / 025583 identical thereto. In some embodiments, the plurality of antigens comprises an amino acid sequence corresponding to SEQ ID NO: 42 or a sequence at least 70% identical thereto. In some embodiments, the amino acid sequence corresponding to SEQ ID NO: 42 or a sequence at least 70% identical thereto further comprises a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 63, or a sequence at least 70% identical thereto.
[0019] In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 108 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 109 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 110 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 111 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 112 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 113 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 114 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 115 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 116 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 117 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 118 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 119 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 120 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 121 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence -55- WO 2024 / 220936 PCT / US2024 / 025583 corresponding to SEQ ID NO: 122 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 123 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 124 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 125 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 126 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 127 or a sequence at least 90% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 128 or a sequence at least 90% identical thereto.
[0020] In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 108 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 109 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 110 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 111 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 112 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 113 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 114 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 115 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 116 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 117 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 118 or a sequence at least 95% identical thereto. In some -56- WO 2024 / 220936 PCT / US2024 / 025583 embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 119 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 120 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 121 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 122 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 123 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 124 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 125 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 126 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 127 or a sequence at least 95% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 128 or a sequence at least 95% identical thereto.
[0021] In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 108 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 109 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 110 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 111 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 112 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 113 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 114 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence -57- WO 2024 / 220936 PCT / US2024 / 025583 corresponding to SEQ ID NO: 115 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 116 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 117 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 118 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 119 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 120 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 121 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 122 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 123 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 124 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 125 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 126 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 127 or a sequence at least 98% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 128 or a sequence at least 98% identical thereto.
[0022] In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 108 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 109 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 110 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 111 or a sequence at least 99% identical thereto. In some -58- WO 2024 / 220936 PCT / US2024 / 025583 embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 112 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 113 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 114 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 115 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 116 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 117 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 118 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 119 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 120 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 121 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 122 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 123 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 124 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 125 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 126 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 127 or a sequence at least 99% identical thereto. In some embodiments, the plurality of antigens comprises a polypeptide with amino acid sequence corresponding to SEQ ID NO: 128 or a sequence at least 99% identical thereto. -59- WO 2024 / 220936 PCT / US2024 / 025583
[0023] In some embodiments, the vaccine composition comprises eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16- 23, or 29. In some embodiments, the vaccine composition comprises eight distinct antigens comprising amino acid sequences selected from the group consisting of at least 6 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical to any one of such sequences. In some embodiments, the vaccine composition comprises eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical to any one of such sequences. In some embodiments, the vaccine composition comprises at least 10 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical to any one of such sequences. In some embodiments, the vaccine composition comprises at least 12 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical to any one of such sequences. In some embodiments, the vaccine composition comprises at least 14 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical to any one of such sequences. In some embodiments, the vaccine composition comprises at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical to any one of such sequences. In some embodiments, the vaccine composition further comprises a pharmaceutically acceptable carrier.
[0024] In some embodiments, the vaccine composition comprises eight or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16- 22, 24, 38-42. In some embodiments, the vaccine composition comprises eight or more distinct antigens comprising amino acid sequences selected from the group consisting of at least 6 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical to any one of such sequences. In some embodiments, the vaccine composition comprises eight or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16- 22, 24, 38-42, or sequences at least 70% identical to any one of such sequences. In some embodiments, the vaccine composition comprises at least 10 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical to any one of such sequences. In some embodiments, the vaccine composition comprises at least 12 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least -60- WO 2024 / 220936 PCT / US2024 / 025583 70% identical to any one of such sequences. In some embodiments, the vaccine composition comprises at least 14 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical to any one of such sequences. In some embodiments, the vaccine composition comprises at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical to any one of such sequences. In some embodiments, the vaccine composition further comprises a pharmaceutically acceptable carrier.
[0025] In some embodiments, the vaccine composition comprises four or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 38- 39, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises six or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 38-39, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises eight or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 38-39, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises antigens comprising SEQ ID NOS: 2-9, 38-39, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises four or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 16-22, 24, 40-41, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises six or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 16-22, 24, 40-41, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises eight or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 16-22, 24, 40-41, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises antigens comprising SEQ ID NOS: 16-22, 24, 40-41, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises an antigen comprising SEQ ID NO: 42, or a sequence at least 90% identical thereto.
[0026] In some embodiments, the vaccine composition comprises four or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 108-115, 124-125, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises six or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 108-115, 124-125, or sequences at least 90% identical to any one of such sequences. In some embodiments, the -61- WO 2024 / 220936 PCT / US2024 / 025583 vaccine composition comprises eight or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 108-115, 124-125, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises antigens comprising SEQ ID NOS: 108-115, 124-125, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises four or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 116-123, 126-127, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises six or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 116-123, 126-127, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises eight or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 116-123, 126-127, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises antigens comprising SEQ ID NOS: 116-123, 126-127, or sequences at least 90% identical to any one of such sequences. In some embodiments, the vaccine composition comprises an antigen comprising SEQ ID NO: 128, or a sequence at least 90% identical thereto.
[0027] In some embodiments, each antigen of a plurality of antigens is present in the vaccine composition in an amount of less than about 5 micrograms (pg). In some embodiments, each antigen of a plurality of antigens is present in the vaccine composition in an amount of less than about 5 pg, less than about 4 pg, less than about 3 pg, less than about 2 pg, or less than about 1 pg. In some embodiments, the plurality of antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, at least 16, or at least 17 distinct antigens. In some embodiments, the plurality of antigens comprises no more than 30 antigens. In some embodiments, the plurality of antigens comprises no more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, or 6 antigens. In some embodiments, the plurality of antigens comprises no more than 25 antigens. In some embodiments, the plurality of antigens comprises no more than 20 antigens.
[0028] The present disclosure provides a nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of antigens as disclosed herein. In some embodiments, the one or more nucleic acids are a messenger RNA (mRNA). In some embodiments, the mRNA is encapsulated in lipid nanoparticles. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 1 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of -62- WO 2024 / 220936 PCT / US2024 / 025583 an amino acid sequence corresponding to SEQ ID NO: 2 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 43, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 44, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 4 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 45, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 5 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 46, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 6 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 47, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 7 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 48, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 8 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 49, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or -63- WO 2024 / 220936 PCT / US2024 / 025583 consisting of an amino acid sequence corresponding to SEQ ID NO: 9 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 50, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 10 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 11 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 12 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 13 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 14 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 15 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 51, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 17 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 52, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 53, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids -64- WO 2024 / 220936 PCT / US2024 / 025583 encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 54, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 20 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 55, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 56, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 22 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 57, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 23 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 58, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 25 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 26 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 27 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 28 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 29 or -65- WO 2024 / 220936 PCT / US2024 / 025583 a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 30 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 31 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 32 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 33 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 34 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 35 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 36 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 37 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 38 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 59, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 39 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 60, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 40 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 61, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 41 or a sequence at least -66- WO 2024 / 220936 PCT / US2024 / 025583 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 62, or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 42 or a sequence at least 70% identical thereto. In some embodiments, the one or more nucleic acids encoding for the antigen further encode for a transmembrane domain. In some embodiments, the transmembrane domain comprises the sequence of SEQ ID NO: 63, or a sequence at least 70% identical thereto. In some embodiments, the nucleic acid vaccine composition comprises a nucleic acid having any one of the sequences described in Table 3. In some embodiments, the nucleic acid vaccine composition comprises a nucleic acid having any one of SEQ ID NOS: 64-84. In some embodiments, the nucleic acid encodes a signal peptide sequence. In some embodiments, the nucleic acid encodes a transmembrane domain. In some embodiments, the nucleic acid encodes an extracellular domain.
[0029] In some embodiments, the one or more nucleic acids encoding for an antigen encode a signal peptide, extracellular domain, and transmembrane domain. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 85 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 86 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 87 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 88 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 89 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 90 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 91 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 92 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 93 or -67- WO 2024 / 220936 PCT / US2024 / 025583 a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 94 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 95 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 96 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 97 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 98 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 99 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 100 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 101 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 102 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 103 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 104 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 105 or a sequence at least 90% identical thereto.
[0030] In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 108 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 109 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 110 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence -68- WO 2024 / 220936 PCT / US2024 / 025583 corresponding to SEQ ID NO: 111 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 112 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 113 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 114 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 115 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 116 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 117 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 118 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 119 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 120 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 121 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 122 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 123 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 124 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 125 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 126 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of -69- WO 2024 / 220936 PCT / US2024 / 025583 an amino acid sequence corresponding to SEQ ID NO: 127 or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 128 or a sequence at least 90% identical thereto.
[0031] In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 108 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 109 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 110 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 111 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 112 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 113 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 114 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 115 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 116 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 117 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 118 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 119 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 120 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 121 or a sequence at least 95% identical thereto. In some -70- WO 2024 / 220936 PCT / US2024 / 025583 embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 122 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 123 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 124 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 125 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 126 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 127 or a sequence at least 95% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 128 or a sequence at least 95% identical thereto.
[0032] In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 108 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 109 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 110 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 111 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 112 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 113 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 114 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 115 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence -71- WO 2024 / 220936 PCT / US2024 / 025583 corresponding to SEQ ID NO: 116 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 117 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 118 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 119 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 120 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 121 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 122 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 123 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 124 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 125 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 126 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 127 or a sequence at least 98% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 128 or a sequence at least 98% identical thereto.
[0033] In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 108 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 109 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 110 or a sequence at least 99% identical thereto. In some embodiments, the one or more -72- WO 2024 / 220936 PCT / US2024 / 025583 nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 111 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 112 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 113 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 114 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 115 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 116 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 117 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 118 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 119 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 120 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 121 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 122 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 123 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 124 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 125 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 126 or a sequence at least 99% identical thereto. In some -73- WO 2024 / 220936 PCT / US2024 / 025583 embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 127 or a sequence at least 99% identical thereto. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 128 or a sequence at least 99% identical thereto.
[0034] In some embodiments, the one or more nucleic acids are RNAs and comprise an RNA sequence selected from SEQ ID NOS: 64-84. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 64, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 65, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 66, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 67, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 68, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 69, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 70, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 71, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 72, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 73, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 74, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 75, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 76, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 77, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 78, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 79, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 80, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 81, or a sequence at least 90% identical thereto. In some -74- WO 2024 / 220936 PCT / US2024 / 025583 embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 82, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 83, or a sequence at least 90% identical thereto. In some embodiments, the one or more nucleic acids comprise RNA corresponding to SEQ ID NO: 84, or a sequence at least 90% identical thereto.
[0035] In some embodiments, the one or more nucleic acids encode eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16- 23, or 29, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode six distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode ten distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode twelve distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode fourteen distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode sixteen distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29, or sequences at least 70% identical to any one of such sequences.
[0036] In some embodiments, the one or more nucleic acids encode eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16- 22, 24, 38-42, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode six distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16- 22, 24, 38-42, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode ten distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode twelve distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16- -75- WO 2024 / 220936 PCT / US2024 / 025583 22, 24, 38-42, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode fourteen distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical thereto. In some embodiments, the one or more nucleic acids encode sixteen distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical to any one of such sequences.
[0037] In some embodiments, the one or more nucleic acids encode four or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 38-39, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode six or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 38-39, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode eight or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 38-39, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode antigens comprising SEQ ID NOS: 2-9, 38-39, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode four or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 16-22, 24, 40-41, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode six or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 16-22, 24, 40-41, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode eight or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 16-22, 24, 40-41, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode antigens comprising amino acid sequences corresponding to SEQ ID NOS: 16-22, 24, 40-41, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode an antigen comprising SEQ ID NO: 42, or a sequence at least 90% identical thereto.
[0038] In some embodiments, the one or more nucleic acids encode four or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 108-115, 124-125, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode six or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 108-115, 124-125, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or -76- WO 2024 / 220936 PCT / US2024 / 025583 more nucleic acids encode eight or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 108-115, 124-125, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode antigens comprising SEQ ID NOS: 108-115, 124-125, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode four or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 116-123, 126-1271, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode six or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 116-123, 126-127, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode eight or more distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 116-123, 126-127, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode antigens comprising SEQ ID NOS: 116-123, 126-127, or sequences at least 90% identical to any one of such sequences. In some embodiments, the one or more nucleic acids encode an antigen comprising SEQ ID NO: 128, or a sequence at least 90% identical thereto.
[0039] In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 1. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 2. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 3. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 4. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 5. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 6. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 7. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 8. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 9. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 10. In some embodiments, the one or more nucleic acids encode for an antigen -77- WO 2024 / 220936 PCT / US2024 / 025583 comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 11. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 12. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 13. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 14. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 15. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 16. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 17. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 18. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 19. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 20. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 21. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 22. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 23. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 24. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 25. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 26. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 27. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 28. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 29. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 30. In some embodiments, the one or more nucleic acids encode for an antigen comprising -78- WO 2024 / 220936 PCT / US2024 / 025583 or consisting of an amino acid sequence corresponding to SEQ ID NO: 31. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 32. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 33. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 34. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 35. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 36. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 37. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 38. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 39. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 40. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 41. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 42.
[0040] In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 85. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 86. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 87. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 88. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 89. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 90. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 91. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 92. In some -79- WO 2024 / 220936 PCT / US2024 / 025583 embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 93. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 94. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 95. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 96. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 97. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 98. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 99. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 100. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 101. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 102. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 103. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 104. In some embodiments, the one or more nucleic acids encode for an antigen comprising or consisting of an amino acid sequence corresponding to SEQ ID NO: 105.
[0041] In some embodiments, the one or more nucleic acids encode eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16- 23, or 29. In some embodiments, the one or more nucleic acids encode six distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16- 23, or 29. In some embodiments, the one or more nucleic acids encode eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16- 23, or 29. In some embodiments, the one or more nucleic acids encode ten distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16- 23, or 29. In some embodiments, the one or more nucleic acids encode twelve distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16- 23, or 29. In some embodiments, the one or more nucleic acids encode fourteen distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16- -80- WO 2024 / 220936 PCT / US2024 / 025583 23, or 29. In some embodiments, the one or more nucleic acids encode sixteen distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16- 23, or 29. In some embodiments, the one or more nucleic acids encode eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16- 22, 24, 38-42. In some embodiments, the one or more nucleic acids encode six distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16- 22, 24, 38-42. In some embodiments, the one or more nucleic acids encode eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42. In some embodiments, the one or more nucleic acids encode ten distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42. In some embodiments, the one or more nucleic acids encode twelve distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42. In some embodiments, the one or more nucleic acids encode fourteen distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42. In some embodiments, the one or more nucleic acids encode sixteen distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42.
[0042] In some embodiments, the nucleic acid vaccine composition further comprises a pharmaceutically acceptable carrier. In some embodiments, the one or more nucleic acids that encode a plurality of antigens are present in the nucleic acid vaccine composition in an amount of less than about 5 micrograms (pg) such as, for example, from about 1 ng to about 5 pg. In some embodiments, the one or more nucleic acids that encode a plurality of antigens are present in the nucleic acid vaccine composition in an amount of less than about 3 micrograms (pg) such as, for example, from about 1 ng to about 3 pg. In some embodiments, the one or more nucleic acids that encode a plurality of antigens are present in the nucleic acid vaccine composition in an amount of less than about 5 pg, less than about 4 pg, less than about 3 pg, less than about 2 pg, or less than about 1 pg. In some embodiments, the one or more nucleic acids that encode a plurality of antigens are present in the nucleic acid vaccine composition in an amount of more than 1 ng. In some embodiments, the plurality of antigens comprises at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 distinct antigens. In some embodiments, the plurality of antigens comprises no more than 30 antigens. In some embodiments, the plurality of antigens comprises no more than 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, or 6 antigens. In some embodiments, the plurality of antigens comprises no more than 25 antigens. In some embodiments, the plurality of antigens comprises no more than 20 antigens. -81- WO 2024 / 220936 PCT / US2024 / 025583
[0043] The present disclosure provides a method for preventing an influenza infection in a subject. In some embodiments, the method comprises administering to the subject a vaccine composition as described herein. In another aspect, the present disclosure provides a method of inducing an immune response (e.g., a protective immune response) in a subject by administering to the subject a vaccine composition as disclosed herein. Generation of an immune response via administration of a vaccine composition as described herein can do one or more of: (1) protect a human against influenza virus infection, (2) decrease the likelihood of infection (or decrease the severity of one or more symptoms associated with infection) by an influenza virus, or (3) enhance the immune system of the subject to resist subsequent infection by an influenza virus. The vaccine composition may be administered intramuscularly, subcutaneously, intramuscularly, intranasally, or orally. The nucleic acid vaccine composition can be formulated for delivery as a mRNA / LNP, or DNA. An infection rate in subjects receiving the vaccine may be reduced by 2% (or more) relative or more relative to a placebo control or relative to a subject who did not receive the vaccine composition.
[0044] The term “about” as used herein, refers to a range that is 10% greater than or less than (±) a stated numerical value within the context of the particular usage.
[0045] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, references to “a method” include one or more methods, and / or steps of the type described herein and / or which will become apparent to those persons skilled in the art upon reading this disclosure.
[0046] As used in this specification and the appended claims, reference to a sequence at least 70% identical to a described sequence refers to at least about 70%, about 75%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% identical to the identified sequence. EXAMPLES Example 1: Serum activity to mRNA antigens in mice
[0047] Mice were injected with either Centi-Flu (mRNA encoding a mixture of 16 hemagglutinin antigens, including eight Hl, corresponding to SEQ ID NOs. 2-9; and eight H3, corresponding to SEQ ID NOs. 16-22 and 24) or Flu-Biv (mRNA encoding a mixture of 2 hemagglutinin antigens, including one Hl (SEQ ID NO. 4) and one H3 (SEQ ID NO. 17). All mRNA vaccine compositions were complexed in lipid nanoparticles (LNPs). Specifically, the same LNP composition as BNT162b2 was used. The serum was collected 16 days after -82- WO 2024 / 220936 PCT / US2024 / 025583 immunization and measured by ELISA for antibodies that bind to recombinant hemagglutinin proteins of H3N2 Hong Kong / 1 / 1968 (present in Centi-Flu), H3N2 California / 07 / 2004 (present in Centi-Flu and Flu-Biv), H3N2 Alaska / 01 / 2021 (present in Centi-Flu), H3N2 A / Victoria / 361 / 2011 (heterologous to both Centi-Flu and Flu-Biv), or H3N2 A / Maryland / 02 / 2021 (heterologous to both Centi-Flu and Flu-Biv). FIG. 2A suggests that at a lower matched per-antigen dose, Flu-Biv induced no response while Centi-Flu induced a robust response. For example, when the mice were injected with Centi-Flu LNP at 0.031 pg per antigen (=0.5 ug total mRNA) or Flu-Biv at 0.031 pg per antigen (=0.063 ug total mRNA), Flu-Biv induced no response, while Centi-Flu induced a robust response. Furthermore, this difference cannot be explained by the total antigen dose, as Flu-Biv at 0.25 ug per antigen (=0.5 ug total mRNA) still exhibits a weaker response in all unmatched antigens than Centi-Flu at 0.031 ug / antigen (=0.5 ug total mRNA). FIG. 2B suggests that at a higher per-antigen dose, Flu-Biv induced a weak response, while Centi-Flu induced a more potent response. For example, when the mice were injected with Centi-Flu LNP at 0.25 pg per antigen (=4 ug total mRNA) or Flu- Biv at 0.25 pg per antigen (=0.5 ug total mRNA), Flu-Biv induced a weak response, while Centi- Flu induced a robust response. Furthermore, this difference cannot be explained by the total antigen dose, as Flu-Biv at 2 ug per antigen (=4 ug total mRNA) still exhibits a weaker response in all unmatched antigens than Centi-Flu at 0.25 ug / antigen (=4 ug total mRNA). Therefore, it is the unique combination of (1) using six or more homologous distinct antigen components and (2) mRNA encoding each component at a low dose, that achieves the desired serological effect.
[0048] One example set of eight homologous distinct antigen components encoded by mRNA in the Centi-Flu vaccine composition are A / Hong Kong / 1 / 1968 (SEQ ID NO. 22), A / Nanchang / 933 / 1995 (SEQ ID NO. 20), A / Califomia / 07 / 2004 (SEQ ID NO. 17), A / Memphis / 1 / 1980 (SEQ ID NO. 21), A / Alaska / 01 / 2021 (SEQ ID NO. 18), A / Indiana / 11 / 2018 (SEQ ID NO. 16), A / Cambodia / e0826360 / 2020 (SEQ ID NO. 19), and A / Bilthoven / 1971 / 1976 (SEQ ID NO. 24). FIG. 4 shows that any two of these eight H3N2 homologous distinct antigen components have pairwise sequence identity less than 96%, and greater than 80%. Any subset of six of these eight constitute sets of six homologous distinct antigen components with pairwise sequence identity less than 96% and greater than 80%.
[0049] mRNA generation from DNA plasmids and subsequent encapsulation in lipid nanoparticles (LNPs) was performed using methods well-known in the art, summarized here. DNA plasmids were constructed that comprise, under the SP6 promoter, the same 5’ UTR as used in the clinically approved BNT162b2 vaccine (SEQ ID NO: 106), DNA encoding an antigen component, the same 3’ UTR as used in BNT162b2 (SEQ ID NO: 107), and a poly- adenosine(120) tail. An alternative 3’ UTR from human HBA1 is shown as SEQ ID NO: 129. -83- WO 2024 / 220936 PCT / US2024 / 025583 The plasmids were linearized using a Notl restriction site and utilized as templates for in vitro transcription (IVT) using SP6 RNA polymerase and a mix of nucleoside triphosphates. Nl- methyl-pseudouridine-5’-triphosphate was used instead of uridine-5’-triphosphate for IVT. The Vaccinia enzymatic capping system (New England BioLabs) was used to generate capped mRNA. Purified mRNA was further encapsulated in the same LNP formulation as BNT162b2 (46.3% ionizable lipid ALC-0315, 9.4% phospholipid DSPC, 1.6% ALC-0159 PEG-lipid, and 42.7% cholesterol) to obtain the LNP-encapsulated RNA.
[0050] Codon optimization of nucleic acid sequences may be performed using various methods well-known in the art, including LinearDesign. Table 5. Table of UTR Sequences SEQ ID NO: Sequence Description 106 GAGAATAAACTAGTATTCTTCTGGTCCCCACAGACTCAG AGAGAACCCGCCACC 5’ UTR sequence 107 TGATGACTCGAGCTGGTACTGCATGCACGCAATGCTAGC TGCCCCTTTCCCGTCCTGGGTACCCCGAGTCTCCCCCGA CCTCGGGTCCCAGGTATGCTCCCACCTCCACCTGCCCCA CTCACCACCTCTGCTAGTTCCAGACACCTCCCAAGCACG CAGCAATGCAGCTCAAAACGCTTAGCCTAGCCACACCCC CACGGGAAACAGCAGTGATTAACCTTTAGCAATAAACG AAAGTTTAACTAAGCTATACTAACCCCAGGGTTGGTCAA TTTCGTGCCAGCCACACCCTGGAGCTAGCA 3’ UTR sequence 129 GCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCC TCCCCCCAGCCCCTCCTCCCCTTCCTGCACCCGTACCCCC GTGGTCTTTGAATAAAGTCTGAGTGGGCGGCA Alternative 3 ’ UTR sequence
[0051] Serum ELISA assays in all Examples were performed as follows: The indicated proteins (5ug / mL) were added to microtiter plates (CoStar), in coating buffer (0.1 M sodium bicarbonate, pH 8.6). After incubation at 4°C overnight and blocking with 3% bovine serum albumin (BSA) in PBS, for 1 hour at 37°C, serially diluted serum / plasma in blocking buffer was added to individual wells and incubated for 1 hour at 37°C. Then, plates were washed three times with 0.05% PBST. Horseradish peroxidase (HRP)-conjugated anti-IgG secondary antibody was added to wells and incubated for 1 hour at 37°C.After washing three times with PBST, 2,2'- azino-bis-3-ethylbenzothiazoline-6-sulfonic (Thermo Fisher Scientific Inc., Waltham, MA, USA) or 3,3',5,5'-tetramethylbenzidineliquid substrate system (Thermo Fisher Scientific Inc.) was added to the wells. Absorbance was measured at 405 or 650 nm, respectively, using a microplate spectrophotometer (Multiskan GO, Thermo Fisher Scientific Inc.). -84- WO 2024 / 220936 PCT / US2024 / 025583 Example 2: Serum activity to mRNA antigens in ferret
[0052] Ferrets were immunized once with mRNA encoding any one of eight distinct antigens complexed with a lipid nanoparticle (LNP). Specifically, ferrets were immunized with 1 pg of LNP-encapsulated mRNA encoding the hemagglutinin corresponding to H3N2 Alaska / 01 / 2021 (SEQ ID NO: 18), H3N2 Califomia / 07 / 2004 (SEQ ID NO: 17), H3N2 Cambodia / 2020 (SEQ ID NO: 19), H3N2 Indiana / 11 / 2018 (SEQ ID NO: 16), H3N2 Bilthoven / 1761 / 1976 (SEQ ID NO: 24), H3N2 Nanchang / 933 / 1995 (SEQ ID NO: 20), or H3N2 Memphis / 1 / 1980 (SEQ ID NO: 21). Serum was obtained 28 days after immunization. Serum reactivity to the recombinant protein of each antigen with which the ferrets were immunized was measured, as shown in FIG. 3A. The antigen-matched serum reactivity (i.e., serum from mice immunized with a given antigen tested against that same antigen) was very weak in all cases (EC50 not attained in any group even at the highest tested serum dilution of 1:100).
[0053] Ferrets were immunized with LNP-encapsulated mRNAs encoding the hemagglutinin corresponding to 8 H3N2 antigens (SEQ ID NOs: 18, 24, 9, 19, 16, 22, 20, 21), each at about 0.5 pg per antigen (total of 4 pg of H3N2 antigens). Serum reactivity to the recombinant protein of each antigen with which the ferrets were immunized was measured, as shown in FIG. 3B. The Centi-Flu immunized ferrets exhibited potent responses against all immunized antigens, as shown in FIG. 3B. It suggests that the single antigen at a low per-antigen dose (1 ug per antigen) is insufficient, but Centi-Flu at an even lower per-antigen dose (0.5 ug per antigen) induces potent and broad reactivity. Therefore, it is the unique combination of (1) using six or more homologous distinct antigen components and (2) mRNA encoding each component at a low dose, that achieves the desired serological effect.
[0054] All LNP-encapsulated RNA constructs were generated as described in Example 1. Serum ELISA was performed as described in Example 1.
[0055] One exemplary set of eight homologous distinct antigen components encoded by mRNA in the Centi-Flu vaccine composition are A / Hong Kong / 1 / 1968 (SEQ ID NO. 22), A / Nanchang / 933 / 1995 (SEQ ID NO. 20), A / Califomia / 07 / 2004 (SEQ ID NO. 17), A / Memphis / 1 / 1980 (SEQ ID NO. 21), A / Alaska / 01 / 2021 (SEQ ID NO. 18), A / Indiana / 11 / 2018 (SEQ ID NO. 16), A / Cambodia / e0826360 / 2020 (SEQ ID NO. 19), and A / Bilthoven / 1971 / 1976 (SEQ ID NO. 24). FIG. 4 shows that any two of these eight H3N2 homologous distinct antigen components have pairwise sequence identity less than 96%, and greater than 80%. Any subset of six of these eight constitute sets of six homologous distinct antigen components with pairwise sequence identity less than 96% and greater than 80%. Example 3: Hemagglutination Inhibition Tests on Immunized Mice -85- WO 2024 / 220936 PCT / US2024 / 025583
[0056] Mice were immunized twice (dO, d21) with an LNP-encapsulated mixture of 20 mRNAs (“LNP20”). Specifically, the 20 mRNAs encode antigens comprising SEQ ID NOS: 85-104, provided in Table 3; for example, using mRNA sequences provided in Table 2 (SEQ ID NOS: 64-83). Each mRNA of the mixture encoded for one influenza hemagglutinin (10 Hl antigens, 10 H3 antigens). Mice were immunized with a total mRNA dose of 18 pg, 6 pg, 2 pg, or 0.7 pg. Hemagglutination inhibition (HAI) was tested using serum drawn at 35 days post-immunization (dpi). HAI was tested against strains included in the LNP20 mixture (H1N1 A / Puerto Rico / 8 / 1934, H1N1 A / California / 04 / 2009, and H3N2 A / Alaska 01 / 2021); as well as against heterologous strains not included in the LNP20 mixture (H1N1 A / Connecticut / 01 / 2021, H1N1 A / New Caledonia / 20 / 99, H3N2 A / Fujian / 411 / 2002, H3N2 A / Darwin / 9 / 2021, and B / Michigan / 01 / 2021). HAI titers >40 were observed for all strains except B / Michigan / 01 / 2021, which is expected since LNP20 did not include mRNA encoding any influenza B hemagglutinin antigens.
[0057] The results are depicted in FIG. 5. This demonstrates the potent and broad humoral response induced by LNP20. Example 4: Hemagglutination Inhibition Tests on Immunized Mice
[0058] Mice were immunized twice (dO, d21) with an LNP-encapsulated mixture of 18 mRNAs (“LNP18”). Each mRNA encoded for one influenza hemagglutinin (8x Hl, 8x H3, 2x HAB). Specifically, the mRNAs of LNP18 encode antigens comprising SEQ ID NOS: 85-100 provided in Tablr 3; for example, using mRNA sequences provided in Table 2 (SEQ ID NOS: 64, 67-79, and 82-83). LNP18 further comprises mRNAs encoding two HAB strains: B / Guangdong- Maonan / 316 / 2021 and B / Utah / 02 / 2012. Mice were immunized with a total mRNA dose of 12 pg. Hemagglutination inhibition (HAI) was tested using serum drawn at 63 days post immunization (dpi). HAI was tested against strains included in the LNP20 mixture (H1N1 A / Brisbane / 59 / 2007, H1N1 A / Califomia / 04 / 2009, and H3N2 A / Alaska / 01 / 2021); as well as against heterologous strains not included in the LNP20 mixture (all others). HAI titers >40 were observed for 13 / 16 strains, and >32 for 15 / 16 strains.
[0059] The results are depicted in FIG. 6. This demonstrates the potent and broad humoral response induced by LNP18. Example 5: Hemagglutination Inhibition Tests on Immunized Rats
[0060] Rats were immunized twice (dO, d21) with an LNP-encapsulated mixture of 18 mRNAs (“LNP18”). Each mRNA encoded for one influenza hemagglutinin (8x Hl, 8x H3, 2x HAB). Specifically, the mRNAs of LNP18 encode antigens comprising SEQ ID NOS: 85-100 provided in Tablr 3; for example, using mRNA sequences provided in Table 2 (SEQ ID NOS: 64, 67-79, and 82-83. Rats were immunized with a total mRNA dose of 12 pg. Hemagglutination inhibition -86- WO 2024 / 220936 PCT / US2024 / 025583 (HAI) was tested using serum drawn at 63 days post-immunization (dpi). HAI was tested against strains included in the LNP20 mixture (H1N1 A / Brisbane / 59 / 2007, H1N1 A / California / 04 / 2009, and H3N2 A / Alaska / 01 / 2021); as well as against heterologous strains not included in the LNP20 mixture (all others). HAI titers >40 were observed for 12 / 16 strains, and >32 for 14 / 16 strains.
[0061] The results are depicted in FIG. 7. This demonstrates the potent and broad humoral response induced by LNP18.
[0062] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby. -87- WO 2024 / 220936 PCT / US2024 / 025583 CLAIMS WHAT IS CLAIMED IS: 1. A vaccine composition comprising a plurality of distinct antigens, the vaccine composition comprising at least one of: (a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3; (b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical to SEQ ID NO: 16; (c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18; (d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical to SEQ ID NO: 19; (e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical to SEQ ID NO: 21; (f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical to SEQ ID NO: 24; (g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38 or a sequence at least 70% identical to SEQ ID NO: 38; (h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39 or a sequence at least 70% identical to SEQ ID NO: 39; (i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40 or a sequence at least 70% identical to SEQ ID NO: 40; (j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41 or a sequence at least 70% identical to SEQ ID NO: 41; or (k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42 or a sequence at least 70% identical to SEQ ID NO: 42. 2. The vaccine composition of claim 1, wherein the vaccine composition comprises at least one of: (a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3; (b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16; (c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18; (d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19; (e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21; (f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24; (g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38; -88- WO 2024 / 220936 PCT / US2024 / 025583 (h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39; (i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40; (j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41; or (k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42. 3. The vaccine composition of claim 1 or 2, wherein the plurality of distinct antigens comprises eight distinct antigens, each of which comprises amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42 or sequences at least 90% identical thereto. 4. The vaccine composition of any one of claims 1-3, wherein the plurality of distinct antigens comprises twelve distinct antigens, each of which comprises amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42 or sequences at least 90% identical thereto. 5. The vaccine composition of any preceding claim, wherein the plurality of distinct antigens comprises eighteen distinct antigens, each of which comprises amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42 or sequences at least 90% identical thereto. 6. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3. 7. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18. 8. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19. 9. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21. 10. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24. 11. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38. -89- WO 2024 / 220936 PCT / US2024 / 025583 12. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39. 13. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40. 14. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41. 15. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42. 16. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 2. 17. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 4. 18. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 5. 19. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 6. 20. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 7. 21. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 8. 22. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16. -90- WO 2024 / 220936 PCT / US2024 / 025583 23. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 17. 24. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 20. 25. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 22. 26. The vaccine composition of any preceding claim, wherein the plurality of distinct antigens comprises eighteen distinct antigens selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical thereto. 27. The vaccine composition of any preceding claim, wherein the plurality of distinct antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NO: 2- 9, 16-22, 24, 38-42, or sequences at least 70% identical thereto. 28. The vaccine composition of any preceding claim, further comprising a pharmaceutically acceptable carrier. 29. The vaccine composition of any preceding claim, wherein each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 5 micrograms (pg), such as between 1 ng and 5 pg. 30. The vaccine composition of claim 29, wherein each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 3 pg, such as between 1 ng and 3 pg. 31. The vaccine composition of any preceding claim, wherein the plurality of antigens comprises at 6, at least 8, at least 10, at least 12, at least 14, at least 16 or at least 17 distinct antigens. 32. The vaccine composition of any preceding claim, wherein the composition has no more than 30, no more than 25, or no more than 20 distinct antigens. 33. The vaccine composition of any preceding claim, wherein the plurality of antigens are collectively sufficient to elicit an immune response in a subject yet each individual antigen of the plurality of antigens in present in the composition in an amount that is insufficient to elicit in an immune response in a subject. 34. The vaccine composition of any preceding claim, wherein the vaccine composition comprises SEQ ID NOS: 2-9, 16-22, 24, and 38-42. -91- WO 2024 / 220936 PCT / US2024 / 025583 35. The vaccine composition of any preceding claim, wherein the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 90% identical thereto. 36. The vaccine composition of any preceding claim, wherein the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 95% identical thereto. 37. The vaccine composition of any preceding claim, wherein the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 98% identical thereto. 38. The vaccine composition of any preceding claim, wherein the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 99% identical thereto. 39. The vaccine composition of any preceding claim, wherein the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128. 40. A nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of distinct antigens, wherein the plurality of distinct antigens comprises at least one of: (a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3; (b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical to SEQ ID NO: 16; (c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18; (d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical to SEQ ID NO: 19; (e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical to SEQ ID NO: 21; (f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical to SEQ ID NO: 24; (g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38 or a sequence at least 70% identical to SEQ ID NO: 38. (h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39 or a sequence at least 70% identical to SEQ ID NO: 39. -92- WO 2024 / 220936 PCT / US2024 / 025583 (i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40 or a sequence at least 70% identical to SEQ ID NO: 40. (j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41 or a sequence at least 70% identical to SEQ ID NO: 41. (k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42 or a sequence at least 70% identical to SEQ ID NO: 42. 41. The nucleic acid vaccine composition of claim 40, wherein: the plurality of distinct antigens comprises at least one of: (a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3; (b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16; (c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18; (d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19; (e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21; (f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24; (g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38; (h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39; (i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40; (j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41; or (k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42. 42. The nucleic acid vaccine composition of claim 40 or 41, wherein the one or more nucleic acids comprise messenger RNA (mRNA). 43. The nucleic acid vaccine composition of claim 42, wherein the mRNA is encapsulated in lipid nanoparticles (LNPs). 44. The nucleic acid vaccine composition of any one of claims 40-43, wherein each nucleic acid encoding for each distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 5 pg. 45. The nucleic acid vaccine composition of any one of claims 40-44, wherein each nucleic acid encoding for each distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 3 pg. 46. The nucleic acid vaccine composition of any one of claims 40-44, wherein the one or more nucleic acids encode eight distinct antigens, each of which is selected from a group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42. -93- WO 2024 / 220936 PCT / US2024 / 025583 47. The nucleic acid vaccine composition of any one of claims 40-44, wherein the one or more nucleic acids encode twelve distinct antigens, each of which is selected from a group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42. 48. The nucleic acid vaccine composition of any one of claims 40-44, wherein the one or more nucleic acids encode eighteen distinct antigens, each of which is selected from a group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42. 49. The nucleic acid vaccine composition of any one of claims 40-48, wherein the one or more nucleic acids encode for at least five distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 38-42. 50. The nucleic acid vaccine composition of any one of claims 40-49, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3. 51. The nucleic acid vaccine composition of any one of claims 40-50, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18. 52. The nucleic acid vaccine composition of any one of claims 40-51, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19. 53. The nucleic acid vaccine composition of any one of claims 40-52, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21. 54. The nucleic acid vaccine composition of any one of claims 40-53, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24. 55. The nucleic acid vaccine composition of any one of claims 40-54, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38. 56. The nucleic acid vaccine composition of any one of claims 40-55, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39. 57. The nucleic acid vaccine composition of any one of claims 40-56, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40. -94- WO 2024 / 220936 PCT / US2024 / 025583 58. The nucleic acid vaccine composition of any one of claims 40-57, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41. 59. The nucleic acid vaccine composition of any one of claims 40-58, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42. 60. The nucleic acid vaccine composition of any one of claims 40-59, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 2. 61. The nucleic acid vaccine composition of any one of claims 40-60, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 4. 62. The nucleic acid vaccine composition of any one of claims 40-61, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 5. 63. The nucleic acid vaccine composition of any one of claims 40-62, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 6. 64. The nucleic acid vaccine composition of any one of claims 40-63, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 7. 65. The nucleic acid vaccine composition of any one of claims 40-64, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 8. 66. The nucleic acid vaccine composition of any one of claims 40-65, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16. 67. The nucleic acid vaccine composition of any one of claims 40-66, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 17. 68. The nucleic acid vaccine composition of any one of claims 40-67, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 20. -95- WO 2024 / 220936 PCT / US2024 / 025583 69. The nucleic acid vaccine composition of any one of claims 40-68, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 22. 70. The nucleic acid vaccine composition of any one of claims 40-69, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38. 71. The nucleic acid vaccine composition of any one of claims 40-70, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39. 72. The nucleic acid vaccine composition of any one of claims 40-71, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40. 73. The nucleic acid vaccine composition of any one of claims 40-72, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41. 74. The nucleic acid vaccine composition of any one of claims 40-73, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42. 75. The nucleic acid vaccine composition of any one of claims 40-74, wherein the one or more nucleic acids encode for at least eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42. 76. The nucleic acid vaccine composition of any one of claims 40-75, wherein the plurality of distinct antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42. 77. The nucleic acid vaccine composition of any one of claims 40-76, further comprising a pharmaceutically acceptable carrier. 78. The nucleic acid vaccine composition of any one of claims 40-77, wherein each nucleic acid encoding a distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 5 micrograms (pg), such as from about 1 ng to about 5 pg. 79. The nucleic acid vaccine composition of claim 78, wherein each nucleic acid encoding a distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 3 pg, such as from about 1 ng to about 3 pg. -96- WO 2024 / 220936 PCT / US2024 / 025583 80. The nucleic acid vaccine composition of any one of claims 40-79, wherein the plurality of antigens comprises at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 distinct antigens. 81. The nucleic acid vaccine composition of any one of claims 40-80, wherein the one or more nucleic acids encode for no more than 30, no more than 25, or no more than 20 distinct antigens. 82. The nucleic acid vaccine composition of any one of claims 40-81, wherein, upon administration of the vaccine to a subject, the vaccine elicits an immune response in the subject yet none of the plurality of distinct antigens is individually expressed at a level that is sufficient to elicit an immune response in a subject by itself. 83. The nucleic acid vaccine composition of any one of claims 40-82, wherein the nucleic acid vaccine composition is formulated as a LNP-encapsulated mRNA, DNA, or viral vector. 84. The nucleic acid vaccine composition of any one of claims 42-83, wherein the one or more nucleic acids encode for SEQ ID NOS: 2-9, 16-22, 24, and 38-42. 85. The nucleic acid vaccine composition of any one of claims 40-84, wherein the one or more nucleic acids further encode a transmembrane domain. 86. The nucleic acid vaccine composition of claim 85, wherein the transmembrane domain comprises any one of SEQ ID NOS: 43-63. 87. The nucleic acid vaccine composition of any one of claims 40-86, wherein the one or more nucleic acids encode each of SEQ ID NOS: 43-63. 88. The nucleic acid vaccine composition of any one of claims 40-87, wherein the one or more nucleic acids further encode a signaling peptide. 89. The nucleic acid vaccine composition of any one of claims 40-88, wherein the one or more nucleic acids comprise any one of SEQ ID NOS: 64-84. 90. The nucleic acid vaccine composition of any one of claims 40-89, wherein the one or more nucleic acids comprise each of SEQ ID NOS: 64-84. 91. The nucleic acid vaccine composition of any one of claims 40-90, wherein the one or more nucleic acids encode any one of SEQ ID NOS: 85-105. 92. The nucleic acid vaccine composition of any one of claims 40-91, wherein the one or more nucleic acids encode each of SEQ ID NOS: 85-105. 93. The nucleic acid vaccine composition of any one of claims 40-92, wherein the one or more nucleic acids comprise any one of SEQ ID NOS: 64-83. 94. The nucleic acid vaccine composition of any one of claims 40-93, wherein the one or more nucleic acids comprise each of SEQ ID NOS: 64-83. -97- WO 2024 / 220936 PCT / US2024 / 025583 95. The nucleic acid vaccine composition of any one of claims 40-94, wherein the one or more nucleic acids comprise any one of SEQ ID NOS: 64, 67-79, and 82-83 . 96. The nucleic acid vaccine composition of any one of claims 40-95, wherein the one or more nucleic acids comprise each of SEQ ID NOS: 64, 67-79, and 82-83. 97. The nucleic acid vaccine composition of any one of claims 40-94, wherein the one or more nucleic acids encode any one of SEQ ID NOS: 85-104. 98. The nucleic acid vaccine composition of any one of claims 40-95, wherein the one or more nucleic acids encode each of SEQ ID NOS: 85-104. 99. The nucleic acid vaccine composition of any one of claims 40-94, wherein the one or more nucleic acids encode any one of SEQ ID NOS: 85-100. 100. The nucleic acid vaccine composition of any one of claims 40-95, wherein the one or more nucleic acids encode each of SEQ ID NOS: 85-100. 101. The nucleic acid vaccine composition of any one of claims 40-100, wherein the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 1 OS- 128, or sequences at least 90% identical thereto. 102. The nucleic acid vaccine composition of any one of claims 40-101, wherein the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 1 OS- 128, or sequences at least 95% identical thereto. 103. The nucleic acid vaccine composition of any one of claims 40-102, wherein the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 1 OS- 128, or sequences at least 98% identical thereto. 104. The nucleic acid vaccine composition of any one of claims 40-103, wherein the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 1 OS- 128, or sequences at least 99% identical thereto. 105. A vaccine composition comprising a plurality of distinct antigens, the vaccine composition comprising at least one of: (a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3; (b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical to SEQ ID NO: 16; (c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18; (d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical to SEQ ID NO: 19; -98- WO 2024 / 220936 PCT / US2024 / 025583 (e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical to SEQ ID NO: 21; (f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23 or a sequence at least 70% identical to SEQ ID NO: 23; (g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical to SEQ ID NO: 24; (h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25 or a sequence at least 70% identical to SEQ ID NO: 25; (i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27 or a sequence at least 70% identical to SEQ ID NO: 27; (j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29 or a sequence at least 70% identical to SEQ ID NO: 29; (k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33 or a sequence at least 70% identical to SEQ ID NO: 33; (1) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34 or a sequence at least 70% identical to SEQ ID NO: 34; (m)an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36 or a sequence at least 70% identical to SEQ ID NO: 36; and (n) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37 or a sequence at least 70% identical to SEQ ID NO: 37. 106. The vaccine composition of claim 105, wherein: the vaccine composition comprises at least one of: (a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3; (b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13; (c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18; (d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19; (e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21; (f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23; (g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24; (h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25; (i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27; (j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29; (k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33; (1) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34; -99- WO 2024 / 220936 PCT / US2024 / 025583 (m)an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36; and (n) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37. 107. The vaccine composition of claim 106, wherein the plurality of distinct antigens comprises eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8 or sequences at least 70% identical thereto. 108. The vaccine composition of any one of claims 105-107, wherein the plurality of distinct antigens comprises eight distinct antigens, wherein the eight distinct antigens correspond to amino acid sequences selected from the group consisting of SEQ ID NOS: 16-23 or sequences at least 70% identical thereto. 109. The vaccine composition of any one of claims 105-108, wherein the plurality of distinct antigens comprises eight distinct antigens, wherein the eight distinct antigens correspond to amino acid sequences selected from the group consisting of SEQ ID NOS: 1-15 or sequences at least 70% identical thereto. 110. The vaccine composition of any one of claims 105-109, wherein the plurality of distinct antigens comprises six distinct antigens, wherein the six distinct antigens correspond to amino acid sequences selected from the group consisting of SEQ ID NOS: 16-28 or sequences at least 70% identical thereto. 111. The vaccine composition of any one of claims 105-110, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3. 112. The vaccine composition of any one of claims 105-111, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13. 113. The vaccine composition of any one of claims 105-112, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18. 114. The vaccine composition of any one of claims 105-113, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19. 115. The vaccine composition of any one of claims 105-114, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21. -100- WO 2024 / 220936 PCT / US2024 / 025583 116. The vaccine composition of any one of claims 105-115, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23. 117. The vaccine composition of any one of claims 105-116, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24. 118. The vaccine composition of any one of claims 105-117, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25. 119. The vaccine composition of any one of claims 105-118, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27. 120. The vaccine composition of any one of claims 105-119, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29. 121. The vaccine composition of any one of claims 105-120, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33. 122. The vaccine composition of any one of claims 105-121, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34. 123. The vaccine composition of any one of claims 105-122, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36. 124. The vaccine composition of any one of claims 105-123, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37. 125. The vaccine composition of any one of claims 105-124, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 1. 126. The vaccine composition of any one of claims 105-125, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 2. -101- WO 2024 / 220936 PCT / US2024 / 025583 127. The vaccine composition of any one of claims 105-126, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 4. 128. The vaccine composition of any one of claims 105-127, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 5. 129. The vaccine composition of any one of claims 105-128, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 6. 130. The vaccine composition of any one of claims 105-129, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 7. 131. The vaccine composition of any one of claims 105-130, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 8. 132. The vaccine composition of any one of claims 105-131, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16. 133. The vaccine composition of any one of claims 105-132, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 17. 134. The vaccine composition of any one of claims 105-133, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 20. 135. The vaccine composition of any one of claims 105-134, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 22. 136. The vaccine composition of any one of claims 105-135, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 26. 137. The vaccine composition of any one of claims 105-136, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 28. -102- WO 2024 / 220936 PCT / US2024 / 025583 138. The vaccine composition of any one of claims 105-137, wherein the plurality of distinct antigens comprises eighteen distinct antigens selected from the group consisting of SEQ ID NOS: 1-8, 16-23, and 29, or sequences at least 70% identical thereto. 139. The vaccine composition of any one of claims 105-138, wherein the plurality of distinct antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1-8, 16-23, and 29, or sequences at least 70% identical thereto. 140. The vaccine composition of any one of claims 105-139, further comprising a pharmaceutically acceptable carrier. 141. The vaccine composition of any one of claims 105-140, wherein each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 5 micrograms (pg), such as between 1 ng and 5 pg. 142. The vaccine composition of claim 141, wherein each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 3 pg, such as between 1 ng and 3 pg. 143. The vaccine composition of any one of claims 105-142, wherein the plurality of antigens comprises at 6, at least 8, at least 10, at least 12, at least 14, at least 16 or at least 17 distinct antigens. 144. The vaccine composition of any one of claims 105-143, wherein the composition has no more than 30, no more than 25, or no more than 20 distinct antigens. 145. The vaccine composition of any one of claims 105-144, wherein the plurality of antigens are collectively sufficient to elicit an immune response in a subject yet each individual antigen of the plurality of antigens in present in the composition in an amount that is insufficient to elicit in an immune response in a subject. 146. A nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of distinct antigens, wherein the plurality of distinct antigens comprises at least one of: (a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3; (b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13 or a sequence at least 70% identical to SEQ ID NO: 13; (c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18; (d)...
Claims
CLAIMSWHAT IS CLAIMED IS:
1. A vaccine composition comprising a plurality of distinct antigens, the vaccine composition comprising at least one of:(a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3;(b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical to SEQ ID NO: 16;(c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18;(d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical to SEQ ID NO: 19;(e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical to SEQ ID NO: 21;(f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical to SEQ ID NO: 24;(g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38 or a sequence at least 70% identical to SEQ ID NO: 38;(h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39 or a sequence at least 70% identical to SEQ ID NO: 39;(i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40 or a sequence at least 70% identical to SEQ ID NO: 40;(j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41 or a sequence at least 70% identical to SEQ ID NO: 41; or(k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42 or a sequence at least 70% identical to SEQ ID NO: 42.
2. The vaccine composition of claim 1, wherein the vaccine composition comprises at least one of:(a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3;(b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16;(c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18;(d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19;(e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21;(f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24;(g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38;(h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39;(i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40;(j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41; or(k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42.
3. The vaccine composition of claim 1 or 2, wherein the plurality of distinct antigens comprises eight distinct antigens, each of which comprises amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42 or sequences at least 90% identical thereto.
4. The vaccine composition of any one of claims 1-3, wherein the plurality of distinct antigens comprises twelve distinct antigens, each of which comprises amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42 or sequences at least 90% identical thereto.
5. The vaccine composition of any preceding claim, wherein the plurality of distinct antigens comprises eighteen distinct antigens, each of which comprises amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42 or sequences at least 90% identical thereto.
6. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3.
7. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18.
8. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19.
9. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21.
10. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24.
11. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38.
12. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39.
13. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40.
14. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41.
15. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42.
16. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 2.
17. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 4.
18. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 5.
19. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 6.
20. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 7.
21. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 8.
22. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16.
23. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 17.
24. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 20.
25. The vaccine composition of any preceding claim, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 22.
26. The vaccine composition of any preceding claim, wherein the plurality of distinct antigens comprises eighteen distinct antigens selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42, or sequences at least 70% identical thereto.
27. The vaccine composition of any preceding claim, wherein the plurality of distinct antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NO: 2- 9 16-22, 24, 38-42, or sequences at least 70% identical thereto.
28. The vaccine composition of any preceding claim, further comprising a pharmaceutically acceptable carrier.
29. The vaccine composition of any preceding claim, wherein each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 5 micrograms (pg), such as between 1 ng and 5 pg.
30. The vaccine composition of claim 29, wherein each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 3 pg, such as between 1 ng and 3 pg.
31. The vaccine composition of any preceding claim, wherein the plurality of antigens comprises at 6, at least 8, at least 10, at least 12, at least 14, at least 16 or at least 17 distinct antigens.
32. The vaccine composition of any preceding claim, wherein the composition has no more than 30, no more than 25, or no more than 20 distinct antigens.
33. The vaccine composition of any preceding claim, wherein the plurality of antigens are collectively sufficient to elicit an immune response in a subject yet each individual antigen of the plurality of antigens in present in the composition in an amount that is insufficient to elicit in an immune response in a subject.
34. The vaccine composition of any preceding claim, wherein the vaccine composition comprises SEQ ID NOS: 2-9, 16-22, 24, and 38-42.
35. The vaccine composition of any preceding claim, wherein the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 90% identical thereto.
36. The vaccine composition of any preceding claim, wherein the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 95% identical thereto.
37. The vaccine composition of any preceding claim, wherein the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 98% identical thereto.
38. The vaccine composition of any preceding claim, wherein the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128, or sequences at least 99% identical thereto.
39. The vaccine composition of any preceding claim, wherein the vaccine composition comprises twenty-one different sequences selected from the group consisting of SEQ ID NOS: 108-128.
40. A nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of distinct antigens, wherein the plurality of distinct antigens comprises at least one of:(a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3;(b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical to SEQ ID NO: 16;(c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18;(d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical to SEQ ID NO: 19;(e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical to SEQ ID NO: 21;(f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical to SEQ ID NO: 24;(g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38 or a sequence at least 70% identical to SEQ ID NO: 38.(h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39 or a sequence at least 70% identical to SEQ ID NO: 39.(i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40 or a sequence at least 70% identical to SEQ ID NO: 40.(j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41 or a sequence at least 70% identical to SEQ ID NO: 41.(k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42 or a sequence at least 70% identical to SEQ ID NO: 42.
41. The nucleic acid vaccine composition of claim 40, wherein: the plurality of distinct antigens comprises at least one of:(a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3;(b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16;(c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18;(d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19;(e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21;(f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24;(g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38;(h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39;(i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40;(j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41; or(k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42.
42. The nucleic acid vaccine composition of claim 40 or 41, wherein the one or more nucleic acids comprise messenger RNA (mRNA).
43. The nucleic acid vaccine composition of claim 42, wherein the mRNA is encapsulated in lipid nanoparticles (LNPs).
44. The nucleic acid vaccine composition of any one of claims 40-43, wherein each nucleic acid encoding for each distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 5 pg.
45. The nucleic acid vaccine composition of any one of claims 40-44, wherein each nucleic acid encoding for each distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 3 pg.
46. The nucleic acid vaccine composition of any one of claims 40-44, wherein the one or more nucleic acids encode eight distinct antigens, each of which is selected from a group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42.
47. The nucleic acid vaccine composition of any one of claims 40-44, wherein the one or more nucleic acids encode twelve distinct antigens, each of which is selected from a group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42.
48. The nucleic acid vaccine composition of any one of claims 40-44, wherein the one or more nucleic acids encode eighteen distinct antigens, each of which is selected from a group consisting of SEQ ID NOS: 2-9, 16-22, 24 and 38-42.
49. The nucleic acid vaccine composition of any one of claims 40-48, wherein the one or more nucleic acids encode for at least five distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 38-42.
50. The nucleic acid vaccine composition of any one of claims 40-49, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3.
51. The nucleic acid vaccine composition of any one of claims 40-50, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18.
52. The nucleic acid vaccine composition of any one of claims 40-51, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19.
53. The nucleic acid vaccine composition of any one of claims 40-52, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21.
54. The nucleic acid vaccine composition of any one of claims 40-53, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24.
55. The nucleic acid vaccine composition of any one of claims 40-54, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38.
56. The nucleic acid vaccine composition of any one of claims 40-55, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39.
57. The nucleic acid vaccine composition of any one of claims 40-56, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40.
58. The nucleic acid vaccine composition of any one of claims 40-57, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41.
59. The nucleic acid vaccine composition of any one of claims 40-58, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42.
60. The nucleic acid vaccine composition of any one of claims 40-59, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 2.
61. The nucleic acid vaccine composition of any one of claims 40-60, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 4.
62. The nucleic acid vaccine composition of any one of claims 40-61, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 5.
63. The nucleic acid vaccine composition of any one of claims 40-62, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 6.
64. The nucleic acid vaccine composition of any one of claims 40-63, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 7.
65. The nucleic acid vaccine composition of any one of claims 40-64, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 8.
66. The nucleic acid vaccine composition of any one of claims 40-65, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16.
67. The nucleic acid vaccine composition of any one of claims 40-66, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 17.
68. The nucleic acid vaccine composition of any one of claims 40-67, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 20.
69. The nucleic acid vaccine composition of any one of claims 40-68, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 22.
70. The nucleic acid vaccine composition of any one of claims 40-69, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 38.
71. The nucleic acid vaccine composition of any one of claims 40-70, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 39.
72. The nucleic acid vaccine composition of any one of claims 40-71, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 40.
73. The nucleic acid vaccine composition of any one of claims 40-72, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 41.
74. The nucleic acid vaccine composition of any one of claims 40-73, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 42.
75. The nucleic acid vaccine composition of any one of claims 40-74, wherein the one or more nucleic acids encode for at least eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42.
76. The nucleic acid vaccine composition of any one of claims 40-75, wherein the plurality of distinct antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 2-9, 16-22, 24, 38-42.
77. The nucleic acid vaccine composition of any one of claims 40-76, further comprising a pharmaceutically acceptable carrier.
78. The nucleic acid vaccine composition of any one of claims 40-77, wherein each nucleic acid encoding a distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 5 micrograms (pg), such as from about 1 ng to about 5 pg.
79. The nucleic acid vaccine composition of claim 78, wherein each nucleic acid encoding a distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 3 pg, such as from about 1 ng to about 3 pg.
80. The nucleic acid vaccine composition of any one of claims 40-79, wherein the plurality of antigens comprises at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 distinct antigens.
81. The nucleic acid vaccine composition of any one of claims 40-80, wherein the one or more nucleic acids encode for no more than 30, no more than 25, or no more than 20 distinct antigens.
82. The nucleic acid vaccine composition of any one of claims 40-81, wherein, upon administration of the vaccine to a subject, the vaccine elicits an immune response in the subject yet none of the plurality of distinct antigens is individually expressed at a level that is sufficient to elicit an immune response in a subject by itself.
83. The nucleic acid vaccine composition of any one of claims 40-82, wherein the nucleic acid vaccine composition is formulated as a LNP-encapsulated mRNA, DNA, or viral vector.
84. The nucleic acid vaccine composition of any one of claims 42-83, wherein the one or more nucleic acids encode for SEQ ID NOS: 2-9, 16-22, 24, and 38-42.
85. The nucleic acid vaccine composition of any one of claims 40-84, wherein the one or more nucleic acids further encode a transmembrane domain.
86. The nucleic acid vaccine composition of claim 85, wherein the transmembrane domain comprises any one of SEQ ID NOS: 43-63.
87. The nucleic acid vaccine composition of any one of claims 40-86, wherein the one or more nucleic acids encode each of SEQ ID NOS: 43-63.
88. The nucleic acid vaccine composition of any one of claims 40-87, wherein the one or more nucleic acids further encode a signaling peptide.
89. The nucleic acid vaccine composition of any one of claims 40-88, wherein the one or more nucleic acids comprise any one of SEQ ID NOS: 64-84.
90. The nucleic acid vaccine composition of any one of claims 40-89, wherein the one or more nucleic acids comprise each of SEQ ID NOS: 64-84.
91. The nucleic acid vaccine composition of any one of claims 40-90, wherein the one or more nucleic acids encode any one of SEQ ID NOS: 85-105.
92. The nucleic acid vaccine composition of any one of claims 40-91, wherein the one or more nucleic acids encode each of SEQ ID NOS: 85-105.
93. The nucleic acid vaccine composition of any one of claims 40-92, wherein the one or more nucleic acids comprise any one of SEQ ID NOS: 64-83.
94. The nucleic acid vaccine composition of any one of claims 40-93, wherein the one or more nucleic acids comprise each of SEQ ID NOS: 64-83.
95. The nucleic acid vaccine composition of any one of claims 40-94, wherein the one or more nucleic acids comprise any one of SEQ ID NOS: 64, 67-79, and 82-83 .
96. The nucleic acid vaccine composition of any one of claims 40-95, wherein the one or more nucleic acids comprise each of SEQ ID NOS: 64, 67-79, and 82-83.
97. The nucleic acid vaccine composition of any one of claims 40-94, wherein the one or more nucleic acids encode any one of SEQ ID NOS: 85-104.
98. The nucleic acid vaccine composition of any one of claims 40-95, wherein the one or more nucleic acids encode each of SEQ ID NOS: 85-104.
99. The nucleic acid vaccine composition of any one of claims 40-94, wherein the one or more nucleic acids encode any one of SEQ ID NOS: 85-100.
100. The nucleic acid vaccine composition of any one of claims 40-95, wherein the one or more nucleic acids encode each of SEQ ID NOS: 85-100.
101. The nucleic acid vaccine composition of any one of claims 40-100, wherein the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 1 OS- 128, or sequences at least 90% identical thereto.
102. The nucleic acid vaccine composition of any one of claims 40-101, wherein the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 1 OS- 128, or sequences at least 95% identical thereto.
103. The nucleic acid vaccine composition of any one of claims 40-102, wherein the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 1 OS- 128, or sequences at least 98% identical thereto.
104. The nucleic acid vaccine composition of any one of claims 40-103, wherein the vaccine composition comprises twenty-one nucleic acid sequences encoding SEQ ID NOS: 1 OS- 128, or sequences at least 99% identical thereto.
105. A vaccine composition comprising a plurality of distinct antigens, the vaccine composition comprising at least one of:(a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3;(b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16 or a sequence at least 70% identical to SEQ ID NO: 16;(c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18;(d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical to SEQ ID NO: 19;(e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical to SEQ ID NO: 21;(f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23 or a sequence at least 70% identical to SEQ ID NO: 23;(g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical to SEQ ID NO: 24;(h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25 or a sequence at least 70% identical to SEQ ID NO: 25;(i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27 or a sequence at least 70% identical to SEQ ID NO: 27;(j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29 or a sequence at least 70% identical to SEQ ID NO: 29;(k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33 or a sequence at least 70% identical to SEQ ID NO: 33;(l) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34 or a sequence at least 70% identical to SEQ ID NO: 34;(m)an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36 or a sequence at least 70% identical to SEQ ID NO: 36; and(n) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37 or a sequence at least 70% identical to SEQ ID NO: 37.
106. The vaccine composition of claim 105, wherein: the vaccine composition comprises at least one of:(a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3;(b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13;(c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18;(d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19;(e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21;(f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23;(g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24;(h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25;(i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27;(j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29;(k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33;(l) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34;(m)an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36; and(n) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37.
107. The vaccine composition of claim 106, wherein the plurality of distinct antigens comprises eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8 or sequences at least 70% identical thereto.
108. The vaccine composition of any one of claims 105-107, wherein the plurality of distinct antigens comprises eight distinct antigens, wherein the eight distinct antigens correspond to amino acid sequences selected from the group consisting of SEQ ID NOS: 16-23 or sequences at least 70% identical thereto.
109. The vaccine composition of any one of claims 105-108, wherein the plurality of distinct antigens comprises eight distinct antigens, wherein the eight distinct antigens correspond to amino acid sequences selected from the group consisting of SEQ ID NOS: 1-15 or sequences at least 70% identical thereto.
110. The vaccine composition of any one of claims 105-109, wherein the plurality of distinct antigens comprises six distinct antigens, wherein the six distinct antigens correspond to amino acid sequences selected from the group consisting of SEQ ID NOS: 16-28 or sequences at least 70% identical thereto.
111. The vaccine composition of any one of claims 105-110, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3.
112. The vaccine composition of any one of claims 105-111, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13.
113. The vaccine composition of any one of claims 105-112, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18.
114. The vaccine composition of any one of claims 105-113, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19.
115. The vaccine composition of any one of claims 105-114, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21.
116. The vaccine composition of any one of claims 105-115, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23.
117. The vaccine composition of any one of claims 105-116, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24.
118. The vaccine composition of any one of claims 105-117, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25.
119. The vaccine composition of any one of claims 105-118, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27.
120. The vaccine composition of any one of claims 105-119, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29.
121. The vaccine composition of any one of claims 105-120, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33.
122. The vaccine composition of any one of claims 105-121, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34.
123. The vaccine composition of any one of claims 105-122, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36.
124. The vaccine composition of any one of claims 105-123, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37.
125. The vaccine composition of any one of claims 105-124, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 1.
126. The vaccine composition of any one of claims 105-125, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 2.
127. The vaccine composition of any one of claims 105-126, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 4.
128. The vaccine composition of any one of claims 105-127, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 5.
129. The vaccine composition of any one of claims 105-128, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 6.
130. The vaccine composition of any one of claims 105-129, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 7.
131. The vaccine composition of any one of claims 105-130, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 8.
132. The vaccine composition of any one of claims 105-131, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16.
133. The vaccine composition of any one of claims 105-132, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 17.
134. The vaccine composition of any one of claims 105-133, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 20.
135. The vaccine composition of any one of claims 105-134, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 22.
136. The vaccine composition of any one of claims 105-135, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 26.
137. The vaccine composition of any one of claims 105-136, wherein the vaccine composition comprises an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 28.
138. The vaccine composition of any one of claims 105-137, wherein the plurality of distinct antigens comprises eighteen distinct antigens selected from the group consisting of SEQ ID NOS: 1-8, 16-23, and 29, or sequences at least 70% identical thereto.
139. The vaccine composition of any one of claims 105-138, wherein the plurality of distinct antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NO: 1-8, 16-23, and 29, or sequences at least 70% identical thereto.
140. The vaccine composition of any one of claims 105-139, further comprising a pharmaceutically acceptable carrier.
141. The vaccine composition of any one of claims 105-140, wherein each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 5 micrograms (pg), such as between 1 ng and 5 pg.
142. The vaccine composition of claim 141, wherein each antigen of the plurality of distinct antigens is present in the vaccine composition in an amount of less than about 3 pg, such as between 1 ng and 3 pg.
143. The vaccine composition of any one of claims 105-142, wherein the plurality of antigens comprises at 6, at least 8, at least 10, at least 12, at least 14, at least 16 or at least 17 distinct antigens.
144. The vaccine composition of any one of claims 105-143, wherein the composition has no more than 30, no more than 25, or no more than 20 distinct antigens.
145. The vaccine composition of any one of claims 105-144, wherein the plurality of antigens are collectively sufficient to elicit an immune response in a subject yet each individual antigen of the plurality of antigens in present in the composition in an amount that is insufficient to elicit in an immune response in a subject.
146. A nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of distinct antigens, wherein the plurality of distinct antigens comprises at least one of:(a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3 or a sequence at least 70% identical to SEQ ID NO: 3;(b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13 or a sequence at least 70% identical to SEQ ID NO: 13;(c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18 or a sequence at least 70% identical to SEQ ID NO: 18;(d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19 or a sequence at least 70% identical to SEQ ID NO: 19;(e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21 or a sequence at least 70% identical to SEQ ID NO: 21;(f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23 or a sequence at least 70% identical to SEQ ID NO: 23;(g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24 or a sequence at least 70% identical to SEQ ID NO: 24;(h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25 or a sequence at least 70% identical to SEQ ID NO: 25;(i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27 or a sequence at least 70% identical to SEQ ID NO: 27;(j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29 or a sequence at least 70% identical to SEQ ID NO: 29;(k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33 or a sequence at least 70% identical to SEQ ID NO: 33;(l) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34 or a sequence at least 70% identical to SEQ ID NO: 34;(m)an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36 or a sequence at least 70% identical to SEQ ID NO: 36; and(n) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37 or a sequence at least 70% identical to SEQ ID NO: 37.
147. The nucleic acid vaccine composition of claim 146, wherein: the plurality of distinct antigens comprises at least one of:(a) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3;(b) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13;(c) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18;(d) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19;(e) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21;(f) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23;(g) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24;(h) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25;(i) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27;(j) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29;(k) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33;(l) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34;(m)an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36; and(n) an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37.
148. The nucleic acid vaccine composition of claim 146 or 147, wherein the one or more nucleic acids comprise messenger RNA (mRNA).
149. The nucleic acid vaccine composition of claim 148, wherein the mRNA is encapsulated in lipid nanoparticles (LNPs).
150. The nucleic acid vaccine composition of any one of claims 146-149, wherein each nucleic acid encoding for each distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 5 pg.
151. The nucleic acid vaccine composition of any one of claims 146-150, wherein each nucleic acid encoding for each distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 3 pg.
152. The nucleic acid vaccine composition of any one of claims 146-151, wherein the one or more nucleic acids encode for at least eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8.
153. The nucleic acid vaccine composition of any one of claims 146-152, wherein the one or more nucleic acids encode for at least eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 16-23.
154. The nucleic acid vaccine composition of any one of claims 146-153, wherein the one or more nucleic acids encode for at least eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-15.
155. The nucleic acid vaccine composition of any one of claims 146-154, wherein the one or more nucleic acids encode for at least six distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 16-28.
156. The nucleic acid vaccine composition of any one of claims 146-155, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 3.
157. The nucleic acid vaccine composition of any one of claims 146-156, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 13.
158. The nucleic acid vaccine composition of any one of claims 146-157, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 18.
159. The nucleic acid vaccine composition of any one of claims 146-158, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 19.
160. The nucleic acid vaccine composition of any one of claims 146-159, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 21.
161. The nucleic acid vaccine composition of any one of claims 146-160, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 23.
162. The nucleic acid vaccine composition of any one of claims 146-161, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 24.
163. The nucleic acid vaccine composition of any one of claims 146-162, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 25.
164. The nucleic acid vaccine composition of any one of claims 146-163, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 27.
165. The nucleic acid vaccine composition of any one of claims 146-164, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 29.
166. The nucleic acid vaccine composition of any one of claims 146-165, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 33.
167. The nucleic acid vaccine composition of any one of claims 146-166, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 34.
168. The nucleic acid vaccine composition of any one of claims 146-167, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 36.
169. The nucleic acid vaccine composition of any one of claims 146-168, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 37.
170. The nucleic acid vaccine composition of any one of claims 146-169, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 1.
171. The nucleic acid vaccine composition of any one of claims 146-170, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 2.
172. The nucleic acid vaccine composition of any one of claims 146-171, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 4.
173. The nucleic acid vaccine composition of any one of claims 146-172, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 5.
174. The nucleic acid vaccine composition of any one of claims 146-173, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 6.
175. The nucleic acid vaccine composition of any one of claims 146-174, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 7.
176. The nucleic acid vaccine composition of any one of claims 146-175, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 8.
177. The nucleic acid vaccine composition of any one of claims 146-176, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 16.
178. The nucleic acid vaccine composition of any one of claims 146-177, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 17.
179. The nucleic acid vaccine composition of any one of claims 146-178, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 20.
180. The nucleic acid vaccine composition of any one of claims 146-179, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 22.
181. The nucleic acid vaccine composition of any one of claims 146-180, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 26.
182. The nucleic acid vaccine composition of any one of claims 146-181, wherein the one or more nucleic acids encode for an antigen comprising an amino acid sequence corresponding to SEQ ID NO: 28.
183. The nucleic acid vaccine composition of any one of claims 146-182, wherein the one or more nucleic acids encode for at least eight distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29.
184. The nucleic acid vaccine composition of any one of claims 146-183, wherein the plurality of distinct antigens comprises at least 6, at least 8, at least 10, at least 12, at least 14, or at least 16 distinct antigens comprising amino acid sequences selected from the group consisting of SEQ ID NOS: 1-8, 16-23, or 29.
185. The nucleic acid vaccine composition of any one of claims 146-184, further comprising a pharmaceutically acceptable carrier.
186. The nucleic acid vaccine composition of any one of claims 146-185, wherein each nucleic acid encoding a distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 5 micrograms (pg), such as from about 1 ng to about 5 pg.
187. The nucleic acid vaccine composition of claim 186, wherein each nucleic acid encoding a distinct antigen is present in the nucleic acid vaccine composition in an amount of less than about 3 pg, such as from about 1 ng to about 3 pg.
188. The nucleic acid vaccine composition of any one of claims 146-187, wherein the plurality of antigens comprises at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, or at least 17 distinct antigens.
189. The nucleic acid vaccine composition of any one of claims 146-188, wherein the one or more nucleic acids encode for no more than 30, no more than 25, or no more than 20 distinct antigens.
190. The nucleic acid vaccine composition of any one of claims 146-189, wherein, upon administration of the vaccine to a subject, the vaccine elicits an immune response in the subject yet none of the plurality of distinct antigens is individually expressed at a level that is sufficient to elicit an immune response in a subject by itself.
191. The nucleic acid vaccine composition of any one of claims 146-190, wherein the nucleic acid vaccine composition is formulated as an LNP-encapsulated mRNA or DNA or viral vector.
192. The nucleic acid vaccine composition of any one of claims 146-191, wherein the one or more nucleic acids further encode a transmembrane domain.
193. The nucleic acid vaccine composition of claim 192, wherein the transmembrane domain comprises any one of SEQ ID NOS: 43-63.
194. The nucleic acid vaccine composition of any one of claims 146-193, wherein the one or more nucleic acids encode any one of SEQ ID NOS: 43-63.
195. The nucleic acid vaccine composition of any one of claims 146-194, wherein the one or more nucleic acids further encode a signaling peptide.
196. The nucleic acid vaccine composition of any one of claims 146-195, wherein the one or more nucleic acids comprise any one of SEQ ID NOS: 64-84.
197. The nucleic acid vaccine composition of any one of claims 146-196, wherein the one or more nucleic acids comprise each of SEQ ID NOS: 64-84.
198. The nucleic acid vaccine composition of any one of claims 146-197, wherein the one or more nucleic acids encode any one of SEQ ID NOS: 85-105.
199. The nucleic acid vaccine composition of any one of claims 146-198, wherein the one or more nucleic acids encode each of SEQ ID NOS: 85-105.
200. The nucleic acid vaccine composition of any one of claims 146-199, wherein the one or more nucleic acids comprise any one of SEQ ID NOS: 64-83.
201. The nucleic acid vaccine composition of any one of claims 146-200, wherein the one or more nucleic acids comprise each of SEQ ID NOS: 64-83.
202. The nucleic acid vaccine composition of any one of claims 146-201, wherein the one or more nucleic acids comprise any one of SEQ ID NOS: 64, 67-79, and 82-83 .
203. The nucleic acid vaccine composition of any one of claims 146-202, wherein the one or more nucleic acids comprise each of SEQ ID NOS: 64, 67-79, and 82-83.
204. The nucleic acid vaccine composition of any one of claims 146-203, wherein the one or more nucleic acids encode any one of SEQ ID NOS: 85-104.
205. The nucleic acid vaccine composition of any one of claims 146-204, wherein the one or more nucleic acids encode each of SEQ ID NOS: 85-104.
206. The nucleic acid vaccine composition of any one of claims 146-205, wherein the one or more nucleic acids encode any one of SEQ ID NOS: 85-100.
207. The nucleic acid vaccine composition of any one of claims 146-206, wherein the one or more nucleic acids encode each of SEQ ID NOS: 85-100.
208. A vaccine composition comprising twenty-one distinct antigens, wherein each of the twenty-one distinct antigens comprises a sequence selected from SEQ ID NOS: 108-128, ora sequence having at least 90%, at least 95%, at least 98%, at least 99% sequence identity thereto.
209. The vaccine composition of claim 208, wherein each of the twenty-one distinct antigens comprises a sequence selected from SEQ ID NOS: 108-128.
210. The vaccine composition of claim 208 or 209, wherein each of the twenty-one distinct antigens comprises or consists of a sequence selected from SEQ ID NOS: 85-105211. A nucleic acid vaccine composition comprising one or more nucleic acids encoding for at least twenty-one distinct antigens, wherein each the twenty-one distinct antigens comprises a sequence selected from SEQ ID NOS: 108-128, or a sequence having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.
212. The nucleic acid vaccine composition of claim 211, wherein each of the at least twenty-one distinct antigens comprises a sequence selected from SEQ ID NOS: 108-128.
213. The nucleic acid vaccine composition of claim 211 or 212, wherein each of the twenty-one distinct antigens comprises or consists of a sequence selected from SEQ ID NOS: 85-105.
214. The nucleic acid vaccine composition of any one of claims 211-213, wherein the vaccine composition comprises each of SEQ ID NOS: 64-84.
215. A method for preventing an influenza infection in a subject, comprising administering to the subject the vaccine composition of any preceding claim.
216. A method of inducing an immune response in a subject, the method comprising administering to the subject the vaccine composition of any preceding claim.
217. The method of claim 216, wherein the immune response is a protective immune response.
218. The method of claim 216 or 217, wherein the vaccine composition is administered to the subject intramuscularly, subcutaneously, intramuscularly, intranasally, or orally.
219. The method of any one of claims 216-218, wherein the nucleic acid vaccine composition is formulated for delivery as a LNP-encapsulated mRNA or DNA or viral vector.
